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Outline of the thesis and 
general introduction

Chapter 1 1
 Scope and outline of the thesis
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Chapter 1
1 Introduction
Soft tissue sarcomas (STS) comprise a heterogeneous group of malignancies derived from 
mesenchymal cells. The different STS entities are based on pathological and genetical 
characteristics. STS subtypes, except gastro-intestinal stroma tumors (GISTs), are often 
clustered together and referred to as non-GIST STS. Treatment of non-GIST STS has barely 
changed in the past decades and still consists of surgery and, on indication, radiotherapy 
for localized disease. In the advanced setting palliative systemic treatment and sometimes 
local treatment options are indicated. As the occurrence of each distinct subtype is rare in the 
general population, clinical studies frequently include all non-GIST STS patients to collect 
sufficient data. However, this results in a group of patients with a wide variety of tumors 
each with its own genetical profile, origin, localization and behavior, making progress in STS 
research challenging.
Preclinical studies are essential for the understanding of the biology and treatment sensitivity 
in different STS subtypes. One such interesting STS subtype is the synovial sarcoma. Synovial 
sarcomas are identified by their typical translocation between chromosomes X and 18. This 
shared translocation suggests a consistent oncogenic driver within these patients, although 
this has not yet been identified. Nonetheless tumor behavior varies from indolent to very 
aggressive and response to treatment varies. In addition, synovial sarcomas can arise at all 
sites throughout the body and at all ages. Consequently, patients are treated by surgeons, 
radiotherapists and either pediatric or medical oncologists. In the absence of significant 
developments in the management of synovial sarcomas over the last few decades, the survival 
rates have shown hardly any improvement. Therefore, there is an unmet need to optimize 
current treatments and to search for novel potentially effective therapies.
The aim of this thesis is to enable the improvement of the outcome of patients with synovial 
sarcoma by analysis of its epidemiology, current treatments and response biomarkers, and by 
investigating novel targets for treatments.
First, Chapter 2 provides an overview of the literature so far, focusing about the yet not 
understood diversity of synovial sarcoma tumor behavior. Current treatment strategies are 
compared and a summary is given of proposed preclinical therapeutic targets and the required 
clinical studies.
Epidemiology and current treatments options in synovial sarcoma patients
Next, prognostic factors that could add to the understanding of tumor behavior differences 
are investigated in two large retrospective cohort studies. In chapter 3 a study executed in 
a large Dutch cohort with localized synovial sarcomas is described. This study evaluates 
prognostic factors that can contribute to understanding or predicting tumor behavior. In the 
second study, described in chapter 4, an advanced European synovial sarcoma patient group 
is studied likewise. In addition, this study investigates differences between synovial sarcoma 
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1and other non-GIST STS patients in the advanced clinical setting. A better understanding of 
the variables that can predict patient outcome and differences between synovial sarcoma and 
other STS patient characteristics and respone to chemotherapy is of importance to improve 
the design of further clinical studies.
Exploring new targets in synovial sarcoma
The following research will focuss on potential new therapeutic targets for synovial sarcomas 
by screening for genetic alterations, exploring phosphorylation profi les and investigating 
drug responses in vitro and in vivo. Chapter 5 describes the examination of genetic 
alterations in a subset of synovial sarcomas. With next generation sequencing, a cohort of 
synovial sarcomas is investigated for additional mutations besides the translocation that can 
potentially be targeted by novel treatment options. In addition, copy number variations are 
tested to identify differences in genetic gains or losses between the tumors. Furthermore, 
primary tumors are compared with their corresponding metastasis to generate more insight in 
genetic tumor development and lesion heterogeneity. In chapter 6, the functionality of one 
of the potential targets found by sequencing, cyclin D1, is further investigated by extensively 
showing the expression levels of the proteins involved in this pathway. Additionally, the effect 
of inhibiting this pathway in vitro with the CDK4/CDK6/Cyclin D1 inhibitor, palbociclib, is 
examined in synovial sarcoma cell lines. In chapter 7 a panel of different sarcoma cell lines 
is tested for the activation (by phosphorylation) of numerous proteins to identify potential 
novel targets for treatment. Phosphorylation differences between the sarcoma subtypes are 
evaluated. In vitro and in vivo verifi cation in mice bearing synovial sarcomas is performed for 
potential targets found in the synovial sarcoma cell lines, by investigating the effect of specifi c 
oncogenic inhibitors.
Pharmacodynamics and pharmacokinetics in metastatic STS
Finally, we aimed to improve the currently used targeted therapy in STSs, including synovial 
sarcomas. So far, only two targeted treatments approved for advanced non-GIST STS 
patients are available: pazopanib, FDA and EMA approved, which is an orally administered 
angiogenesis inhibitor, and olaratumab, a monoclonal antibody inhibiting the platelet derived 
growth factor receptor alpha (PDGFRα), which is given in combination with doxorubicin, 
which has accelerated approval by FDA and conditional approval by EMA, awaiting results of 
a phase 3 study. Therefore, this last topic addressed in this thesis involves options to improve 
pazopanib treatment in non-GIST STS patients. Currently, response to pazopanib therapy is 
only observed in an undefi ned subset of STS patients with limited survival benefi t. Although 
pazopanib is generably well tolerated one of the serious side effects is liver toxicity. 
Early biomarkers are needed to identify those patients who will benefi t from therapy and to 
avoid treatment of patients with an ineffective, potentially toxic and expensive drug over a 
16
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prolonged period of precious time. A frequently used technique that has proven to be beneficial 
in various malignancies is the use of FDG-PET scans to evaluate early metabolic response. 
This biomarker can be used to identify non-responders in an early stage; however, its ability to 
identify early response for pazopanib in STS patients has not yet been determined. Moreover, 
no relation between metabolic response (pharmacodynamics) and pharmacokinetics of 
pazopanib has been studied in STS so far. Chapter 8 illustrates the potentials and the pitfalls 
of using FDG-PET scans for early response evaluation, both visual and quantitative, in the 
clinical setting. In chapter 9 an exploratory study is described which aims to evaluate the use 
of FDG-PET scans as an early biomarker of pazopanib treatment efficacy in STS patients. 
Hereto, FDG-PET scans are performed before start of pazopanib therapy, two weeks after 
treatment start and compared to treatment outcome after two months. Results will also be 
compared and related to pharmacokinetics of pazopanib. Chapter 10 reports two cases of 
synovial sarcoma patients with serious pazopanib related liver toxicity, where the combined 
treatment with prednisolone to overcome this toxicity is discussed.
Summerizing discussion and future perspectives
Finally, chapter 11 summarizes the results described in this thesis and discusses future 
perspectives on treatment options for soft tissue sarcoma patients, with a specific focus on 
synovial sarcoma patients.
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 Synovial sarcoma diagnosis and management in the era of 
targeted therapies
Myrella Vlenterie, Robin L Jones, and Winette TA van der Graaf
Adapted from: Curr Opin Oncol. 2015 Jul;27(4):316-22.
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Abstract
PURPOSE OF REVIEW: Synovial sarcomas are a distinct soft tissue sarcoma subtype, 
with a predilection for young adults. Despite its common translocation, there is substantial 
heterogeneity in patient outcome. This review discusses recent developments in diagnosis, 
prognostication, and treatments, together with the role of targeted agents and immunotherapy 
in patients with synovial sarcoma.
RECENT FINDINGS: Tumor behavior of synovial sarcomas remains inexplicable and is 
therefore poorly predictable. Although many variables seem to contribute to and influence 
patient outcome, no underlying pathophysiology accounting for the variability in behavior 
has been unraveled. As prognosis remains poor, there is a wistful search for new therapies. 
In preclinical testing, several receptor tyrosine kinases have been suggested as therapeutic 
targets with interesting results in vitro or in vivo. However, translating interesting preclinical 
outcome to clinical results is difficult, to a large extent due to limited patient numbers available 
to participate in clinical trials.
SUMMARY: By defining predictive variables, researchers try to understand the underlying 
cause of this tumor’s biologic behavior and develop new therapeutic targets. Owing to the 
minimal number of prospective studies usually with small patient numbers, the strength of 
improving patient outcome will be in collaborative international studies in this rare tumor 
type.
21
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Introduction
Synovial sarcoma is one of the many subtypes of soft tissue sarcomas (STSs), accounting 
for approximately 6% of all STSs1. Synovial sarcomas can occur at all ages, from premature 
newborns2 ranging to patients above 80 years3,4. There is a predilection for young adults in 
their third decade. The tumor can arise at all sites throughout the body, but is most often 
located in the extremities, hence its historical name. However, despite its tendency to arise 
near joints, its origin is not related to synovial tissue. Interestingly, synovial sarcomas 
show a considerable morphologic heterogeneity in which distinct histological subtypes 
can be distinguished: monophasic, containing spindle-shaped mesenchymal cells; biphasic, 
containing both mesenchymal and well developed glandular epithelial cells; and the poorly 
differentiated subtype. In addition to tumor characteristics and histology, biologic behavior 
also differs. Synovial sarcomas show a range from indolent to highly aggressive behavior, 
resulting in an overall poor prognosis, with a 5-year cancer-specifi c survival of 66%5. In a 
study of 112 patients, local recurrence occurred in 12% and metastases in 39% at 5 years6. 
The course of the disease varies, as tumors can relapse after more than a decade. In contrast to 
the usually early development of metastases in STS in general, a long follow-up study of 62 
patients with synovial sarcoma reported local recurrence and metastases after a mean of 3.6 
(range 0.5–15) and 5.7 years (range 0.5–16), respectively7. 
Despite the heterogeneity in tumor characteristics and behavior, synovial sarcomas share a 
typical genetic similarity: the well known translocation between chromosomes X and 18, 
t(X;18)(p11.2;q11.2), leading to the SS18-SSX1 or SS18-SSX2 (seldom SS18-SSX4) fusion 
protein. This translocation is believed to be an early event, as the fusion type is concordant 
in primary tumors and metastases and constant over the course of the disease8. It occurs in 
more than 95% of the synovial sarcomas, making it a frequently used diagnostic criterion. 
Recently, the activity of the translocation has been further explored. Kadoch and Crabtree 
show oncogenic proliferation through Sox2 activation9. They describe how the fusion of SS18 
with SSX produces a protein that binds to the BAF complex and evicts both the wild-type 
SS18 and the tumor-suppressor BAF47. This altered BAF complex then binds the Sox2 locus 
and reverses polycomb mediated repression, resulting in Sox2 activation, which is essential 
for cell proliferation. However, as this translocation seems consistent in almost all synovial 
sarcoma regardless of its characteristics, it does not explain the variety in tumor behavior. 
Indeed, for decades, researchers have tried to identify variables that predict tumor behavior 
and potentially lead to therapeutic opportunities to improve patient survival.
Predicting tumor behavior
The most confi rmed prognostic factor is stage at diagnosis, with a reported 10-year cancer-
specifi c survival of 69% in patients with localized disease at diagnosis, dropping dramatically 
to 8.9% in patients with initial metastatic disease (p<0.001, n=1268)5. Not surprisingly, the 
main prognostic factor for local recurrence is resection status. In a study of patients with non-
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metastatic disease (n=150), the only predictor of increased risk of local recurrence was margin 
status. For patients with negative margins, the 10-year local recurrence rate was 12% compared 
with 32% for positive or unknown-status margins (p<0.05)10. Apart from stage at diagnosis or 
resection status, prognostic variables can be subdivided into patient and tumor characteristics, 
genetic factors, and immunohistochemical variables. A large multivariate analysis reported 
by Sultan et al. is based on the Surveillance, Epidemiology, and End Results database5. Their 
analysis showed a significantly higher hazard ratio for risk of death for patients with larger 
tumor size (≥5 cm), male sex, and older age. Furthermore, tumor location was also found to 
be a significant prognostic factor. In a study of 255 synovial sarcoma patients with localized 
disease, a multivariate analysis showed that tumors located in the upper extremities had a 
trend toward better survival compared with patients having tumors in the lower extremity. 
Significantly worse survival rates were found in patients with non-extremity primary tumors11. 
However, tumor location was not a significant prognostic factor in the study by Sultan et al. 
who included synovial sarcoma patients with all stages5. 
Translocation subtype is a debatable prognostic variable. The study of Ladanyi et al. (n=243) 
showed that patients with the SSX2 translocation had better reported overall survival (OS) 
rates compared to patients with the SSX1 translocation4. However, the impact was no longer 
significant when stratified for disease status at presentation. In contrast, a study of 141 patients 
by Guillou et al. did not show any correlation between fusion protein status and survival12. 
Recently, the association of SSX1 tumors with worse OS was found to be statistically significant 
in a Chinese study of 88 patients (p<0.001), with additional cell line experiments showing 
significantly more proliferative and invasive characteristics when transfected with the SS18-
SSX1 compared with the SS18-SSX2 gene13. Interestingly, the monophasic subtype is thought 
to be related to the SSX2 translocation, whereas SSX1 tumors are thought to be linked to a 
biphasic phenotype, implicating worse prognosis for patients with biphasic tumors4. However, 
the national cancer database of the American College of Surgeons published a cohort of STS 
patients, including the largest group (n=3765) of synovial sarcoma patients reported so far. 
They found better 5-year OS rates in biphasic synovial sarcoma patients (65%) than those 
with the monophasic subtype (56% p<0.031), and even worse for the poorly differentiated 
synovial sarcomas (52%, p<0.001)1. Therefore, the prognostic value of synovial sarcoma 
histological subtype remains debatable. 
Recently, chromosome instability has been evaluated in synovial sarcomas (n=100) by means 
of the genomic index, which is based on the number and type of chromosomal aberrations. 
In this study, genome complexity was a prognostic factor for lower metastasis-free survival 
(p<0.01). The index also showed a relation to age at diagnosis, with greater instability being more 
frequent in adult (64%) compared with pediatric patients (19%)14. Genomic complexity did not 
predict response to chemotherapy15. Gene-expression profiling in synovial sarcomas reported 
significant overexpression of AURKA and KIF18A in the group of patients with recurrent 
or metastatic lesions compared with patients with localized disease16. Immunohistochemical 
markers have also been investigated. Suggested antibodies that have been reported to be of 
prognostic value include Bcl-2 and c-myc17, survivin18, FGFR319, secernin-120, CXCR4, and 
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IGF-1R22. In the study by Tarkan et al., high mitotic activity was signifi cantly associated 
with worse disease-specifi c survival on multivariate analysis22. Finally, Chinen et al. reported 
the feasibility of detecting and monitoring circulating tumor cells in patients with synovial 
sarcoma23. Although further work is clearly needed, the detection of circulating tumor cells 
could aid the diagnosis and prediction of recurrent and metastatic disease.
Treatment modalities
Treatment has barely changed in the past decades and still involves surgery for localized 
disease, frequently combined with chemotherapy, radiotherapy, or both. A large retrospective 
American study showed that of 1242 patients with synovial sarcoma, 34% were treated 
with surgery alone, 7% were treated with neoadjuvant radiotherapy, 5% with neoadjuvant 
chemotherapy, 25% with postoperative radiotherapy, 7% with postoperative chemotherapy, 
and 22% with the combination of all three. The combination of all three is most often used in 
stage III disease, whereas surgery alone or surgery combined with postoperative radiotherapy 
is most common in stages I and II24. For primary irresectable synovial sarcomas hyperthermic-
isolated limb perfusion with melphalan and tumor necrosis factor-α, followed by surgical 
resection and eventual radiotherapy is also an option26. (Neo)adjuvant radiation may be 
administered depending on the specifi c clinical situation. Retrospective studies have reported 
that radiotherapy has a positive effect on event-free survival3, local recurrence-free survival26, 
and disease-specifi c survival as well as OS27. 
In addition, synovial sarcomas are relatively chemosensitive compared with other adult STS. 
However, the role of adjuvant chemotherapy in adult patients remains controversial, despite 
being an established component of management in children with synovial sarcoma. Brennan et 
al. in a retrospective study showed extended survival rates for children with small completely 
resected tumors treated with surgery alone28. In a prospective nonrandomized European study 
by Ferrari et al. including pediatric patients with synovial sarcoma, neoadjuvant chemotherapy 
was administered to patients with high-risk tumors, and adjuvant chemotherapy to patients 
with intermediate or high risk tumors29. The low-risk patients were treated with surgery alone. 
As this study was nonrandomized, no conclusive recommendations can be made regarding 
the effi cacy of chemotherapy; however, the authors have reported better survival compared 
with previous studies, warranting further evaluation. Neoadjuvant chemotherapy in adults 
may be indicated in patients with locally advanced tumors that would require debilitating 
surgery. Randomized trials have failed to show a survival benefi t for adjuvant chemotherapy 
in adult STS, and it is recommended that adjuvant systemic therapy should be given within the 
context of a clinical trial30. Eilber et al. performed a retrospective study of 101 patients with 
primary synovial sarcoma treated at two institutions, and reported that ifosfamide-based (neo)
adjuvant chemotherapy was effective31. With a median follow-up of 58 months, the 4-year 
disease-specifi c survival was 88% for those who received chemotherapy compared with 67% 
for those who did not (p=0.01). In contrast, neither neoadjuvant nor adjuvant chemotherapy 
affected OS for patients with synovial sarcoma in a retrospective French study (n=237)32. 
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For synovial sarcomas, the most frequent regimes are either doxorubicin monotherapy or 
the combination of doxorubicin/ifosfamide. Different chemotherapy regimens showed no 
significant impact on OS, neither in STS nor in patients with synovial sarcoma33,34. The 
best response rates in patients with synovial sarcoma are seen in combination therapy of 
doxorubicin and ifosfamide, with response rates of 26–40%34,35. 
The multistrata phase 2 study of pazopanib in STS reported in patients with synovial sarcoma 
a progression-free rate at 12 weeks of 49%, and a median PFS of 161 days; in addition, in 
the synovial sarcoma stratum, five of the 37 patients with synovial sarcoma had a partial 
response (PR) (13.5%)36. The subsequent phase 3 trial (PALETTE) randomized patients with 
metastatic STS to receive pazopanib or placebo, and reported a significantly longer PFS in 
the pazopanib arm. The number of patients with synovial sarcoma in this trial was too low to 
draw definitive conclusions regarding the relative benefit of pazopanib in synovial sarcoma 
compared with other STS subtypes37. New chemotherapy drugs include trabectedin, which 
has shown stable disease in 47% and PRs in three of 45 patients with synovial sarcoma38. A 
recent Asian study reported high response rates in patients with advanced synovial sarcoma 
of 43, 50, and 54% with the second-line regimens ifosfamide/ etoposide, cyclophosphamide/ 
doxorubicin/ dacarbazine, and docetaxel/ gemcitabine, respectively39. Another potentially 
active agent is aldoxorubicin, a prodrug of doxorubicin, which binds covalently to serum 
albumin and subsequently accumulates in tumors. In a phase 1/2 trial in patients with solid 
tumors, aldoxorubicin was administered safely at doses several-fold higher than conventional 
doxorubicin, without associated acute cardiotoxicity40.
Figure 2.1: Potential targets in vitro, in vivo, and in humans. This figure demonstrates the 
number of interesting targets in vitro and in vivo diminishing to only a handful of potential 
clinical studies.
25
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Innovative treatments
In preclinical testing, several receptor tyrosine kinases have been suggested as therapeutic 
targets with interesting results in vitro and in vivo (Figure 2.1) Promising results have been 
shown by targeting the WNT signaling pathway in vivo. Additionally, the AKT-mTOR 
pathway has also evidence supporting a potential role preclinically41. However, the translation 
of promising preclinical results to improved clinical outcomes remains challenging and 
elusive, partly because of the limited numbers of patients with synovial sarcoma who entered 
into clinical trials. In the absence of signifi cant developments in the management of synovial 
sarcomas over the last few decades, the survival rate has shown no improvement and the 
evaluation of novel potentially effective therapies continues. 
A phase 1 study evaluating the combination of dual inhibition of cediranib and bevacizumab 
showed one PR in six patients with synovial sarcoma42. Cediranib monotherapy showed one 
PR and one minor response in two patients with synovial sarcoma43. Minimal effect was seen 
with sorafenib, with stable disease of limited duration in 50% of the patients with synovial 
sarcoma (n=12)44, and sunitinib resulting in one stable disease in four patients45. However, a 
study reporting the off-label use of a number of drugs in sarcoma documented a PR rate of 
50% in eight patients with synovial sarcoma treated with sunitinib46. Imatinib has minimal 
activity with three stable diseases at 4 months in 22 patients47. Other targets such as IGFR-
1R have been explored, and in a trial of R1507, four patients out of 23 had stable disease48. 
Furthermore, in a study with fi gitumumab in sarcoma, one patient with synovial sarcoma 
out of fi ve had stable disease49, and in a study of cixutumumab, six patients out of 17 had 
disease stability, although of limited duration50. Gefi tinib, an EGFR inhibitor, showed similar 
results with nondurable stable disease in 10 of 46 patients51. A pilot study in synovial sarcoma 
patients with ipilimumab, targeting CTLA4, was stopped due to low accrual, lack of activity, 
and lack of immune response52. 
Immunotherapy has a long history in sarcoma dating back to the 19th century and the use of 
immunotherapy in sarcoma has waxed and waned since that time, with reports of successful 
immunotherapeutic treatments in several subtypes53. One study reported stable disease for 
seven of 21 patients with synovial sarcoma, the best results being observed in those treated 
with interferon-α combined with SYT-SSX-derived peptide vaccines and an adjuvant54. In 
a study by Robbins et al., using autologous T cells transduced with an NY-ESO-1-reactive 
T-cell receptor in patients with synovial sarcoma tumors expressing NY-ESO-1, objective 
responses were observed in 11 out of 18 (61%) patients, including long-lasting partial and 
complete responses55. There are ongoing trials assessing the combination of immunotherapy 
and radiation as well as an NY-ESO-1 vaccine (Table 2.1). A radioimmunotherapeutic option 
is frizzled homolog 10 (FZD10). FZD10 is a cell-surface receptor for molecules in the Wnt 
pathway. Preclinical research showed overexpression of FZD10 by means of genome-wide 
expression profi ling and immunohistochemistry56. FZD10 transactivation is shown to play a 
critical role in the development and progression of synovial sarcoma57. FZD10 is targeted with 
radioisotope-labeled MAb 92-13, a therapeutic antibody that shows suppressed tumor growth 
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in in vivo synovial sarcoma models58. Its corresponding clinical trial is currently executed in 
patients with synovial sarcoma (Table 2.1).
Conclusion
Synovial sarcomas are composed of a heterogeneous set of tumors with broad biologic 
behavior, despite their common translocation. Future studies should incorporate translational 
studies aimed at evaluating the underlying biology, as well as putative prognostic and predictive 
markers. The recent observed activity of immunotherapy, particularly targeting NY-ESO-1, 
trabectedin, and a variety of angiogenesis inhibitors deserve further exploration. Owing to the 
rarity of this subtype, new studies will require not only international collaboration but also 
greater collaboration between pediatric and adult oncology, due to the age-range affected by 
this disease.
Table 2.1: Currently active clinical trials including synovial sarcoma patients (based on 
ClinicalTrials.gov accessed on 12 January 2015). IMRT: intensity-modulated radiation therapy; 
SyS: synovial sarcoma; STS: soft tissue sarcoma.
clinicaltrials.gov 
Identifier
Patients included Therapy Status Phase
NCT01343043 HLA-A2+ SyS Genetically engineered 
NY-ESO-1 specific T cells
Recruiting Pilot
NCT02059850 SyS, liposarcoma NY-ESO-1 T cells and 
cyclophosphamide
Recruiting Phase I
NCT01241162 SyS, Ewing 
sarcoma, osteogenic 
sarcoma, 
neuroblastoma
Decitabine and 
autotlogous cancer testis 
antigen specific dendritic 
cell vaccine
Recruiting Phase I
NCT01469975 SyS Radiolabelled monoclonal 
antibody targeting Frizzled 
Homolog 19 (SYNFRIZZ)
Recruiting Phase I
NCT01957709 STS Recombinant interferon 
gamma
Recruiting Pilot
NCT01532687 STS Gemcitabine and 
pazopanib
Recruiting Phase II
NCT01883518 STS Dendritic cell vaccine 
loaded with allogeneic 
tumor lysate expression of 
cancer testis antigens
Recruiting Phase II
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clinicaltrials.gov 
Identifi er
Patients included Therapy Status Phase
NCT00876031 rhabdomyosarcoma 
and 
rhabdomyosarcoma-
like STS
Trofosfamide, idarubicin, 
etoposide
Recruiting Phase III
NCT01900743 STS Regorafenib Recruiting Phase II
NCT02122861 Sarcoma and other 
tumors that express 
NY-ESO-1
ID-LV305 Recruiting Phase I
NCT01446809 STS Neo-adjuvant pazopanib 
and chemotherapy
Recruiting Pilot
NCT02301039 STS and bone 
sarcoma
Pembrolizumab (anti PD1 
antibody)
Not yet 
recruiting
Phase II
NCT00720174 STS Cixutumumab and 
doxorubicin
Ongoing, 
currently not 
recruiting
Phase I
NCT01154452 STS Vismodegib and Gamma-
Secretase inhibitor 
RO4929097
Ongoing, 
currently not 
recruiting
Phase I + 
Phase II
NCT00112463 STS Romidepsin Ongoing, 
currently not 
recruiting
Phase II
NCT01614795 STS <30 years Cixutumumab and 
temsirolimus
Ongoing, 
currently not 
recruiting
Phase II
NCT00030667 STS <30 years Imatinib Ongoing, 
currently not 
recruiting
Phase II
NCT02181829 SyS Whole lung IMRT Recruiting
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Abstract 
BACKGROUND: We performed a retrospective nationwide-study to explore age as prognostic 
factor in synovial sarcoma patients. 
METHODS: Data on 613 synovial sarcoma patients were obtained from the Netherlands 
Cancer Registry. The prognostic relevance of age groups (children, adolescent and young 
adults (AYA), adults and elderly) was estimated by Kaplan-Meier survival curves and 
multivariable Cox-proportional hazards modelling. 
RESULTS: 461 patients had localised disease at diagnosis. The 5-year overall survival was 
89.3±4.6%, 73.0±3.8%, 54.7±3.6% and 43.0±7.0% in children (n=54), AYAs (n=148), adults 
(n=204), and elderly (n=55) respectively. Treatment modalities had no significant effect on 
survival in the univariable analysis. Multivariable analysis identified age at diagnosis, tumour 
localisation and tumour size as significant factors affecting overall survival. Both tumour 
localisation and size were equally distributed over the age groups. 
CONCLUSION: We show that outcome of synovial sarcoma patients significantly decreases 
with age regardless of primary tumour site, size and treatment. 
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Introduction
Synovial sarcoma is a soft tissue sarcoma occurring at all ages. In the Netherlands, the 
standard treatment for localised disease in adults consists of radical surgery, with adjuvant 
radiotherapy on indication (marginal excision, R1 resection) or neo-adjuvant radiotherapy 
in case radical resection is deemed unattainable beforehand. Neo-adjuvant chemotherapy 
may be indicated when extensive down staging is necessary for the prospect of a radical 
resection. Adjuvant chemotherapy is mainly given within the context of a clinical trial, with 
a lack of convincing data substantiating survival benefi t1. In paediatric patients however, 
patients are treated according to international (European or Children’s Oncology Group 
(COG)) non-rhabdomyosarcoma protocols as long as the children are candidates for such 
protocols and protocols are active at the time a patient presents with synovial sarcoma. The 
current epidemiological analysis refl ects real life management. Stage at diagnosis is a known 
prognostic factor, with a reported 69% 10-year cancer specifi c survival in patients with local 
disease at diagnosis, dropping to 8.9% in patients with metastasis at diagnosis2. In addition to 
stage at diagnosis, several retrospective studies in patients with localised disease have looked 
at age as a prognostic factor for survival, with children having a more favourable outcome 
compared to adult synovial sarcoma patients. The association between age at diagnosis and 
survival has also been reported in a variety of other sarcomas3. The present retrospective 
nationwide study aimed to investigate a broader range of age groups, including elderly 
patients, thereby explicitly exploring whether other factors, such as tumour size, tumour 
localisation and treatment modalities modifi ed age-related survival differences. 
Patients & methods
Data source and study population: the data were obtained from the Netherlands Cancer 
Registry (NCR). Cases were registered following notifi cation by the Dutch Pathology 
Network (PALGA), supplemented by annual record linkage with the national hospital 
discharge database. Information on patient (age at diagnosis, sex) and tumour characteristics 
(primary tumour site, histology, size, date of diagnosis) as well as hospital characteristics and 
treatment modality (type of primary treatment, resection status) was collected from hospital 
records by trained registrars. Follow-up information on vital status was obtained through 
linkage with the Municipal Personal Records Database (GBA). We obtained consent for the 
design, data abstraction process as well as storage protocols from the national supervisory 
committee of the NCR. All patients histologically diagnosed with synovial sarcoma between 
1989 and 2013 were included. The diagnosis was based on the local pathologist’s diagnosis, 
often complemented with histological review in regional sarcoma panels. No information on 
molecular markers, including the X;18 translocation was available. For survival analyses, we 
only included patients diagnosed with localised disease at presentation. Patients who were 
not treated according to standard care (i.e. did not receive surgery as part of their primary 
treatment) were also excluded from the analyses, as they were considered unrepresentative. 
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Patients were classified as children (<18 years), adolescents and young adults (AYAs; 18-
34 years), adults (35-64 years) and elderly (≥65 years), as they reflect the current Dutch 
situation of oncological age groups in clinical care. Treatment was divided into 1. Surgery 
only, 2. surgery and (neo-)adjuvant radiotherapy, with or without chemotherapy, 3. surgery 
and (neo)adjuvant chemotherapy, and 4. no surgical treatment at all. We defined patients 
receiving surgery combined with chemotherapy as a separate group. We expected this to be 
a common treatment option in children as adjuvant chemotherapy is no standard treatment 
for adult synovial sarcoma patients in The Netherlands, and could therefore be of influence 
on age related survival. Due to the small patient numbers, we were limited in our ability 
to define treatment groups. Consequently, we grouped together who received (neo)adjuvant 
radiotherapy and patients receiving (neo)adjuvant radio- and chemotherapy. 
Data analyses and statistics: distribution of descriptive characteristics over the age groups 
was evaluated with Chi-square tests. Crude survival rates, 5- and 10- year overall survival 
(OS), were calculated using the Kaplan-Meier method, and the log-rank test pooled over the 
strata was used to compare the OS curves. In addition, relative survival (RS) analyses were 
performed as an approximation of disease-specific survival4, with OS being corrected for 
expected mortality according to annual life tables of the general population matched on age, 
gender and calendar year (annually retrieved from Statistics Netherlands). 
To identify independent prognostic factors for survival, we developed Cox proportional 
hazards models for which factors were selected on the basis of both clinical plausibility and 
significance in univariable analyses (p<0.1). In the multivariable analysis, we evaluated 
whether these factors modified the association between age and survival. Variables were 
considered confounders and included in the model on the basis of the log-likelihood test. 
All statistical analyses were two-sided. Except for the selection of variables for the multivariable 
analysis, a p-value <0.05 was considered significant. Statistical calculations and survival 
curves were generated by using IBM SPSS Statistics version 20 and Stata 13.0. Missing data 
on histological subtype, tumour size and tumour depth were considered missing at random, 
and were therefore imputed under fully conditional specification, using the MI command 
in Stata. On the basis of variables used in the regression analysis and those predictive of 
missing values, we generated 50 datasets using chains of 100 iterations. Convergence of the 
imputations was checked graphically and the Cox models were built using both the imputed 
dataset and the dataset restricted to cases with complete data for comparative purposes.
Results
In total, 613 synovial sarcoma patients were retrieved. At diagnosis, 461 patients (75.2%) 
were confirmed with localised disease (Table 3.1). Patients had a median age of 38.0 years 
(range 2-89). Surgery was performed in 416 (90.2%) of the patients, which was most often 
combined with radiotherapy (n=219, 47.5%). This group included patients who received both 
radio- and chemotherapy (n=49). Surgery combined with chemotherapy alone was performed 
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in a minority of the patients, although this treatment modality was provided three times more 
often in children (20.4%) than in the adult age groups (6.9% combined). Surgery was not 
undertaken in a minority of children (3.7%). Interestingly, this proportion was signifi cantly 
higher in all adult patients (10.6%). Among the elderly, more than a quarter of patients did not 
undergo surgery (25.5%).
Compared to general hospitals, academic centres treated a signifi cantly higher proportion 
of children (16.5% versus 7.3%; p=0.005). In addition, academic centres more often treated 
larger tumours (56.9% versus 40.9%; p=0.003) and tumours that were located deeply (54.6% 
versus 38.1%; p=0.031).
Patients’ age showed a gradual decline in overall survival over the years. Overall, patients 
had a 5-, and 10- year OS rate of 63.5±2.4% and 53.8±2.6%, respectively. Subdivided in the 
different age groups, the 5- and 10- year OS rates were <18 years: 89.3±4.6% and 77.0±6.9%, 
18-34 years: 73.0±3.8% and 64.0±4.3%, 35-64 years: 54.7±3.6% and 47.5±3.7%, and ≥65 
years: 43.0±7.0% and 28.4±7.1% (Log Rank test: p<0.001) (Figure 3.1). RS rates did not 
show large discrepancies with the estimates for OS except for the elderly: 5- and 10-year RS 
rates were 52.0% and 46.1%, respectively.
Figure 3.1:  Kaplan-Meier survival curves - The Kaplan-Meier curves of overall survival per 
variable.
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Table 3.1: Patient characteristics – Localised disease. RT: radiotherapy; CT: chemotherapy; # 
the group ‘other’ consisted of lung (n=14), mediastinum (n=8), (retro)peritoneum (n=5), kidney 
(n=3), stomach (n=2) and unknown (n=1), * data before imputation.
Variable Total After  imputation
Children 
<18yr
Young 
adults 
18-34yr
Adults 
35-64yr
Elderly 
≥65ys
p-value 
chi2
Number of patients 461 (100%) 54 (11.7%) 148 (32.1%) 204 (44.3%) 55 (11.9%)
Sex
 ◦ Male
 ◦ Female
248 (53.8%)
213 (46.2%)
31 (57.4%)
23 (42.6%)
88 (59.5%)
60 (40.5%)
98 (48.0%)
106 (52.0%)
31 (56.4%)
24 (43.6%)
0.168
Histology
 ◦ Monophasic
 ◦ Biphasic
 ◦ Unknown
103 (22.3%)
109 (23.6%)
249 (54.0%)
(48.3%)
(51.7%)
15 (53.3%)*
14 (46.7%)*
34 (43.7%)*
44 (56.3%)*
41 (47.3%)*
43 (52.7%)*
13 (59.3%)*
8 (40.7%)*
0.496
Tumour size
 ◦ ≤5cm
 ◦ >5cm
 ◦ Unknown
183 (39.7%)
208 (45.1%)
70 (15.2%)
(45.2%)
(54.8%)
16 (43.7%)*
18 (56.3%)*
73 (53.8%)*
60 (46.2%)*
76 (41.7%)*
100 (58.3%)*
18 (36.3%)*
30 (63.7%)*
0.107
Tumour depth
 ◦ Superficial
 ◦ Deep
 ◦ Unknown
102 (22.1%)
110 (23.9%)
249 (54.0%)
(48.8%)
(51.2%)
8 (46.5%)*
9 (53.5%)*
37 (52.1%)*
35 (47.9%)*
44 (46.0%)*
54 (54.0%)*
13 (52.9%)*
12 (47.1%)*
0.832
Site of origin
 ◦ Extremities
 ◦ Head and neck
 ◦ Trunk
 ◦ Other#
303 (65.7%)
39 (8.5%)
86 (18.7%)
33 (7.2%)
35 (64.8%)
8 (14.8%)
10 (18.5%)
1 (1.9%)
107 (72.3%)
11 (7.4%)
23 (15.5%)
7 (4.7%)
129 (63.2%)
15 (7.4%)
39 (19.1%)
21 (10.3%)
32 (58.2%)
5 (9.1%)
14 (25.5%)
4 (7.3%)
0.161
Primary treatment
 ◦ Surgery only
 ◦ Surgery + RT (+CT) 
 ◦ Surgery + CT 
 ◦ No surgery
158 (34.3%)
219 (47.5%)
39 (8.5%)
45 (9.8%)
16 (29.6%)
25 (46.3%)
11 (20.4%)
2 (3.7%)
51 (34.5%)
76 (51.4%)
14 (9.5%)
7 (4.7%)
77 (37.8%)
94 (46.1%)
11 (5.4%)
22 (10.8%)
14 (25.5%)
24 (43.6%)
3 (5.5%)
14 (25.5%)
<0.001
Hospital of surgery
 ◦ General hospital
 ◦ Academic hospital
 ◦ No surgery
179 (43.0%)
237 (57.0%)
45
13 (25.0%)
39 (75.0%)
59 (41.8%)
82 (58.2%)
87 (47.8%)
95 (52.2%)
20 (48.8%)
21 (51.2%)
0.026
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Variable Total After imputation
Children
<18yr
Young 
adults
18-34yr
Adults
35-64yr
Elderly
≥65ys
p-value
chi2
Resection status
 ◦ R0 / Rx
 ◦ R1 / R2
 ◦ No surgery
361 (86.8%)
55 (13.2%)
45
50 (96.2%)
2 (3.8%)
123 (87.2%)
18 (12.8%)
154 (84.6%)
28 (15.4%)
34 (82.9%)
7 (17.1%)
0.152
Univariable analyses (Table 3.2) identifi ed age at diagnosis, tumour size, tumour depth and 
site of origin as having a signifi cant impact on the prognosis of synovial sarcoma patients 
(p<0.1), and these factors were included in the multivariable analysis. In the multivariable 
analysis (Figure 3.2), age turned out to be an independent prognostic indicator for OS, with 
increasing age at diagnosis contributing to a higher risk of death. Compared to children, AYAs 
had a hazard ratio (HR) of 2.29 (95%CI 1.10-4.77), while this was 4.10 for adults (95%CI 
2.03-8.29) and 6.18 in the elderly (95% CI 2.83-13.49). In addition, patients with a larger 
tumour size did signifi cantly worse compared to tumours ≤5cm (HR 2.89; 95%CI 1.94-4.32). 
Considering primary site, patients with their primary tumour located in the trunk had the 
worst prognosis (HR 2.07; 95%CI 1.39-3.07). Patients with their tumour located in the head 
or neck (HR 1.30; 95%CI 0.73-2.34) or other sites (HR 1.75; 95%CI 0.82-3.71) had similar 
survival rates as patients with a tumour in the extremity. Tumour depth had no signifi cant 
impact (HR 1.44; 95%CI 0.80-2.62). 
Figure 3.2:  Multivariable Cox regression analysis. Multivariable analysis with the hazard ratio 
(HR) for risk of death.
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Table 3.2: Univariable Cox regression analyses. 1Excluding “No surgery”, 2including “No 
surgery”; OS = overall survival, RS = relative survival.
Group OS p-value RS
5y (95% CI) 10y (95% CI) 5y (95% CI) 10y (95% CI)
Total 63.1% (58.3–67.5%) 53.9% (48.8–58.7%) 64.8% (59.9–69.3%) 57.1% (51.7–62.2%)
Age groups
 ◦ <18 years
 ◦ 18–34 years
 ◦ 35–64 years
 ◦ ≥65 years
89.3% (76.0–95.4%)
73.0% (64.7–79.7%)
54.7% (47.4–61.5%)
43.0% (29.2–56.0%)
77.0% (59.8–87.5%)
64.0% (54.9–71.7%)
47.5% (40.0–54.6%)
28.4% (15.7–42.5%)
 
<0.001 89.3% (75.9–95.4%)
73.4% (65.1–80.0%)
55.9% (48.4–62.7%)
52.0% (35.3–67.8%)
77.1% (59.9–87.7%)
64.3% (55.2–72.1%)
49.8% (42.0–57.7%)
46.1% (25.7–68.7%)
Sex
 ◦ Male
 ◦ Female
61.6% (55.0–67.5%)
64.8% (0–0%)
50.7% (43.6–57.3%)
57.8% (50.2–64.5%)
0.169 63.7% (56.8–69.8%)
66.2% (58.9–72.6%)
54.1% (46.5–61.1%)
60.6% (52.7–67.8%)
Histology 
 ◦ Monophasic
 ◦ Biphasic
66.3% (55.6–75.0%)
63.6% (52.9–72.5%)
59.0% (47.2–69.0%)
58.2% (47.2–67.7%)
0.812 67.9% (57.1–76.8%)
65.5% (54.6–74.6%)
61.6% (49.2–72.2%)
62.5% (50.7–72.6%)
Tumour size
 ◦ ≤5cm
 ◦ >5cm
81.5% (74.9–86.6%)
46.4% (39.2–53.3%)
72.9% (65.2–79.2%)
34.7% (27.6–41.9%)
<0.001 83.9% (77.0–89.1%)
47.7% (40.3–54.8%)
77.8% (69.6–84.5%)
36.5% (29.0–44.1%)
Tumour depth
 ◦ Superficial
 ◦ Deep
72.4% (62.1–80.4%)
52.6% (42.1–62.1%)
63.2% (51.6–72.7%)
41.3% (30.3–51.9%)
0.003 74.9% (64.2–83.1%)
54.2% (43.4–63.9%)
66.9% (54.4–77.1%)
43.5% (31.9–54.7%)
Site of origin 
 ◦ Extremities
 ◦ Head and neck
 ◦ Trunk
 ◦ Other
70.4% (64.7–75.4%)
77.4% (59.6–88.1%)
45.8% (34.5–56.4%)
23.2% (9.8–39.9%)
62.6% (56.3–68.2%)
66.1% (46.6–79.9%)
30.2% (19.9–41.1%)
23.2% (9.8–39.9%)
<0.001 72.4% (66.6–77.6%)
78.7% (60.4–89.7%)
46.8% (35.3–57.6%)
24.1% (10.3–41.2%)
66.5% (59.9–72.5%)
68.7% (48.3–83.1%)
31.4% (20.7–42.7%)
25.4% (10.9–43.4%)
Primary treatment
 ◦ Surgery only
 ◦ Surgery + 
radiotherapy 
(+chemotherapy)
 ◦ Surgery + 
chemotherapy
 ◦ No surgery
64.6% (56.2–71.8%)
72.1% (65.3–77.7%)
48.1% (31.1–63.2%)
26.1% (14.0–40.0%)
56.8% (48.1–64.5%)
60.3% (52.5–67.1%)
44.4% (27.5–60.0%)
19.6% (8.8–33.5%)
0.271
<0.0012
66.3% (57.7–73.6%)
74.2% (67.2–80.1%)
48.8% (31.7–64.0%)
27.8% (15.1–42.3%)
60.0% (50.9–68.2%)
64.1% (55.8–71.4%)
45.5% (28.3–61.4%)
21.4% (9.6–36.7%)
Hospital of surgery
 ◦ General hospital
 ◦ Academic hospital
71.0% (63.5–77.2%)
63.9% (57.0–69.9%)
60.8% (52.8–67.8%)
55.1% (47.7–61.9%)
0.372 73.1% (65.4–79.4%)
50.7% (0–0%)
65.1% (56.5–72.7%)
57.8% (0–0%)
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Group OS p-value RS
5y (95% CI) 10y (95% CI) 5y (95% CI) 10y (95% CI)
Resection status
 ◦ R0 / Rx
 ◦ R1 / R2
68.0% (62.7–72.7%)
60.2% (45.1–72.3%)
58.9% (53.1–64.2%)
48.1% (32.3–62.3%)
0.239 69.8% (64.4–74.7%)
61.4% (45.9–73.9%)
62.3% (56.2–67.9%)
50.8% (33.7–66.1%)
Discussion
To our knowledge, this is the largest study reporting on age-related survival in synovial sarcoma 
patients with localised disease. Several smaller studies have attempted to demonstrate this age-
related survival effect in patients with localised synovial sarcoma. Interestingly, almost none 
of these studies, all with different cut-off points, were able to detect a signifi cant prognostic 
effect of age on patient outcome (Table 3.3). Nonetheless, a trend towards worse survival at 
higher age may be presumed, and our study demonstrated a signifi cant survival difference 
across age groups in synovial sarcoma patients with localised disease at diagnosis. As no 
information was available on disease-specifi c survival we also calculated relative survival 
rates to account for the general effect of age on mortality. The association of lower relative 
survival rates accompanying increasing age was also observed here. The drop in survival 
rates between 5 and 10 years across all age groups confi rms the occurrence of late relapses in 
synovial sarcoma. In addition, the data show that this phenomenon occurs in all age groups.
The multivariable analysis identifi ed older age, larger tumour size and primary tumour 
localisation in the trunk as independent prognostic factors for worse overall survival in 
synovial sarcoma patients. As both tumour size and primary tumour localisation were equally 
distributed over the age groups, we do not believe that they accounted for the observed age-
related survival effect. 
Main limitations of this study concern the retrospective character of the data collection, and 
the long period over which data were resembled in which molecular diagnostics were fi rst 
introduced and subsequently improved, which could have improved the fi nal diagnostics. 
However, we do expect misdiagnosed cases to be evenly distributed across all age groups.
As this study is national-wide registry based, it is based on diagnosis made by pathologist 
from different hospitals, of whom many will not be sarcoma-dedicated. This could possibly 
explain the large proportion of pathology reports that lacked information on the synovial 
sarcoma subtype. The same is true with respect to residual disease status where reporting was 
inadequate in more than half of the surgical resections (51.9%). 
In addition, since the SYT-SSX translocation test has become a standard procedure only in 
recent years, translocations status is not yet included in the NCR database. As the fi rst steps 
in sarcoma care centralization have only been taking place in the Netherlands since 2012, 
improvements in pathology reporting are to be expected in the forthcoming years. 
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Table 3.3: Literature review age related studies of SyS patients with localised disease at 
diagnosis. *p-value based on the multivariable analysis. OS = overall survival, RR = relative 
survival, EFS= event free survival, DSS = disease-specific survival, yr = year
Study Nr of patients Age groups Stage Outcome p-value
Present study 461 <18 years 
18-34 years 
35-64 years 
≥65 years
Localised disease 5yr OS 89%  
10yr OS 77% 
5yr OS 73%  
10yr OS 64% 
5yr OS 55%  
10yr OS 48% 
5yr OS 43%  
10yr OS 28% 
OS p<0.001*
6 250 <18 years
18-65 years
>65 years
Localised disease 5yr OS 89%
5yr OS 71%
5yr OS 73%
p=0.09*
7 215 ≤16 years
17-30 years
>30 years
Localised disease, with 
macroscopic resection
5yr OS 78.5%
5yr OS 72.4%
5yr OS 66.0%
Not reported
8 150 ≤ 20 years
>20 years
Localised disease 10yr OS 69%
10yr OS 54%
p=0.04*
9 138 <10 years
10-21 years
Localised disease 3yr OS 100%
3yr OS 96%
p=0.7827
10 128 ≤ 33 years
>33 years
Localised disease 5yr DSS 66.9%
5yr DSS 58.7%
p=0.294
11 102 ≤30 years
>30 years
Localised disease 5yr EFS 70.9% 
5yr EFS 68.6%
p=0.47
12 77 ≤11 years
12-20 years
Localised disease 5yr OS 81%
5yr OS 80%
p=0.60
13 69 <40 years
>40 years
Stage I-III 5yr OS 63%
5yr OS 65%
p=0.808
14 51 <20 years
≥20 years
Localised disease 5yr OS 100% 
5yr OS 55.2%
p=0.042*
 
Synovial sarcomas may well consist of hitherto undetermined subtypes, with different 
types occurring at different ages. Therefore, we hypothesize that tumour-genetic differences 
underlie the age effect, which has also been suggested in the study by Lagarde5, who showed 
increased chromosome instability in adult versus pediatric synovial sarcoma patients.
In conclusion, our study demonstrated that outcomes of patients with synovial sarcoma 
significantly decreases with age regardless of primary tumour site, size and treatment. However, 
none of the variables included in this study seems to provide an adequate explanation for 
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the observed difference in survival. The results of this study are of utmost importance when 
designing future clinical studies for localised synovial sarcoma, taking age as prognostic 
factor into account. Further exploration of differences in tumour biology between different 
age groups may aid in adapting new treatments directed at tumour-specifi c characteristics.
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Abstract
INTRODUCTION: Previous studies in metastatic soft tissue sarcomas (STS) showed that 
synovial sarcomas tend to have better survival rates and a higher chemosensitivity than other 
STS subtypes. However, data are derived from relatively small subgroups and statistical 
significance of these observations is lacking. Larger cohorts are necessary to define and 
confirm the specific characteristics of this subtype.
PATIENTS AND METHODS: Patient data were retrieved from 15 European Organisation 
for Research and Treatment of Cancer advanced first-line STS trials. Patient characteristics, 
survival and treatment response of synovial sarcoma patients were compared to other STS 
patients. Univariable and multivariable analyses were performed to evaluate prognostic 
factors.
RESULTS: In total, 3330 advanced STS patients were retrieved, of whom 313 had a synovial 
sarcoma. Synovial sarcoma patients were significantly younger (median 40 versus 52 years), 
more often had extremity primary tumours and had a better performance status (PS 0: 50.2 
versus 43.4%) compared to other STS patients. Additionally, synovial sarcoma patients had 
a significantly better response to chemotherapy (responders: 27.8 versus 18.8%) and better 
survival rates (prgression free survival (PFS): 6.3 versus 3.7 months; overall survival (OS): 
15.0 versus 11.7 months). Age, PS, and presence of metastatic disease were defined as 
prognostic factors for PFS and OS in the univariable analysis. The last two factors were 
confirmed in the multivariable analysis for OS.
DISCUSSION: Advanced synovial sarcomas are a distinct subgroup of STS, with a better 
response to systemic chemotherapy and longer PFS and OS. These results should be taken 
into account in the design of future synovial sarcoma specific studies.
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Introduction
Synovial sarcoma is a soft tissue sarcoma (STS) subtype, which accounts for approximately 
6% of all STS1. Synovial sarcomas occur at all ages and primary tumours are localised 
throughout the body, with a predilection for the extremities of young adults. They show a range 
from indolent to highly aggressive behaviour, resulting in a 5-year cancer specifi c survival of 
66%2. In contrast to the usually early recurrence (median 38.3 months) and development 
of metastases (median 41.3 months) in primary STS3, a long follow-up study with synovial 
sarcoma patients reported local recurrence and metastases after a mean of 3.6 (range 0.5–15) 
and 5.7 years (range 0.5–16), respectively4. Its unique t(X;18)(p11.2;q11.2) translocation 
helps to defi ne the diagnosis and distinguishes this subtype from other STS. The mechanism 
underlying the translocation, which produces a SS18-SSX fusion protein has recently been 
elucidated5. In essence, the fusion protein displaces the wild-type SS18 protein from mSWI/
SNF (BAF) tumour suppressor complexes resulting in upregulation of Sox2 expression and 
downstream signalling. When synovial sarcoma patients are diagnosed with metastatic or non-
resectable disease, palliative chemotherapy can be given to prolong survival. Interestingly, 
synovial sarcoma patients with advanced disease receiving palliative chemotherapy have 
better survival rates compared to other advanced STS patients, and this has been confi rmed 
in several different studies6-10. The explanation for the better survival rates could possibly 
be the younger age at diagnosis or increased chemosensitivity. However, so far no study has 
had suffi cient numbers of patients and performed these specifi c synovial sarcoma analyses 
to set new survival endpoints, or to explicitly defi ne the prognostic differences between 
this particular subtype and other advanced STS patients. We believe further exploration of 
these differences could help us understand the reported better survival rates of this specifi c 
subtype. Also, suffi cient basic knowledge about potential prognostic factors in the different 
STS subtypes is a pre-requisite for successfully designing future STS studies that will aim 
to address the effi cacy of chemotherapeutic and novel systemic therapies. Therefore, we 
performed a retrospective study based on the EORTC Soft Tissue and Bone Sarcoma Group 
database. We studied the demographics and outcome of a large subset of advanced synovial 
sarcoma patients treated in fi rst-line palliative chemotherapy studies between 1976 and 2012 
and compared these results with other advanced STS patients treated in these studies. 
Patients and Methods
STUDY POPULATION: the EORTC database was used to extract patient information from 
15 EORTC trials of patients with locally advanced and metastatic STS treated with fi rst-line 
systemic treatment between 1976 and 2012. Details on eligibility criteria, treatment regimens 
and outcomes have been published previously11-24. Patients who received prior (adjuvant or 
palliative) chemotherapy, for whom histology was gastrointestinal stromal tumour (GIST) or 
missing, or for whom survival time was missing, were excluded from this analysis.
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END-POINTS: The end-points of interest were progression free survival (PFS), overall 
survival (OS) and response to chemotherapy. PFS was the time elapsing from study 
registration or randomization, depending on the study, to first progression or death, whichever 
occurred first. Patients were censored who were alive and without progressive disease at the 
last follow-up. OS was the time between the study registration or randomization and reported 
date of death. Patients alive at the last follow-up were censored. Response to chemotherapy 
was evaluated in all trials using World Health Organisation response criteria or Response 
Evaluation Criteria in Solid Tumours. 
EXPLORED COVARIATES: Demographic data included age, sex, and performance 
status (PS) at study entry. Additionally, data on disease localisation and involvement of 
metastases were collected. Variables related to the history of sarcoma included the use of 
prior radiotherapy and prior surgery, and the time since the first diagnosis of sarcoma (in 
years). Histological subtype as reviewed by a panel of reference pathologists, was preferred 
to the use of local diagnosis, to ensure the consistency and homogeneity of the data. The 
local histological diagnosis was used in approximately 40% of patients. Histological subtypes 
were aggregated in two groups: synovial sarcoma and other STS subtypes. The treatment 
was aggregated in five categories: anthracyclines alone (doxorubicin (DOX) 75, Caelyx 50, 
epirubicin 75, epirubicin 3*50, epirubicin 1*150), ifosfamide (IFO) alone (IFO 5 g/m2/24 
h, IFO 3 days 3 g/m2, IFO 9 g/m2 continuously in 3 days, IFO 12 g/m2 continuously in 3 
days), the combination of DOX and IFO (DOX 50-IFO 5, DOX 75-IFO 5, DOX 75-IFO 
10), CYVADIC (cyclophosphamide, vincristine, DOX and dacarbazine) and other treatments 
(brostallicin, trabectedine).
STATISTICAL METHODS: The statistical test used for comparing the baseline characteristics 
among the synovial sacoma patients versus the other STS patients was a chi-square (or a Fisher) 
test for categorical covariates and a (non-parametric) Kruskall-Wallis test for the continuous 
variables. PFS and OS are visualised through Kaplan-Meier curves and compared between the 
group of synovial and non-synovial STS patients using a logrank test. Response to treatment 
is compared between the two patient groups using a trend test for the ordinal assessment 
(complete response (CR), partial response (PR), stable disease (SD) and progressive disease 
(PD)). Stratified analyses for these parameters are performed using the Cochran-Mantel-
Haenszel (CMH) general association test. 
For the prognostic factor analysis, only synovial sarcoma patients were considered. 
Hazard ratios (HRs) were calculated for the covariates investigated in the study, including 
demographic data pertaining to the patients, information related to the history of the sarcoma 
and its treatment, the histology characteristics and treatment received within the context of 
the aforementioned clinical trials. As the information on prior radiotherapy or prior surgery 
was not collected in the more recent trials (62012, 62061 and 62091), these variables were 
not considered in the univariable and multivariable analyses. The potential prognostic value 
of all other factors was first investigated by univariable analysis, using univariable Cox or 
logistic regression models according to the outcome. The prognostic value of the factors was 
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subsequently assessed in a multivariable model, using backward selection. The PFS and OS 
Kaplan-Meier curves are presented for factors that were found to be signifi cant.
To protect against a considerable loss of information for the multivariable analysis due to 
the substantial amount of missing data in the assessment of site of primary, we considered 
for this covariate the “missing” as a separate category in all the models. Sensitivity analyses 
were performed to study the impact of this approach on the fi nal interpretation of the models. 
Collinearity between the factors of interest could affect the outcome of the multivariable 
analyses. To assess whether such correlations were present, the variance infl ation factor (VIF) 
for each covariate was determined, with a cut-off of VIF >5 implicating high multicollinearity 
requiring remedial measures25, however no multicollinearity was found between the included 
parameters. The statistical signifi cance was set at 0.05 for all analyses described in this report. 
All analyses were performed using SAS v9.4.
Table 4.1:  EORTC studies included. R = randomized; CYVADIC = cyclophosphamide, 
vincristine, doxorubicin, dacarbazine; DOX = doxorubicin; IFO = ifosfamide; EPI = epirubicin
Study Trt Arm A (N) Trt arm B (N) Trt Arm C (N)
N contributing 
to this substudy
Total = 3330
1. EORTC 62761 R. Ph II CYVADIC FU (191) CYVADIC Cy (121) 270
2. EORTC 62801 R. Ph II/III DOX 75 (106) EPI 75 (104) 187
3. EORTC 62842 Ph II DOX 50 + IFO 5 (203) 189
4. EORTC 62851 R. Ph III DOX 75 (295) DOX 50 + IFO 5 (297) CYVADIC FU (157) 669
5. EORTC 62883 Ph II DOX 75 + IFO 5 (111) 104
6. EORTC 62901 R. Ph II/III DOX 75 (112) EPI 3*50 (111) EPI 1*150 (111) 315
7. EORTC 62903 R. Ph III DOX 50 + IFO 5 (157) DOX 75 + IFO 5 (157) 295
8. EORTC 62912 R. ph II IFO 5 (93) IFO 3*3 (89) 102
9. EORTC 62941 R. Ph II DOX 75 (42) DOCETAXEL (44) 40
10. EORTC 62953 Ph II IFO 12 (124) 92
11. EORTC 62962 R. Ph II DOX 75 (45) Caelyx (50) 89
12. EORTC 62971 R. Ph III DOX 75 (110) IFO 3*3 (109) IFO 9 (107) 294
13. EORTC 62012 R. Ph III DOX 75 (228) DOX 75 + IFO 10 (227) 435
14. EORTC 62061 R. Ph II DOX 75 (39) Brostallicin (N=79) 116
15. EORTC 62091 R. Ph II DOX 75 (43) Trabectedin 3hrs (N=47) 
Trabectedin 24hrs 
(N=43) 
133
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Results
In total, 3711 locally advanced and/or metastatic patients treated with first-line systemic 
treatment were retrieved from the EORTC database, of which 3330 were included for 
the descriptive part of this report (Figure 4.1, Table 4.1). Of these, 313 patients were 
diagnosed with a synovial sarcoma. Of the other subtypes, the largest group consisted of 
leiomyosarcomas (35.2%). Compared to other STS patients, metastatic synovial sarcoma 
patients were significantly more often male (61 versus 48%), had a better PS (PS 0: 50 versus 
43%) and had a significantly lower median age at diagnosis (40 versus 52 years) (Table 
4.2). The primary tumour of a significant number of metastatic synovial sarcomas had been 
located in the extremities (56%) in comparison with the other STS (23%). Detailed tumour 
localisation is reported below Table 4.2, with the trunk being the most common non-extremity 
primary site in metastatic synovial sarcomas. Pulmonary metastases were significantly more 
prevalent in synovial sarcoma patients (80%) than in other patients (55%). The median 
follow-up of synovial sarcoma patients who were alive at the time of their respective study 
clinical cut-off date was 18.6 months (interquartile range (IQR): 9-35 months), comparable 
to the 18.5 months (IQR: 7.1-38.0) of other STS patients. Synovial sarcoma patients had a 
significantly higher PFS (median: 6.3 months, 95% confidence interval (CI) 5.9-7.0; 1 year 
% 18.7, 95%CI 14.6-23.3) and OS (median: 15.0 months, 95%CI 13.9-16.4; 1 year % 63.7, 
95%CI 57.9-68.8) compared to the PFS (median: 3.7 months, 95%CI 3.5-3.9; 1 year % 16.6, 
95%CI 15.3-18.0) and OS (median: 11.7 months, 95%CI 11.2-12.1; 1 year % 48.8, 95%CI 
46.5-50.2) of other STS patients, with a p-value of 0.002 and 0.011 respectively (Figure 4.2). 
As patients with a synovial sarcoma were significantly younger than patients with another 
STS subtype, a sensitivity analysis was performed, stratified by the age categories, to study 
whether the better outcome would be driven by the age difference. The difference in PFS and 
OS is now less evident, with a p-value of 0.066 and 0.052 respectively, so at least part of the 
observed difference can be attributed to age. Table 4.3 provides the distribution of response 
per treatment category and for synovial sarcoma patients versus other STS patients. The 
analysis of treatment response indicated that there were 87 (27.8%) synovial sarcoma patients 
Figure 4.1: CONSORT diagram. CONSORT diagram. GIST = gastrointestinal stromal tumour. 
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responding to chemotherapy, in contrast to 568 (18.8%) of other STS patients. This difference 
is signifi cant between the two groups considering CR, PR, SD and PD as separate categories 
(trend test p-value <0.001). This remains signifi cant when stratifi ed for age considering the 
CR, PR, SD and PD categories (CMH test: p<0.001).
The univariable analysis investigated the potential prognostic value of different variables for 
PFS and OS in synovial sarcoma patients (Table 4.4). As expected, a worse PS resulted in a 
higher HR, and patients with metastatic disease had a two-fold HR than patients with local 
disease only. A higher age also contributed to a higher HR in both PFS as OS. There was no 
effect of any specifi c treatment in the prognostic factor analysis. In the multivariable analysis, 
age, PS, and metastatic site involved remained signifi cant for PFS, however age was not 
Figure 4.2:  Survival in synovial sarcoma patients versus other STS patients. Kaplan-Meier 
curves comparing progression free survival (A) and overall survival (B) between synovial 
sarcoma and other STS patients. STS = soft tissue sarcomas.
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confirmed for OS. Kaplan-Meier curves for all significant variables for both PFS and OS are 
shown in Figure 4.3. In a univariable analysis for treatment response, none of the variables 
treatment, gender, age, PS, primary tumour site, metastatic sites involved or time since initial 
diagnosis were significant.
Figure 4.3: Survival curves for different variables, including performance status, age and 
metastatic site involved, in synovial sarcoma patients. Kaplan-Meier curves showing the 
effect of the parameters with significant effect in the univariable analysis in synovial sarcoma 
patients for both progression free survival (A, C and E) and overall survival (B, D and F). 
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Table 4.2:  Patient characteristics. DOX = doxorubicin; CYVADIC = cyclophosphamide, 
vincristine, doxorubicin, dacarbazine; IFO = ifosfamide. 1Performance status was measured on 
the World Health Organisation (WHO) scale (except for two trials in which it is retrospectively 
converted from Karnosky scale to the WHO scale). As few patients have a level 2 or 3, the levels 
2 and 3 were combined in one category named “performance status 2+”. 2Metastatic site involved 
captures whether metastatic lesions were present at the time of this assessment. 3Frequencies of 
disease involvement at entry are not cumulative frequencies. 4Consisting of trunk (n=15; 4.8%), 
head and neck (n=12; 3.8%), abdominal (n=10; 3.2%), thorax (n=9; 2.9%), gastrointestinal 
(n=3; 1.0%), skin (n=1; 0.3%), visceral gynaecological (n=1; 0.3%) and other (n=1; 0.3%). Of 
87 (27.8%) patients information about primary tumour localisation was missing. 5Consisting 
of lower extremity (n=129; 41.2%) and upper extremity (n=45; 14.4%). 6Consisting of trunk 
(n=131; 4.3%), head and neck (n=78; 2.6%), abdominal (n=454; 15.0%), thorax (n=170; 5.6%), 
gastrointestinal (n=172; 5.7%), skin (n=20; 0.7%), visceral gynaecological (n=342; 11.3%), 
genitourinary (n=44; 1.5%), visceral breast (n=24; 0.8%), other visceral (n=20; 0.7%) and other 
(n=18; 0.6%). Of 837 (27.7%) patients information about primary tumour localisation was 
missing. 7Consisting of lower extremity (n=538; 17.8%) and upper extremity (n=169; 5.6%)
Tumour type
Total
(N=3330)
P-value 
a Chi-square test
b Kruskal -Wallis test
Synovial sarcoma
(N=313)
Other types
(N=3017)
N (%) N (%) N (%)
Treatment Descr. only
 Anthracyclines 121 (38.7) 1167 (38.7) 1288 (38.7)
 DOX+IFO 112 (35.8) 955 (31.7) 1067 (32.0)
 CYVADIX 30 (9.6) 389 (12.9) 419 (12.6)
 IFO 42 (13.4) 347 (11.5) 389 (11.7)
 other 8 (2.6) 159 (5.3) 167 (5.0)
Gender <0.001a
 Male 191 (61.0) 1446 (47.9) 1637 (49.2)
 Female 122 (39.0) 1567 (51.9) 1689 (50.7)
 Missing 0 (0.0) 4 (0.1) 4 (0.1)
Age <0.001 a
 < 35 years 117 (37.4) 402 (13.3) 519 (15.6)
 35-64 years 181 (57.8) 2163 (71.7) 2344 (70.4)
 >=65 years 12 (3.8) 405 (13.4) 417 (12.5)
 Missing 3 (1.0) 47 (1.6) 50 (1.5)
 Median (years) 40 52 51 <0.001b
 Range 18 - 81 10 - 88 10 - 88
 Q1-Q3 27 - 51 42 - 60 41 - 60
Performance status1 0.022 a
 PS 0 157 (50.2) 1310 (43.4) 1467 (44.1)
 PS 1 136 (43.5) 1388 (46.0) 1524 (45.8)
 PS 2+ 16 (5.1) 262 (8.7) 278 (8.3)
 Missing 4 (1.3) 57 (1.9) 61 (1.8)
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Tumour type
Total 
(N=3330)
P-value 
a Chi-square test 
b Kruskal -Wallis test
Synovial sarcoma 
(N=313)
Other types 
(N=3017)
N (%) N (%) N (%)
Site of primary tumour <0.001 a
 Other 52 (16.6)4 1473 (48.8)6 1525 (45.8)
 Extremity 174 (55.6)5 707 (23.4)7 881 (26.5)
 Missing 87 (27.8) 837 (27.7) 924 (27.7)
Prior Surgery 0.353 a
 No 31 (9.9) 287 (9.5) 318 (9.5)
 Partial 56 (17.9) 651 (21.6) 707 (21.2)
 Total 78 (24.9) 703 (23.3) 781 (23.5)
 Missing 148 (47.3) 1376 (45.6) 1524 (45.8)
Prior radiotherapy <0.001 a
 No 170 (54.3) 2003 (66.4) 2173 (65.3)
 Yes 128 (40.9) 768 (25.5) 896 (26.9)
 Missing 15 (4.8) 246 (8.2) 261 (7.8)
Time since initial diagnosis 0.013 a
 <=6 months 132 (42.2) 1516 (50.2) 1648 (49.5)
 6-12 months 44 (14.1) 353 (11.7) 397 (11.9)
 1-2 yrs. 44 (14.1) 407 (13.5) 451 (13.5)
 > 2yrs 81 (25.9) 587 (19.5) 668 (20.1)
 Missing 12 (3.8) 154 (5.1) 166 (5.0)
 Median (months) 8.6 6.4 6.6 0.003 b
 Range 0.0 - 229.6 0.0 - 346.5 0.0 - 346.5
 Q1-Q3 1.8 - 28.2 1.4 - 18.6 1.4 - 19.5
Metastatic Site involved2 0.003
 No 26 (8.3) 434 (14.4) 460 (13.8)
 Yes 286 (91.4) 2573 (85.3) 2859 (85.9)
 Missing 1 (0.3) 10 (0.3) 11 (0.3)
Disease involvement at registration3 
 Bone metastases 31 (9.9) 321 (10.6) 352 (10.6) 0.687
 Liver metastases 14 (4.5) 562 (18.6) 576 (17.3) <0.001
 Lung metastases 251 (80.2) 1669 (55.3) 1920 (57.7) <0.001
 Other metastases 83 (26.5) 1239 (41.1) 1322 (39.7) <0.001
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Table 4.3:  Response to treatment. DOX = doxorubicin; CYVADIC = cyclophosphamide, 
vincristine, doxorubicin, dacarbazine; IFO = ifosfamide; CR = complete response; PR = partial 
response; SD = stable disease; PD = progressive disease
Treatment
Total
(N=313)
Tumour type
Anthra-
cyclins
(N=121)
DOX + 
IFO
(N=112)
CY-
VADIC
(N=30)
IFO
(N=42)
other
(N=8)
Synovial
sarcoma
(N=313)
Other
types
(N=3017)
Total
(N=3330)
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Best overall response       
 CR 1 (0.8) 7 (6.3) 3 (10.0) 0 (0.0) 0 (0.0) 11 (3.5) 11 (3.5) 106 (3.5) 117 (3.5) 
 PR 25 (20.7) 29 (25.9) 7 (23.3) 14 (33.3) 1 (12.5) 76 (24.3) 76 (24.3) 462 (15.3) 538 (16.2) 
 SD 55 (45.5) 57 (50.9) 9 (30.0) 20 (47.6) 3 (37.5) 144 (46.0) 144 (46.0) 1149 (38.1) 1293 (38.8) 
PD 33 (27.3) 13 (11.6) 9 (30.0) 4 (9.5) 4 (50.0) 63 (20.1) 63 (20.1) 1045 (34.6) 1108 (33.3) 
 Not evaluable 7 (5.8) 6 (5.4) 2 (6.7) 4 (9.5) 0 (0.0) 19 (6.1) 19 (6.1) 255 (8.5) 274 (8.2) 
Table 4.4:  Univariable analyses in synovial sarcoma patients. PFS = progression free survival; 
CI = confi dence interval; df = degrees of freedom; DOX = doxorubicin; IFO = ifosfamide; 
CYVADIC = cyclophosphamide, vincristine, doxorubicin, dacarbazine. In bold the signifi cant 
p-values. In italics the missing categories.
PFS
Patients
(N)
Observed
Events
(O)
Median 
(95% CI)
(Months)
% at 1 Year(s)
(95% CI)
Hazard Ratio
(95% CI)
P-Value
(Score test)
Treatment
Anthracyclins 121 115 5.06 (4.30, 6.05) 17.5 (11.2, 24.9) 1.00 0.070 (df=4) 
DOX+IFO 112 110 7.47 (6.51, 8.74) 21.4 (14.4, 29.4) 0.79 (0.60, 1.02)  
CYVADIX 30 29 6.08 (2.99, 10.84) 23.3 (10.3, 39.4) 0.81 (0.54, 1.21)  
ifo ALONE 42 40 7.20 (5.91, 9.23) 15.5 (6.4, 28.5) 0.89 (0.62, 1.27)  
other 8 8 2.27 (0.99, 8.97) 0.0 ( , ) 1.96 (0.95, 4.02)  
Gender
Male 191 186 6.37 (5.29, 7.06) 16.0 (11.2, 21.7) 1.00 0.098 
Female 122 116 6.34 (5.49, 8.25) 23.0 (15.9, 31.0) 0.82 (0.65, 1.04)  
Age
 < 35 years 117 110 8.15 (6.44, 8.64) 21.1 (14.1, 29.0) 1.00 0.000 (df=2) 
35-64 years 181 177 5.98 (4.90, 6.87) 18.2 (12.9, 24.2) 1.24 (0.98, 1.58)  
≥ 65 years 12 12 1.64 (0.99, 5.75) 0.0 ( , ) 4.12 (2.24, 7.57)  
Performance 
status
PS 0 157 153 7.59 (6.44, 8.74) 24.7 (18.2, 31.7) 1.00 0.000 (df=2) 
PS 1 136 129 5.91 (4.14, 6.54) 13.7 (8.5, 20.2) 1.34 (1.06, 1.70)  
PS 2+ 16 16 3.55 (1.81, 4.83) 0.0 ( , ) 2.91 (1.72, 4.91)  
Site of 
primary
Other 52 49 7.13 (5.06, 8.94) 22.0 (11.9, 34.2) 1.00 0.455 (df=2) 
Extremity 174 170 6.21 (5.29, 7.10) 16.1 (11.0, 21.9) 1.22 (0.89, 1.69)  
Missing 87 83 6.28 (4.76, 8.08) 22.2 (14.0, 31.5) 1.15 (0.81, 1.63)  
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PFS
Patients 
(N)
Observed 
Events 
(O)
Median  
(95% CI) 
(Months)
% at 1 Year(s) 
(95% CI)
Hazard Ratio 
(95% CI)
P-Value 
(Score test)
Time since 
initial 
diagnosis
≤ 6 months 132 125 5.91 (4.76, 6.97) 18.5 (12.3, 25.6) 1.00 0.191 (df=3)
6-12 months 44 44 6.57 (4.83, 8.15) 9.1 (2.9, 19.7) 1.22 (0.86, 1.73)
1-2 years 44 44 5.98 (3.58, 6.51) 15.9 (7.0, 28.1) 1.21 (0.86, 1.72)
> 2 years 81 78 8.28 (5.62, 9.23) 25.6 (16.6, 35.6) 0.87 (0.65, 1.16)
Metastatic 
site involved
No 26 20 13.57 (8.25, 41.63) 51.1 (30.1, 68.7) 1.00 0.000 
Yes 286 281 6.21 (5.62, 6.70) 16.0 (12.0, 20.5) 3.46 (2.08, 5.75)  
OS
Patients 
(N)
Observed 
Events 
(O)
Median  
(95% CI) 
(Months)
% at 1 Year(s) 
(95% CI)
Hazard Ratio 
(95% CI)
P-Value 
(Score test)
Treatment
Anthracyclins 121 98 14.85 (12.16, 16.23) 62.6 (53.1, 70.8) 1.00 0.914 (df=4) 
DOX+IFO 112 98 14.98 (12.94, 18.89) 66.3 (56.7, 74.3) 1.02 (0.77, 1.35)  
CYVADIX 30 25 15.80 (8.44, 23.13) 58.6 (38.7, 74.1) 0.98 (0.63, 1.52)  
ifo ALONE 42 30 15.34 (11.73, 19.68) 65.6 (48.9, 78.0) 0.92 (0.61, 1.38)
other 8 3 10.45 (0.99, N) 29.2 (1.0, 71.9) 1.63 (0.51, 5.19)  
Gender
Male 191 161 14.92 (13.31, 16.66) 62.7 (55.2, 69.2) 1.00 0.212 
Female 122 93 15.57 (13.14, 18.99) 65.4 (55.9, 73.3) 0.85 (0.66, 1.10)  
Age
 < 35 years 117 95 17.35 (14.92, 20.57) 73.1 (63.8, 80.4) 1.00 0.018 (df=2) 
35-64 years 181 147 14.19 (12.25, 15.70) 59.4 (51.7, 66.2) 1.29 (1.00, 1.67)  
>= 65 years 12 9 10.45 (1.28, 20.30) 45.0 (15.5, 71.0) 2.33 (1.17, 4.64)  
Performance 
status
PS 0 157 121 17.74 (15.47, 19.71) 75.9 (68.2, 82.0) 1.00 0.000 (df=2) 
PS 1 136 114 13.27 (10.81, 15.57) 55.6 (46.6, 63.6) 1.54 (1.19, 1.99)  
PS 2+ 16 15 6.05 (3.12, 8.25) 14.3 (2.4, 36.3) 6.39 (3.66, 11.15)  
Site of 
primary
Other 52 42 14.42 (11.56, 18.73) 63.6 (48.6, 75.3) 1.00 0.953 (df=2) 
Extremity 174 142 15.47 (13.27, 18.14) 63.1 (55.3, 69.9) 0.99 (0.70, 1.40)  
Missing 87 70 14.52 (12.16, 16.89) 64.8 (53.4, 74.1) 1.04 (0.71, 1.52)  
Time since 
initial 
diagnosis
<= 6 months 132 107 14.19 (12.39, 15.87) 61.4 (52.3, 69.3) 1.00 0.194 (df=3)
6-12 months 44 39 14.39 (9.82, 16.43) 64.6 (48.3, 77.0) 1.12 (0.77, 1.61)
1-2 years 44 37 18.14 (12.16, 21.88) 67.6 (51.6, 79.4) 0.86 (0.59, 1.26)
> 2 years 81 61 18.33 (12.65, 23.06) 64.5 (52.6, 74.1) 0.75 (0.55, 1.04)
Metastatic 
site involved
No 26 15 20.93 (12.02, N) 75.4 (53.2, 88.1) 1.00 0.001 
Yes 286 238 14.92 (13.40, 16.07) 62.8 (56.8, 68.3) 2.42 (1.41, 4.14)  
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Discussion
STS are a heterogeneous group of histological diagnoses. They are partly genetically defi ned 
entities that are often lumped together in clinical trials to create larger cohorts. Previously 
most clinical trials on chemotherapy in advanced sarcomas included many histological 
subtypes, while more recently stratifi cations to a certain number of more frequently occurring 
histological subtypes, such as synovial sarcoma, have been used, acknowledging that each 
subtype has its own features and clinical behaviour and can therefore infl uence study results. 
When designing studies for subtypes in STS, it is of utmost importance to have good clinical 
outcome data as comparators. Moreover, it is important to defi ne features that may explain 
differences in response to treatment and survival. 
Previously, the EORTC database has been used to validate clinical behaviour of some specifi c 
sarcoma subtypes, including angiosarcoma and malignant peripheral nerve sheath tumours. 
Both subtypes showed similar clinical outcome compared to the other STS subtypes26,27. 
Interestingly, our retrospective study in more than 300 synovial sarcoma patients shows that 
PFS and OS in this specifi c subtype of STS are considerably better than other STS patients. 
This pooled database shows that synovial sarcoma patients are younger and have better PS, 
which may partly explain the better survival rates, and, when stratifying survival rates for 
age, the signifi cance difference between synovial sarcoma and non-synovial STS patients 
diminishes. Furthermore, synovial sarcoma patients show superior responses to chemotherapy 
than other STS patients, with no specifi c superior treatment regimen. However, even though 
not signifi cant, IFO seemed to be the most active drug, compared to anthracycline alone. 
Until now a limited number of smaller studies have investigated prognostic factors in advanced 
synovial sarcoma patients. A single centre study including 104 advanced synovial sarcoma 
patients showed with a univariable analysis that age (<35 years) and response to fi rst-line 
chemotherapy were prognostic factors for survival28. A second single centre study, including 
33 advanced synovial sarcoma patients, identifi ed in a multivariable analysis, lymph node 
metastases and extra-pulmonary metastases as independent factors associated with OS29. In 
our substantially larger study we re-evaluated possible prognostic factors. Even though age 
has shown to be a signifi cant prognostic factor for OS in localised disease30, in this cohort with 
advanced synovial sarcomas, age was only a signifi cant prognostic factor for PFS, but not for 
OS. Furthermore, better PS has been identifi ed to be a main prognostic factor in this and several 
advanced STS studies, stressing the relevance of patient selection when comparing palliative 
treatment options7,8,10. Additionally, we confi rm the superior chemosensitivity, with higher 
response rates in synovial sarcoma patients compared to other STS patients. Further analysis 
on prognostic factors for response to chemotherapeutic treatment in synovial sarcoma patients 
shows that not any specifi c treatment regimen was superior to another. Patient demographics, 
including age and PS, showed no signifi cant effect on treatment response. Recently, Chakiba 
et al, evaluated an eventual relationship between genomic complexity of synovial sarcomas 
and response to neo-adjuvant chemotherapy, but this could not be established31. 
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Our study has the limitations related to the retrospective character of the analysis where 
heterogeneity may have been introduced by merging data from several clinical trials performed 
over a longer period of time. In addition, part of the studies were performed before 2000, 
which could results in GIST patients to be classified as leiomyosarcomas and therefore to be 
included in our results. Since the contribution of some of the studies to the synovial sarcoma 
patient subset was small, adjusting for this heterogeneity by performing an analysis stratified 
by study was believed to be infeasible. Alternatively, an analysis stratifying by treatment 
rather than study would virtually exclude the small subgroup of patients who participated in 
the 62061 or 62091 treated with brostallicin or trabectedin. Therefore unadjusted results are 
provided, unless specified otherwise. With respect to treatment data, non-randomized trials 
were combined to randomized trials to increase the available sample size. Therefore selection 
biases could have occurred. Some variables contained substantial amounts of missing data, 
partly because not all variables were recorded in all studies. To reduce the loss of power in the 
multivariable analysis, two variables included a seperate category “missing”. 
In conclusion, with this large analysis of pooled data from 15 trials in advanced synovial 
sarcomas, we provide strong evidence that synovial sarcoma patients distinguish themselves 
from other STS, as patients are younger, have better PS and higher chemosensitivity, and show 
better survival rates. The results of this study can be used as new landmark when specifically 
designing trials for synovial sarcoma patients.
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 Next generation sequencing in synovial sarcoma reveals novel 
gene mutations
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Abstract
Over 95% of all synovial sarcomas (SyS) share a unique translocation, t(X;18), however, they 
show heterogeneous clinical behavior. We analyzed multiple SyS to reveal additional genetic 
alterations besides the translocation. Twenty-six SyS from 22 patients were sequenced for 
409 cancer-related genes using the Comprehensive Cancer Panel (Life Technologies, USA) 
on an Ion Torrent platform. The detected variants were verified by Sanger sequencing and 
compared to matched normal DNAs. Copy number variation was assessed in six tumors using 
the Oncoscan array (Affymetrix, USA). In total, eight somatic mutations were detected in 
eight samples. These mutations have not been reported previously in SyS. Two of these, in 
KRAS and CCND1, represent known oncogenic mutations in other malignancies. Additional 
mutations were detected in RNF213, SEPT9, KDR, CSMD3, MLH1 and ERBB4. DNA 
alterations occurred more often in adult tumors. A distinctive loss of 6q was found in a 
metastatic lesion progressing under pazopanib, but not in the responding lesion. Our results 
emphasize t(X;18) as a single initiating event in SyS and as the main oncogenic driver. Our 
results also show the occurrence of additional genetic events, mutations or chromosomal 
aberrations, occurring more frequently in SyS with an onset in adults.
73
Next Generation Sequencing in synovial sarcoma
5
Introduction
Synovial sarcoma (SyS) accounts for approximately 8% of all soft tissue sarcomas. Synovial 
sarcomas occur at all ages and sites throughout the body, with a predilection for the extremities 
of young adults. Patients with a synovial sarcoma have a 5-year cancer-specifi c survival rate 
of 66%, with a remarkable better outcome for children as compared to adults1. Tumors can 
be aggressive, leading to early metastases and recurrences, or can be more indolent occurring 
as a long existing swelling that may recur years after the initial diagnosis2. Predicting tumor 
behavior has been attempted by relating survival to various tumor and patient characteristics. 
Several of these characteristics have been proven to be of negative prognostic value, including 
large tumor size, primary tumor location in non-extremities and older age at diagnosis. The 
mechanism(s) underlying the differences in tumor behavior, however, remain to be resolved3. 
The treatment of localized disease involves surgery often supplemented with (neo)adjuvant 
radiotherapy and, occasionally, with (neo)adjuvant chemotherapy or a combination of both. 
Metastatic disease is treated by palliative chemotherapy or by applying the angiogenesis 
inhibitor pazopanib, with limited survival benefi t4.
Genetic profi ling is believed to be the way forward to explore tumor behavior and to discover 
new therapeutic targets. Currently, genetic screening is being implicated in standard clinical 
practice for several cancers, including melanomas, lung and colon cancers. Interestingly, 
similar mutations are shared by different cancer types, and within one cancer type different 
genetic subtypes can be found, explaining its biologic behavior and/or therapy response. In 
addition, differences in mutations have been observed between primary tumors and their 
metastases, thereby providing insight in tumor evolution and therapy resistance5,6. Importantly, 
these insights have led to the development of new targeted therapies based on the use of 
monoclonal antibodies and tyrosine kinase inhibitors. 
Sarcomas have also been subject to genetic screening, which has led to diagnostic 
implementation in several subtypes7, including gene amplifi cations in well-differentiated 
and dedifferentiated liposarcomas8 or distinct chromosomal translocations in, among others, 
myxoid liposarcomas9. Additionally, the discovery and treatment of the targetable alterations 
in hot spot regions in the KIT or PDGFRA genes in gastrointestinal stromal tumors (GIST) has 
signifi cantly improved overall survival of these patients10,11.
A unique reciprocal translocation between chromosome X and 18 in over 95% of SyS tumors 
was already reported in 1994, leading to fusions between one of the SSX genes (1, 2 or 4) 
and the SS18 (SYT) gene12,13. This translocation is not found in any other human neoplasm. 
It has been shown that the SSX and SS18 (fusion) proteins participate in the SWI/SNF and 
Polycomb complexes, respectively, known to be involved in epigenetic gene (de)regulation14, 
15. As knockdown of the fusion protein leads to cell death in vitro and in vivo and introduction 
of the translocation in mice forms histologically alike tumors16-18, the translocation is believed 
to act as the central oncogenic driver in SyS19. Next to its signifi cance as a diagnostic marker, 
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the clinical targeting of this translocation has so far remained elusive20,21. Also the putative 
predictive value of SyS translocation subtypes has stayed unclear 22,23. 
Table 5.1: Previously reported non-synonymous mutations in synovial sarcoma. *abstract only; 
CL=cell lines.
Gene Examined part Frequency Sample size Somatic Reference
TP53 Exon 2-11 0 5 N/A 48
Exon 5-9 6 (12%) 49 Not validated 49
Unknown 1 1 Yes 50*
Exon 5-8 2 (6%) 34 Not validated 51
TERT C250T + C228T 1 25 + 5CL Not validated 52
EGFR Exon 18-21 1 (8%) 12 Not validated 53
Exon 18-21 1 (50%) 2 Yes 54
CDH1 Exon 4-9 12 (24%) 49 Yes 55
Exon 4-9 5 (12.5%) 40 Not validated 56
Unknown 1 (6%) 16 Not validated 57
CTNNB1 Exon 3 4 (8%) 49 Not validated 58
Exon 3 0 15 N/A 59
Unknown 2 (12.5%) 16 Not validated 57
Exon 3 1 (20%) 5CL Not validated 38
APC Exon 15 4 (8%) 49 Yes 60
Unknown 0 16 N/A 57
Coding region 0 5CL N/A 38
HRAS Codon 12 and 13 3 (6%) 49 Not validated 49
PTEN Exon 5-9 2 (7%) 30 Not validated 25
Unknown 7 (14%) 49 Unknown 61*
PI3KCA Exon 9 and 20 2 (7%) 30 Not validated 25
Exon 1, 9, 20 0 23 N/A 62
Exon 9, 20 0 8 N/A 26
PDGFRA Exon 12 & 18 1 (8%) 12 Not validated 28*
Exon 12-16 & 18-21 0 25 + 2CL N/A 39
Exome mutation in SETD2, TP53, 
TRRAP, BCL9 and other 
mutations in non cancer 
related genes
1 (14%) 7 Yes 29
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Besides the X;18 translocation, additional genomic alterations have been reported in SyS. 
First, patients with Li-Fraumeni syndrome (loss of p53 function) or neurofi bromatosis 
(altered function of NF1 gene) have a higher risk for SyS24. Secondly, Sanger sequencing of 
synovial sarcomas has revealed mutations in several cancer-related genes, including TP53, 
TERT, CDH1, CTNBB1, APC, HRAS, PTEN, PI3KCA, EGFR, BCL9, SETD2, TRRAP and 
PDGFRA (Table 5.1). The targeted sequencing of other cancer-related genes, including 
KRAS25, BRAF25,26, CDKN1A27, KIT28 (abstract only), JAK2, FOXL2, IDH1, AKT1 and EZH226 
did not reveal any pathogenic mutations. Since the percentages of affected tumors differ 
widely in comparable studies its reproducibility may be questioned, and in most studies (10 of 
15) the detected variations were not verifi ed in the corresponding normal DNAs. Joseph et al. 
performed whole-exome sequencing of a small cohort of SyS (n = 7), resulting in a relatively 
low mutation call29. Besides several mutations of unknown function, driver mutations in TP53 
and SETD2 were found in one sample each. Thirdly, in addition to these nucleotide alterations, 
gross chromosomal aberrations have been detected by comparative genomic hybridization 
(CGH)30-32, providing further insight into its genomic complexity next to the recurrent X;18 
translocation. A recent array CGH (aCGH) and gene expression profi ling study by Przybyl et 
al. in a subset of SyS revealed up-regulation of the AURKA and KIF18A genes in aggressive 
untreated primary tumors and its corresponding metastases or local recurrences, compared to 
untreated primary tumors from patients who did not develop metastases/local recurrences33. 
Finally, the study of Lagarde et al. showed that there is a correlation between genomic 
complexity, based on the number and type of chromosomal aberrations, and metastasis-free 
survival. Their study also showed a relation to age at diagnosis, with a larger instability being 
more frequent in adults than children34. This observation could explain why children show 
better survival rates than adults. 
Here we used next generation sequencing in a relatively large SyS cohort to assess the 
occurrence of genomic alterations, including mutations and gross chromosomal changes. 
Materials and Methods
PATIENTS AND TISSUE SAMPLES: Tumor samples were obtained from the archives of the 
Department of Pathology at the Radboud University Medical Center, Nijmegen (1990-2013). 
In total, 36 frozen and 5 formalin-fi xed, paraffi n embedded (FFPE) tumor tissue samples, 
representing 37 patients, were included. In all patients the specifi c t(X;18) translocation was 
identifi ed by reverse transcriptase polymerase chain reaction (RT-PCR). Patient follow-up 
was retrieved from clinical records. All research was performed in consultation and agreement 
with the medical ethical committee.
MUTATIONAL ANALYSIS: Genomic DNA was extracted by incubating the frozen/FFPE 
tissue samples in 5% Chelex-100 in lysis buffer and proteinase K twice overnight. All samples 
were examined by a pathologist to evaluate the neoplastic cell load: all tumor cases contained 
more than 70% neoplastic cells. The control samples did not contain neoplastic cells. Extracted 
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DNA samples were quantified using the Qubit (Invitrogen) and quality was checked by size 
ladder PCR before library preparation. Libraries were generated using Life Technologies Ion 
AmpliSeq™ Comprehensive Cancer Panel according to the manufacturer’s recommendations. 
This panel consists of approximately 16 000 primer pairs covering 409 genes with known 
cancer associations. 10ng of genomic DNA from each sample was used to prepare barcoded 
libraries using IonXpress barcoded adapters (Life Technologies). Libraries were combined to 
a final concentration of 3ng/ml using the Ion Library Quantification Kit (Life Technologies, 
USA), and emulsion PCR was performed using the Ion Torrent OneTouchTM 2 System. 
Samples were sequenced on the Ion Torrent semi-conductor sequencer (Life Technologies, 
USA) using Ion 316 or 318 chips. Sequencing reads were aligned to the 409 genes based on 
the Human Genome version 19 using Sequence Pilot v4.2.0 (JSI medical systems GmbH). 
Also read depth and uniformity of coverage across individual amplicons were assessed. In data 
analysis the cut-off was set at mutations found in ≥20% of the reads. Only non-synonymous 
and non-sense variations in coding regions were included. Mutations were filtered for known 
single nucleotide polymorphisms and variations found earlier in our own research database. 
All mutations left after filtering were confirmed by Sanger sequencing with specifically 
designed primer sets (Supplementary data 5.1), and if confirmed, the presence or absence of 
this specific mutation was verified in normal non-neoplastic tissue from the corresponding 
patient (extracted from FFPE normal tissue). PCR reactions were performed using the 
AmpliTaq Gold 360 Master Mix (Life Technologies, USA) with 1 µl DNA and the following 
program: 95°C (10 min); 95°C (30 sec), 58/60°C (30 sec), 72°C (1 min), 38 cycles; and 72°C 
for 7 min. PCR products were analyzed by agarose gel electrophoresis. Subsequently, samples 
were submitted to DNA sequencing using the BigDye Terminator reaction mix, and samples 
were analyzed on the 3730 Sequence Analyzer (Applied Biosystems). All validation was done 
in duplicate, including the DNA extraction process. 
We extended our cohort with cohort 2 (n = 15) and analyzed these by Sanger-sequencing for 
the mutations that were identified in the first cohort. We also included all coding exons of 
KRAS and CCND1 (primers are listed in Supplementary data 5.1). 
ONCOSCAN: DNA was extracted from 3 FFPE and 3 frozen tissues and purified with ethanol 
precipitation to a concentration of 12 ng/μl. The samples were processed with the OncoScan™ 
FFPE Assay, a whole-genome copy number assay, according to the manufacturers’ protocol of 
the OncoScan™ FFPE Assay Kit Protocol by Affymetrix. The data was analyzed with Nexus 
Copy Number 7.5.2, standard edition, BioDiscovery, Inc. 2014.
IMMUNOHISTOCHEMISTRY: 4 µm sections of FFPE tissue were pretreated in a 
PreTreatment module (Lab Vision) in either sodium citrate buffer (pH6.7) for 30 min at 100°C 
(CCND1) or in ethylenediaminetetraacetic acid (EDTA) buffer (pH9) for 10 min at 96°C 
(MLH1, MSH2, MSH6, PMS2). After blocking of endogenous peroxidase with 3% hydrogen 
peroxide in methanol, sections were incubated for 1h at room temperature (RT) with the 
primary antibody against Cyclin D1 (ILM 30442, clone SP4; 1:40 dilution; Immunologic), 
MLH1 (551092, clone G168-15; 1:40 dilution; BD Pharmingen), MSH2 (NA26, clone GB12; 
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1:40 dilution; Calbiochem), MSH6 (ab92471, clone EPR3945; 1:500 dilution; Abcam) 
or PMS2 (556415, clone A16-4; 1:100 dilution; BD Pharmingen). Next, sections were 
incubated with PowerVision poly-HRP-anti-Ms/Rb/Rt (Immunologic) for 30 min at RT and 
visualized using bright 3,3′-diaminobenzidine (DAB). Counterstaining was performed with 
haematoxylin. Immunostaining was evaluated by a pathologist. 
Table 5.2:  Patient characteristics. NS = not signifi cant (p > 0.05)
Cohort 1 (n=22) Cohort 2 (n=15) Patients with a mutation
Age
 ◦ Children (<18 years)
 ◦ Adult (≥18 years)
6 (27.3%)
16 (72.7%)
2 (13.3%)
13 (86.7%)
(p = NS)
1 (12.5%)
7 (24.1%)
Sex
 ◦ Male
 ◦ Female
16 (72.7%)
6 (27.3%)
6 (40%)
9 (60%)
(p = NS)
6 (27.3%)
2 (13.3%)
Tumor localization
 ◦ Extremity
 ◦ Non-extremity
 ◦ Unknown
12 (54.5%)
9 (40.9%)
1 (4.5%)
9 (40%)
6 (60%)
0
(p = NS)
4 (19.0%)
4 (26.7%)
0
Histology
 ◦ Monophasic
 ◦ Biphasic
 ◦ Unknown
11 (50%)
8 (36.4%)
3 (13.6%)
10 (66.7%)
3 (20%)
2 (13.3%)
(p = NS)
4 (19.0%)
3 (27.3%)
1 (20.0%)
Translocation
 ◦ SSX1
 ◦ SSX2
14 (63.6%)
8 (36.4%)
11 (73.3%)
4 (26.7%)
(p = NS)
6 (24.0%)
2 (16.7%)
Follow up
 ◦ 5 year overall survival 62% 67%
(p = 0.026)
29.2% 
Results
We included patients of all ages (range 11-78 years; including 8 children (< 18years) and 19 
adults (≥18years)) and both sexes (female: 15, male: 22). Patients were diagnosed between 
1990 and 2014. Follow-up data was available for 32 (86%) patients. For the screening of 
somatic mutations by means of next generation sequencing, we included 26 tumors from 22 
patients (cohort 1) of whom suffi cient tissue with matched normal tissue was available in 
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the local tissue bank from our hospital pathology database. We included tumors with both 
histology and translocation subtypes (Table 5.2). The tumors encompassed 18 primary tumors, 
6 metastatic tumors and 2 recurrences. Seventy-seven % (n = 20) of the tumor samples were 
from chemotherapy naïve patients, three tumor samples were from patients treated with neo-
adjuvant chemotherapy, one couple consisting of two metastatic lesions were derived from one 
patient treated with pazopanib, and one recurrence was from a localization previously treated 
with adjuvant radiotherapy. Of four patients paired lesions were available: three patients with 
a metastasis and the corresponding primary tumor, and one patient, as mentioned above, with 
two metastases that responded differently to pazopanib. 
The 26 tumors were sequenced using the Comprehensive Cancer Panel, containing 409 
cancer-related genes including all previous found mutated genes in SyS, except for TERT and 
CDKN1A. In total 77,995 variants were called in the 26 tumors (range 755 - 5713). 96 single 
nucleotide variants remained after filtering. These remaining variants were verified by Sanger 
sequencing. Of these, 57 variants (59%) could be confirmed. All were compared to matched 
normal DNA. In total, 49 of the 57 variants were also detected in normal DNA and were, 
thus, considered to be polymorphisms. Eight variants were not found in the normal tissues 
and are therefore assigned as somatic mutations (Table 5.3). These mutations were identified 
in the genes: KRAS, CCND1, RNF213, SEPT9, KDR (VEGFR2), CSMD3, MLH1 and ERBB4 
(HER4) (Figure 5.1). Seven of these mutations were found in primary tumor samples derived 
from therapy naïve patients. The KRAS mutation was found in a tumor sample from a patient 
who was treated with neo-adjuvant chemotherapy. The mutations in the oncogenes KRAS and 
CCND1 genes are well-established oncogenic mutations in other cancer types. The sample 
harboring the CCND1 mutation was further evaluated by immunohistochemistry, showing 
abundant over-expression of the protein (Figure 5.2). The sample harboring the MLH1 
Figure 5.1: Sanger verification, shows the 8 verified mutations by Sanger sequencing in tumor 
tissue (top) with the corresponding normal tissue (bottom).
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mutation was also evaluated by immunohistochemistry for MLH1, MSH2, MSH6 or PMS2 
expression in accordance to the effect of MLH1 in Lynch35. However, no lack of expression 
of any of these proteins was found (data not shown) in the tumor sample with the MLH1 
mutation. 
No additional mutations were found in the metastatic lesions compared to the primary tumor. 
Since all mutations were found only once, we extended our cohort with a second cohort 
(Cohort 2, total n = 15), one primary tumor sample was derived from a patient who was 
treated with neo-adjuvant chemotherapy, the rest were primary tumor samples from therapy 
naïve patients, to test whether the identifi ed mutations might occur recurrently. In addition, 
we extended the sequencing with coding exons 1-5 of the CCND1 gene and coding exons 2-5 
of the KRAS gene, as the mutations that we found in these genes are proven pathogenic and, 
therefore, these two genes were considered to be of particular interest. However, no additional 
mutations were found in cohort 2 which means that after analysis of 41 tumors with these 
platforms, at maximum one mutation was found in each tumor, and no similar mutations were 
observed.
Table 5.3:  Sanger verifi ed mutations
Nr Gene Chr Exon
HG19 
notation mRNA
Amino 
acid Type
1A RNF213 Ring fi nger 
protein 213 
17 29 78319549 c.7414T>C p.F2472L Missense
1B CCND1 Cyclin D1 11 5 69466021 c.859C>G p.P287A Missense
1C SEPT09 Septin-9 17 5 75483596 c.1004G>A p.R335H Missense
1D KRAS V-Ki-ras2 
Kirsten rat 
sarcoma viral 
oncogene 
homolog 
12 2 25398285 c.34C>A p.G12C Missense
1E KDR 
(a.k.a. 
VEGFR2)
Kinase insert 
domain 
receptor 
4 18 55963862 c.2581T>A p.T861S Missense
1F CSMD3 CUB and 
Sushi 
multiple 
domains 3 
8 2 114327017 c.184TAAAT>A
AAAA
p.IF62FF Missense
1G MLH1 MutL 
homolog 1 
3 12 37067195 c.1106C>T p.S369F Missense
1H ERBB4 
(a.k.a. 
HER4)
Receptor 
tyrosine-
protein 
kinase 
erbB-4 
2 25 212285269 c.3032T>A p.E2V Missense
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In addition to the above mutation screen, we also used the primary dataset of cohort 1 to 
search for the presence of copy number variations (CNVs). To this end, we compared the 
aligned number of reads per gene generated by NGS in tumor tissue with the aligned number 
of reads per gene in healthy tissue. By doing so, chromosomal aberrations, like partial loss 
of chromosome 3 or gain of chromosome 8, were detected in approximately half of the SyS. 
We confirmed these results in 6 samples with genome wide CNV analysis using the Oncoscan 
FFPE assay from Affimetrix (Figure 5.3A). Interestingly, differences in copy number 
alterations were seen in 2 of the 4 paired tumor lesions (Figure 5.3B) with additional deletions, 
duplications and loss of earlier duplications between the primary tumor and its corresponding 
metastasis. A specific loss of 6q was found in the metastatic lesion which progressed under 
pazopanib treatment in contrast to the responding metastatic lesion. An additional (partial) 
deletion of chromosome 6q was found in 2 other tumors of cohort 1. Another recurrent finding 
was loss of heterozygosity (LOH) in 5 of the 6 tumor samples at 3q13.33. Overall, tumors 
with chromosomal aberrations were more frequently seen in adults (34.5%) compared to 
children (12.5%), however this was not significant (p = 0.07).
Discussion
Synovial sarcoma is a rare sarcoma subtype, which is characterized by a recurring X;18 
translocation. Tumors show a heterogeneous clinical behavior. An in-depth genetic 
characterization may lead to an explanation of the clinical differences in tumor behavior and, 
ultimately, the identification of new therapeutic targets. 
Using a next generation sequencing platform, we detected pathogenic mutations that have so 
far not been reported in synovial sarcoma. In contrast to earlier reports, all mutations were 
Figure 5.2: Immunohistochemistry of cyclin D1. A shows the abundant overexpression of 
cyclin D1 by immunohistochemical staining. B is the positive control (tonsil). Photos are made 
with 20x enlargement.
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unique in nature, and no recurrent mutations were found. Also, no mutations were found in 
previously reported mutated genes in SyS (Table 5.1). 
Although each mutated gene may be involved in tumorigenesis, only two mutations that we 
identifi ed in the KRAS and CCDN1 genes are presently known to be functionally important 
for driving cancer. Cyclin D1, encoded by the CCND1 gene, is a cell cycle regulator. It can 
associate with the cyclin-dependent kinases (CDKs) CDK4 and CDK6 to phosphorylate the 
retinoblastoma protein (RB) during the G1 phase of the cell cycle. Phosphorylation of cyclin 
D1 at threonine at codon 286 is required for its ubiquitination, nuclear export and degradation. 
Mutations at codon 287, by which the proline changes to threonine or serine, have been 
reported in endometrial carcinomas36. These mutations result in nuclear accumulation of 
the active Cyclin D1/CDK complex, which is refractory to rapid degradation via the 26S 
proteasome. In our cohort, we identifi ed a c.859C>G (p.P287A) mutation and, concomitantly, 
we observed a cyclin D1 accumulation by immunohistochemistry. The protein encoded by 
the KRAS gene is involved in recruiting and activating proteins necessary for the propagation 
of growth factor and other receptor signaling, such as c-RAF and PI3-kinase. The single 
nucleotide substitution c.34C >A that we found represents an activating mutation known to 
result in oncogenesis in several adenocarcinomas. Non small cell lung cancer cell lines with 
this mutant had activated phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein/
extracellular signal-regulated kinase kinase (MEK) signaling37. Both mutations are involved 
in different pathways known to be activated in SyS, i.e. the WNT - β-catenin pathway which 
targets CCND138, and KRAS targeting the PI3K pathway39. The effect of the other mutations 
is not clear and therefore they could be passenger-mutations. As all eight mutations are found 
in genes involved in different pathways, including regulation of EGFR degradation (SEPT9)40 
or the EGFR-pathway (ERBB4)41, angiogenesis (KDR42, RNF21343), proliferation (CSMD344) 
and mismatch repair (MLH135) pathways, no uniform suitable therapeutic target has emerged. 
The 5-year overall survival was signifi cantly worse in patients whose tumor harbored an 
additional mutation, which should be further investigated in a larger cohort. Mutations were 
more often found in adult tumors compared to tumors with an onset in patient younger than 
18 years (Table 5.2). 
Besides mutations, structural chromosomal aberrations have also been reported in SyS. In our 
cohort, approximately half of the samples showed chromosomal aberrations. Some tumors 
had multiple alterations whereas others showed only a few or none. Also both large, including 
whole chromosomes, and small alterations were found. Similarly as Lagarde et al. reported, 
we found more stable genomes in children compared to adults34. Probably due to our small 
cohort this was not signifi cant in our study. It is unknown if the amount of chromosomal 
aberrations is related to the aggressiveness of the tumor or a cause of the aggressive behavior, 
as genomic instability itself is related to aging and related to cancer45. Also, Chakiba et al. 
evaluated a possible association between genomic instability and response to chemotherapy, 
but no relation was found46. The deletion of 6q that we found may be an exception that 
typically raises interest in resistance mechanisms to pazopanib. As the working mechanism 
of pazopanib in sarcomas is still not unraveled, resistance may occur in various pathways, 
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Figure 5.3: Oncoscan results. A shows an overview of the number of copy-number-variations 
in 6 synovial sarcomas with aggregated gains (blue) and losses (red) of the different cases. 
The width of the bars indicates the number of cases with the gain or loss. B shows the copy 
number variations per sample (one per row). Gains and losses of the different chromosomes 
are represented by respectively blue and red lines, under the different chromosomes (depicted 
in columns). The length of these lines indicates the size of the gain or loss. The yellow/orange 
lines indicate loss of heterozygosity. BI and BII are two individual lesions showing a partial loss 
of chromosome 6q. BIII is a primary lesion (top line) with its corresponding metastasis (bottom 
line), showing a partial overlap of chromosomal aberrations but also differences. BIV are two 
metastases from the same patient. It shows a new deletion of chromosome 6q in the progressive 
metastasis under pazopanib treatment (bottom) compared to the metastasis responding to 
pazopanib (top).
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including anti-angiogenic pathways. Partial 6q loss has been reported before in SyS30-32,47, 
but so far no clinical correlation was found between 6q loss (or any other chromosomal 
aberration) and the clinical behavior of SyS. 
Our study underlines the diversity in SyS genomes beyond the well-known X;18 translocation. 
It emphasizes the challenge in fi nding new druggable targets in this disease and encourages 
a personalized medicine approach because of the overlapping mutations with other cancer 
types. As was shown by the sets of primary tumor and metastases, tumor evolution is unlikely 
to be explained by additional mutations although our sample size was small, but change in 
chromosomal alterations can be found. This study also warrants further investigation of a 
putative correlation between chromosomal aberrations (i.e. deletion of 6q) and resistance to 
pazopanib. From this study we conclude that not only mutations or copy number changes 
may underlie the immense complexity of human cancers, including SyS, and, based on our 
and previous results, also further epigenetic research might be a way to explore the genetic 
nature of SyS.
Supplementary data 5.1:  Primer sequences. *KRAS c.34C>A primers contain a M13 sequence 
(underlined). The annealing temperature of this PCR is 58°C, all other PCRs had an annealing 
temperature of 60°C.
Primer Sequence 5'-3' PCR product size (bp)
ERBB4 3032T>A FW CGTATGAAGCTTCCCAGTCC
111
ERBB4 3032T>A RV GAAAGCCTGAGGGACCAAGT
RNF213 7414T>C FW CGGAGGAACAACTGCAGACA
128
RNF213 7414T>C RV TAGCTTCCGTTGTGTTGGCT
CSMD3 184TAAAT>AAAAA FW gtgcccagctcttaaactgc
178
CSMD3 184TAAAT>AAAAA RV GTCCTTTTAAAGTTCCACCACA
KDR 2581T>A FW ttgactctagGTAAGCCTCTTGG
104
KDR 2581T>A RV TTGACTGCTACTGTCCTGCAA
SEPT09 1004G>A FW GGCTTGGGTAAATCCACCTT
119
SEPT09 1004G>A RV TGCGTGATGGACTTGATCTC
MLH1 1106C>T FW TGGGGAGATGGTTAAATCCA
132
MLH1 1106C>T RV AGAGGCTGCAGAAATGCATC
CCND1 859C>G FW AGAACATGGACCCCAAGG
182
CCND1 859C>G RV GGAGAGGAGGGACTGTCAGG
KRAS 34C>A FW* TGTAAAACGACGGCCAGTAGGCCTGCTGAAAATGACTG
115
KRAS 34C>A RV* CAGGAAACAGCTATGACCTGGATCATATTCGTCCACAAAA
KRAS exon 2 FW cgtctgcagtcaactggaat
339
KRAS exon 2 RV agaatggtcctgcaccagtaa
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Primer Sequence 5'-3' PCR product size (bp)
KRAS exon 3 FW cagactgtgtttctcccttctca
285
KRAS exon 3 RV tgcatggcattagcaaagac
KRAS exon 4 FW tgacaaaagttgtggacaggtt
390
KRAS exon 4 RV aagaagcaatgccctctcaa
KRAS exon 5 FW cttcttgcacatggctttcc
274
KRAS exon 5 RV gtggttgccaccttgttacc
CCND1 exon 1 FW AGCTGCCCAGGAAGAGC
270
CCND1 exon 1 RV gcaacaagttgcagggaagt
CCND1 exon 2 FW ctgccaagcgcgatg
416
CCND1 exon 2 RV tcggaggagcagatatgtca
CCND1 exon 3 FW ccttgagtccccagcattc
441
CCND1 exon 3 RV ggacatcttcccagacagca
CCND1 exon 4 FW acagcctccttccctctctc
203
CCND1 exon 4 RV ctgggacatcaccctcactt
CCND1 exon 5 FW acctctccccaccctctct
275
CCND1 exon 5 RV GGAGAGGAGGGACTGTCAGG
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Abstract
BACKGROUND: In synovial sarcomas alterations in the cyclin D1-CDK4/6-Rb axis have 
been described. Also, β-catenin, a cyclin D1 regulator, is often overexpressed. Additionally, 
studies have shown that the t(X;18) translocation influences tumor behavior partly through 
cyclin D1 activation. We investigated how alterations in the cyclin D1-CDK4/6-Rb axis impact 
prognosis and studied effects of targeting this axis with the CDK4/6 inhibitor palbociclib. 
METHODS: Synovial sarcoma samples (n = 43) were immunohistochemically stained for 
β-catenin, cyclin D1, p16, p21, p27, Rb, and phospho-Rb. Fluorescent in situ hybridization 
(FISH) was performed to detect CCND1 amplification or translocation. In 4 synovial sarcoma 
cell lines sensitivity to palbociclib was investigated using cell viability assays, and effects on 
the sensitive cell lines were evaluated on protein level and by cell cycle arrest. 
RESULTS: Expression of nuclear phospho-Rb and nuclear β-catenin in the patient samples 
was associated with poor survival. FISH showed a sporadic translocation of CCND1 in a 
subset of tumors. An 8-fold CCND1 amplification was found in 1 cell line, but not in the 
patient samples investigated. Palbociclib effectively inhibited Rb-phosphory lation in 3 cell 
lines, resulting in an induction of a G1 arrest and proliferation block. 
CONCLUSION: In this series nuclear phospho-Rb and nuclear β-catenin expression were 
negative prognostic factors. In vitro data suggest that palbociclib may be a potential treatment 
for a subset of synovial sarcoma patients. Whether this effect can be enhanced by combination 
treatment deserves further preclinical investigations. 
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Introduction
Synovial sarcoma (SyS) is a subtype of soft tissue sarcomas (STS), characterized by a 
chromosomal translocation t(X;18). Localized disease is treated with surgery, occasionally 
with additional radiotherapy or chemotherapy. Palliative chemotherapy can be given once 
patients have advanced disease, with poor survival rates. Although the fi eld of targeted 
treatment for carcinomas is developing rapidly, trials with targeted therapies for rare cancers 
such as sarcoma are scarce, and pazopanib is currently the only registered targeted treatment 
for non-gastrointestinal stromal tumor (GIST) STS, including SyS1. To improve prognosis for 
this group of patients, knowledge on actionable targets in this sarcoma subtype is desperately 
needed. Among others, cyclin D1 has been suggested as a potential therapeutic target. 
Cyclin D1 is a cell cycle regulator essential for progression from G1 to S phase. Deregulated 
expression via mutations, gene rearrangements, or amplifi cation of CCND1 has been reported 
in various cancer types2-4. Also alterations of other proteins involved in the cyclin D1-
CDK4/6-Rb axis (e.g., p16, retinoblastoma (Rb) protein, and p21) may lead to uncontrolled 
progression through the cell cycle5,6. Even though the exact working mechanism of the SyS 
translocation is still unknown, it has been shown that the SS18-SSX fusion gene is associated 
with cyclin D1 expression in SyS cells. Downregulation of the fusion gene expression by 
siRNA drastically decreased cyclin D1 levels, resulting in reduced cell proliferation7-9. To 
further investigate the axis through which cyclin D1 is affected, several mechanisms have 
been postulated. 
Cai et al. demonstrated that siRNA-mediated downregulation of the SS18-SSX2 gene product 
in SyS cell lines resulted in a decreased expression of (phospho)-ERK1/2 and cyclin D1, 
suggesting a direct link between this translocation and ERK1/2 and cyclin D1 activation10. This 
was supported by a study showing that inhibition of the MEK/ERK-pathway with sorafenib 
led to downregulation of the expression of cyclin D1 and Rb protein with consecutive cell 
cycle arrest11. It has also been suggested that the translocation associates with deregulated 
cyclin D1 activity via the Wnt/β-catenin-pathway. Indeed, this ‘‘cellular dedifferentiation’’ 
pathway is constitutively active in a SYT-SSX2 transgenic mouse model, with corresponding 
cyclin D1 expression, and inhibition of Wnt signaling through functional knock-out of the 
β-catenin gene reduced tumor formation12,13. In line with this, blocking β-catenin with small 
molecule inhibitors in SyS cell lines resulted in cyclin D1 downregulation14. Moreover, 
cyclin D1 activity could also be regulated by the PI3K/Akt-pathway. In vitro, PI3K inhibition 
resulted in decreased cell proliferation, which was linked to reduced cyclin D1 and increased 
levels of p2715. Others have shown that cyclin D1-positive and nuclear β-catenin negative 
SyS were positive for phospho-Akt16. It has also been suggested that the SSX2 gene product 
stimulates miR-17 expression, which subsequently inhibits p2117. Additionally, heterozygous 
loss of p16 has been reported in SyS tumors, and recently we reported the occurrence of a 
CCND1 mutation with additional nuclear overexpression of cyclin D1 in a patient sample18-20. 
All these studies suggest that the cyclin D1-CDK4/6-Rb axis integrates inputs from the Wnt/ 
β-catenin, PI3K/AKT, and ERK-pathways in SyS making the cyclin D1-CDK4/6- Rb axis an 
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interesting target for treatment of SyS patients. However, so far no published data is available 
on the specific exploration of inhibiting this target in SyS. One such potential active drug 
could be palbociclib. Palbociclib (PD-0332991) is a highly selective drug, inhibiting the 
CDK4/6-cyclin D1 kinase activity while showing little or no activity to other enzymes. It was 
proven to reduce Rb phosphorylation at the 2 sites that are specifically phosphorylated by 
CDK4 and CDK6. Significant antitumor activity was detected only at doses where there was 
a sustained and significant reduction of these sites on Rb21. Palbociclib has recently been FDA 
approved for the treatment of postmenopausal women with estrogen receptor (ER)-positive, 
human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial 
therapy in metastatic disease in combination with letrozole. In sarcoma, the only phase 2 
studies have been performed in liposarcoma22. In SyS, no study on palbociclib has been done 
yet. Therefore, we here evaluated the cyclin D1-CDK4/6-Rb axis and tested palbociclib as a 
possible treatment for SyS patients. 
Materials and Methods
PATIËNT CHARACTERISTICS: Tumor samples from 43 patients, diagnosed with SyS 
between 1988 and 2015, were retrieved from the files of the department of Pathology of the 
Radboud University Medical Centre (Radboud UMC). Patient follow-up data was retrieved 
from the clinical records. The study was performed in accordance with the Code of Conduct 
of the Federation of Medical Scientific Societies in the Netherlands. 
IMMUNOHISTOCHEMISTRY: Immunohistochemistry for cyclin D1, p16, p21, p27, 
β-catenin, Rb, and phospho-Rb was performed on 4-μm thick formalin-fixed paraffin-
embedded (FFPE) tissue microarray (TMA) sections using standard procedures. The 
specifications for each antibody are listed in Supplementary Table 6.1. After incubation 
with primary antibody and washing, antibodies were visualized using PowerVision poly-
HRP-anti- Ms/Rb/Rt (ImmunoLogic), visualized using bright 3,30-diaminobenzidine (DAB, 
ImmunoLogic) and counterstained with hematoxylin. Immunostaining was scored by 3 
individual researchers, and consensus was reached (scoring systems are explained below in 
Figure 6.1 and Supplementary Figure 6.1). Only results from primary tumors were included 
in the analysis, in order to obtain a representative view on survival. A Kaplan–Meier analysis 
was performed with a log-rank test to calculate survival differences, which were considered 
to be significant at p>0.05. 
FISH: For the detection of gene rearrangements, fluorescent in situ hybridization (FISH) was 
performed on 2-μm thick FFPE TMA sections that were pretreated in sodium citrate buffer 
(pH6) by heating in a microwave oven for 10 min, followed by a digestion step with pepsin 
(200 U/ml) for 15 min at 37 ˚ C. The CCND1 DNA split probe (Y5414, DAKO) was applied to 
the sections and heat denatured for 5 min at 82 ˚C and hybridized at 45 ˚C overnight. Sections 
were mounted in Vectashield mounting medium with DAPI (Vector Laboratories). Fifty cells 
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were counted, and >10% fusion breakage was considered a translocation. Amplifi cations were 
considered when >6 CCND1 signals were detected in >10% of the cells. 
CELL CULTURE: The 2 patient-derived SyS cell lines harboring the SSX1 translocation 
(Yamato-SS and Aska-SS) were generously provided by K. Itoh. The 2 patient-derived SyS 
cell lines harboring the SSX2 translocation (SYO-1 and CME-1) were generously provided 
by A. Kawai and C. Lanzi, respectively. Yamato-SS and Aska-SS were cultured in DMEM 
4.5 g/l glucose (Lonza), 1 mM sodium pyruvate (PAA) medium, SYO-1 in DMEM 4.5 g/l 
glucose, and CME-1 in RPMI-1640 medium (Lonza). Media were supplemented with 10 % 
fetal bovine serum (FBS, Gibco) and 1 % penicillin/streptomycin (Lonza). All cells were 
maintained at 37˚C in a humidifi ed atmosphere of 5 % CO2/ 95% air. 
MTT ASSAY: Cell viability (defi ned as metabolic cell activity) was assessed by MTT assay. 
Cells were seeded in triplicate in 96-well plates overnight for attachment and then incubated 
Figure 6.1:  I Proteins involved in the cyclin D1-CDK4/6-Rb axis. A: Both nuclear (N) 
staining of β-catenin and nuclear (N) staining of phospho-Rb was scored as negative or 
positive. The cutoff was set at staining in at least 20% of the cells. All images are taken at 
x200 magnifi cation, insets are at x400 magnifi cation. B: Levels of the proteins involved 
in the cyclin D1-CDK4/6-Rb axis on western blot. Different expression levels can be seen 
between the 4 synovial sarcoma cell lines. C: Kaplan–Meier survival curves for β-catenin 
and phospho-Rb expression levels, which resulted in an overall survival difference
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for 2 times the doubling time of the cell line, with palbociclib (PD-0332991, Pfizer) (0–10,000 
nM). Next, MTT (Sigma-Aldrich) was added to each well and cells were incubated for 3.5 
h. Afterward, the formazan crystals were dissolved in MTT solvent (isopropanol with 0.1% 
Nonidet P-40 and 4 mM fuming hydrochloric acid) and absorbance was measured at 560 
nm using an ELISA reader. IC50 values were calculated using GraphPad Prism Version 5.03 
software. 
Table 6.1: Patient characteristics.
Parameter Frequency (%) n = 43
Age
Children <18 years
Adults ≥18 years 
10 (23.3%)
33 (76.7%)
Sex
Male
Female
28 (65.1%)
15 (34.9%)
Tumor localization
Extremities
Head/neck
Other
Unknown
27 (62.8%)
6 (14.0%)
5 (11.6%)
5 (11.5%)
Histology
Monophasic
Biphasic
Unknown
17 (39.5%)
13 (30.2%)
13 (30.2%)
Neo-adjuvant treatment
None
Chemotherapy
Radiotherapy
Unknown
34 (79.1%)
3 (7.0%)
0
6 (14.0%)
Expression of nuclear cyclin D1
Negative
Positive 
Missing
12 (27.9%)
29 (67.4%)
2 (4.7%)
Expression of nuclear Rb
Negative
Positive 
Missing
33 (76.7%)
9 (20.9%)
1 (2.3%)
Expression of nuclear phospho-Rb
Negative
Positive 
Missing
31 (72.1%)
11 (25.6%)
1 (2.3%)
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Parameter Frequency (%) n = 43
Expression of cytoplasmic p16
Low
High
Missing
27 (62.8%)
12 (27.9%)
4 (9.3%)
Expression of nuclear p21
Negative
Positive 
Missing
34 (79.1%)
6 (14.0%)
3 (7.0%)
Expression of cytoplasmic p27
Low
High
Missing
25 (58.1%)
16 (37.2%)
2 (4.7%)
Expression of β-catenin
Nuclear
Cytoplasmic
Membranous
Negative
Positive
Missing
Negative
Positive
Missing
Negative
Positive
Missing
11 (25.6%)
30 (69.8%)
2 (4.7%)
7 (16.3%)
34 (79.1%)
2 (4.7%)
30 (69.8%)
11 (25.6%)
2 (4.7%)
CELL CYCLE ASSAY: SyS cells were dissociated with trypsin and fi xated in 70% ethanol 
after treatment with different concentrations of palbociclib at different time points. Propidium 
iodide solution (Sigma-Aldrich, 50 µg/ml in PBS) was added to the fi xated cells to achieve 
DNA staining, and cells were treated with RNAse A (Qiagen, 100 µg/ml). All samples were 
measured using fl ow cytometry (CyAn ADP Analyzer, Beckman Coulter) and analyzed by 
FlowJo software (version 10). Hereby viable single cells were selected by gating. 
WESTERN BLOT: After treatment of cells with different concentrations of palbociclib, cells 
were trypsin-harvested and proteins extracted with RIPA buffer (Cell Signaling Technology), 
supplemented with 1 mM PMSF were loaded (40 µg of cell extract, determined using the 
BCA protein assay kit, Thermo Fisher Scientifi c) and separated by SDS-PAGE under reducing 
conditions and subsequently transferred to nitrocellulose membranes (Protan). Primary 
antibodies were incubated overnight at 4˚C (Supplementary Table 6.1). Next, the blots were 
incubated with a goat-anti-rabbit/ mouse IgG Alexa Fluor 680 conjugated secondary antibody 
(Thermo Fisher Scientifi c). α-Tubulin was used as loading control. The fl uorescent signals 
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were analyzed with the Odyssey CLx Infrared Imaging System (LI-COR Biosciences) and 
Image Studio Analysis Software Version 4.0. All experiments, including MTT assays, cell 
cycle assays and western blots, were performed in duplicate. 
MUTATION ANALYSIS: For all 4 SyS cell lines the mutation hot spots of TP53 (exon 
4–9) were analyzed by PCR amplification using the AmpliTaq Gold 360 Master Mix (Life 
Technologies) with 1μl DNA and the following program: 95˚C (10 min); 95˚C (30 s), 58˚C 
(30 s), 72˚C (1 min), 38 cycles; and 72˚C for 7 min. Samples were submitted to Sanger DNA 
sequencing using the BigDye Terminator reaction mix, and samples were analyzed on the 
3730 Sequence Analyzer (Applied Biosystems). The known CTNNB1 G34L mutation was 
verified in the SYO-1 cell line. All exons (1–5) of CCND1 were sequenced as described 
previously20.
Results
CLINICAL DATA: Only 3 of 43 patients (7%) were treated with neoadjuvant chemotherapy 
(including 1 patiënt <18 years), none had neoadjuvant radiotherapy, and of 14% treatment 
status was unknown. Survival data was available for 31 patients (72%). 
PROTEIN EVALUATION BY IMMUNOHISTOCHEMISTRY AND WESTERN BLOT: A 
total of 43 primary tumors were immunohistochemically stained for cyclin D1, p21, p27, 
p16, β-catenin, phospho-Rb, and Rb (Figure 6.1a, Supplementary Figure 6.1). Of the patient 
samples, 72.1% had detectable expression of nuclear cyclin D1 (Table 6.1). Expression of 
both nuclear phospho-Rb and nuclear β-catenin was an indicator of poor prognosis (Figure 
6.1c, p<0.05). We observed a significant correlation between Rb and phospho-Rb (p = 0.005). 
No correlation was found between expression of β-catenin and phospho-Rb. The 4 SyS cell 
lines were evaluated for expression of the same proteins by western blot. Expression levels 
differed between the cell lines (Figure 6.1b). The Yamato-SS had the highest expression of 
cyclin D1, whereas the CME-1 cell line expressed a high level of p16, with a corresponding 
lower level of cyclin D1. 
Figure 6.2: Genetic alterations. CCND1 breakage in patient tumor sample (left), as indicated 
by the arrows and CCND1 amplification in the Yamato-SS cell line (right) by FISH analysis. 
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GENETIC ALTERATIONS: FISH analysis showed sporadic breakage, in 10–20% of the cells, 
of CCND1 in 15% of the patient samples. Additionally, an 8-fold amplifi cation of CCND1 
was found in the Yamato-SS cell line (Figure 6.2). The known CTNNB1 G34L mutation was 
confi rmed in the SYO-1 cell line14. The Yamato-SS cell line harbored a homozygous TP53 
mutation in exon 8 (c.817C>T/p.R273C, rs121913343). This deactivating TP53 mutation 
could explain the lack of downstream target p21 found by western blot. None of the cell lines 
harbored a mutation in CCND1. 
PALBOCICLIB SENSITIVITY In vitro: MTT assays revealed a dose-dependent growth 
inhibition by palbociclib in all cell lines, in which 3 cell lines (Yamato-SS, Aska-SS, and SYO-
1) had an IC50 value of 0.83 μM ±0.16, 0.98 μM ±0.17, and 0.12 μM ±0.01, respectively. Since 
a concentration below 1.2 μM is considered feasible as plasma concentration in patients, IC50 
values below this concentration are considered sensitive23. The CME-1 cell line had an IC50 
value of 8.0 μM ±1.32 and is therefore regarded resistant to palbociclib. Palbociclib resulted 
in a concentration-dependent reduction of phospho-Rb levels, already observed after 4 h of 
incubation. Inhibition of Rb phosphorylation was best seen at 24 h (Figure 6.3a). Evaluation 
of the G1 arrest was done by analyzing DNA content of the cells (propidium iodide staining) 
(Figure 6.3a). A G0/G1 arrest was induced in the 3 sensitive cell lines at 24 h. In the resistant 
CME-1 cell line no effect of palbociclib on the cell cycle was observed (data not shown). 
Figure 6.3:  Western blot and cell cycle analysis. A: Protein evaluation by western blot shows 
a decrease in phospho-Rb at increasing concentrations of palbociclib at different time points in 
the Yamato-SS, Aska-SS and SYO-1 cell lines. As expected, no effect can be seen on cyclin D1 
expression. B: This column shows the cell cycle analysis. The bars indicate the G0/G1 phase, 
and show an increase in G0/G1 arrest in Yamato-SS, Aska-SS and SYO-1 cell lines.
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Discussion
Palbociclib is a well-tolerated drug with significant progression-free survival (PFS) benefit 
in patients, in combination with letrozole, for the treatment of postmenopausal women with 
ER-positive, HER2-negative advanced breast cancer as initial therapy for their metastatic 
disease24. Patients with STS have been tested for palbociclib as well. A phase II study in well-
differentiated and dedifferentiated liposarcoma patients showed a partial response in 1 of 29 
evaluable patients, with a median PFS of 18 weeks22. Even though the cyclin D1-CDK4/6-
Rb axis has been thought to play a role in SyS, so far no studies have reported on the effects 
of inhibiting this axis in SyS. Here, we used patient tumor samples and 4 SyS cell lines to 
evaluate genetic alterations of CCND1 and the expression patterns of the proteins playing a 
possible role in deregulation of this axis (Figure 6.4). We showed CCND1 amplification in a 
SyS cell line and CCND1 rearrangement in a small percentage of cells in a subset of patient 
samples, although possible fusion partners and the significance of these rearrangements in a 
small subset of tumor cells remain elusive. Even though cyclin D1 is regularly reported to be 
a downstream target of several possibly activated pathways in SyS, potentially induced by its 
fusion gene, the exact working mechanism of the translocation in respect to cyclin D1 remains 
unknown. We show a significant relation between nuclear β-catenin expression and overall 
survival of SyS patients, which is in line with previous studies16,25. We provide information on 
the different localizations of β-catenin expression (Table 6.1); however, as only the nuclear 
expression has effect on cyclin D1, we used this localization for prognostic evaluation. In 
addition, we show that nuclear expression of phospho-Rb correlates with overall survival. 
This might be a new potential prognostic indicator, and further validation is needed in a larger 
cohort. 
Figure 6.4: Cyclin D1-CDK4/6-Rb axis. Highlighted are the proteins that have been 
investigated by immunohistochemistry and western blot.
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Based on the presumed involvement of deregulated cyclin D1 activity in SyS, we used 
palbociclib, a potent inhibitor of this axis, in 4 SyS cell lines. Interestingly, previous studies 
showed that palbociclib was considerably less active in a number of non-synovial soft tissue 
sarcoma cell lines (IC50 values of 8.95–26.63 μM), suggesting that an aberrant cyclin D1-
CDK4/6-Rb axis is a specifi c feature for the SyS subtype of soft tissue sarcomas26. One SyS 
cell line had a noticeably higher IC50 (CME-1), probably explained by the immortalization 
with SV40 large T antigen. This binds to p53 and affects p53 transcriptional activity. SV40 
large T antigen also affects Rb activity, which leads to a bypassing of the G1/S checkpoint 
with a resulting constitutive activation of the cell cycle27,28. 
As palbociclib does not result in a 100% G1 arrest, combination therapy will be necessary 
to induce the effect, which may thus potentially translate into higher activity in the 
clinic. Numerous potential combination therapies can be investigated, including various 
chemotherapeutics, small molecule inhibitors, and targeted antibodies, etc. Very recently, a 
new insight in the translocation and the Wnt pathway was established with a study reporting 
that the translocation induces a partial Wnt expression signature in the absence of Wnt ligands, 
using β-catenin as a transcriptional de-repressor29. With these functional studies, insight into 
the pathophysiology improves, which will hopefully result in rationale-based combination 
treatments. 
In conclusion, this study shows an extensive overview on the activity of the cyclin D1-
CDK4/6-Rb axis in SyS, in which genetic deregulation of CCND1 is rare. Further research 
is necessary to examine the potential signaling mechanisms between this axis and β-catenin, 
as this was not subject of our research. Nuclear phospho-Rb and β-catenin expression is 
correlated negatively with overall survival in SyS patients, which has a potential prognostic 
role, but should be validated in a separate dataset. Palbociclib induces a cell cycle arrest 
with corresponding phospho-Rb decrease in SyS cell lines, making palbociclib a potential 
treatment option for SyS patients. Whether this effect can be enhanced by combination 
treatments deserves further preclinical investigations. 
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Supplementary Table 6.1: antibodies
Immunohistochemistry Western blot
Antigen Antibody Heat Induced Epitope Retrieval (HIER) Dilution Dilution
p21 #ms-230-P1, clone DCS-60.2, 
Thermo Scientific
30 min in 10 mM sodium 
citrate buffer pH6,7
1/20 -
p21 #2946, clone DCS60, 
Cell Signaling Technology
- - 1/2000
p16 #550834, clone G175-405, BD 
Biosciences
10 min in 10 mM sodium 
citrate buffer pH6
1/4 1/300
β-catenin #610153, clone 14/Beta-
Catenin, BD Biosciences
10 min in EDTA buffer pH9 1/400 1/2000
pRb #8516, clone D20B12, Cell 
Signaling Technology
10 min in 10 mM sodium 
citrate buffer pH6
1/200 1/1000
Rb #9309, clone 4H1, 
Cell Signaling Technology
10 min in 10 mM sodium 
citrate buffer pH6
1/200 -
p27 #ab32034, clone Y236, Abcam 10 min in 10 mM sodium 
citrate buffer pH6
1/200 1/1000
cyclin 
D1
ILM 30442 C1, clone SP4, 
Immunologic
30 min in 10 mM sodium 
citrate buffer pH6,7
1/20 1/300
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Supplementary Figure 6.1:  Nuclear staining of the proteins cyclin D1, Rb and p21 was scored 
as negative or positive. The cut off was set at staining in at least 20% of the cells; if less than 
20% of the cells were stained, the sample was considered negative. Nuclear and cytoplasmic 
staining for p16 and p27, respectively, was scored as negative/mild (low), or moderate/strong 
(high) in at least 20% of cells. All images are taken at x200 magnifi cation.
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Abstract
Despite intensive multimodal treatment of sarcomas, a heterogeneous group of malignant 
tumors arising from connective tissue, survival remains poor. Candidate-based targeted 
treatments have demonstrated limited clinical success, urging an unbiased and comprehensive 
analysis of oncogenic signaling networks to reveal therapeutic targets and personalized 
treatment strategies. Here we applied mass spectrometry–based phosphoproteomic profiling 
to the largest and most heterogeneous set of sarcoma cell lines characterized to date and 
identified novel tyrosine phosphorylation patterns, enhanced tyrosine kinases in specific 
subtypes, and potential driver kinases. ALK was identified as a novel driver in the Aska-SS 
synovial sarcoma (SyS) cell line via expression of an ALK variant with a large extracellular 
domain deletion (ALKΔ2–17). Functional ALK dependency was confirmed in vitro and in vivo 
with selective inhibitors. Importantly, ALK immunopositivity was detected in 6 of 43 (14%) 
of SyS patient specimens, one of which exhibited an ALK rearrangement. High PDGFRα 
phosphorylation also characterized SyS cell lines, which was accompanied by enhanced 
MET activation in Yamato-SS cells. Although Yamato-SS cells were sensitive to crizotinib 
(ALK/MET-inhibitor) but not pazopanib (VEGFR/PDGFR-inhibitor) monotherapy in 
vitro, synergistic effects were observed upon drug combination. In vivo, both drugs were 
individually effective, with pazopanib efficacy likely attributable to reduced angiogenesis. 
MET or PDGFRα expression was detected in 58% and 84% of SyS patients, respectively, with 
coexpression in 56%. Consequently, our integrated approach has led to the identification of 
ALK and MET as promising therapeutic targets in SyS.
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Introduction
Sarcomas are a heterogeneous group of malignant tumors arising in the bone or other connective 
tissue. Despite multimodal treatment options comprising intensive polychemotherapy, 
radiotherapy, and surgery, the survival of advanced sarcoma patients, with the exception 
of those exhibiting gastrointestinal stromal tumors (GIST), has not improved substantially 
during the last decade1,2, and side effects may affect quality of life. This emphasizes the need 
for novel, targeted systemic therapies. In recent years, the specifi c targeting of oncogenic 
signaling proteins with either small-molecule tyrosine kinase inhibitors (TKI) or antibodies 
has been the subject of numerous preclinical and clinical studies in sarcoma. Of these, only 
the multikinase VEGFR/PDGFR/KIT-inhibitor pazopanib showed an increase in progression-
free survival (PFS) in a phase III study, leading to its registration in advanced nonadipocytic 
soft-tissue sarcoma (STS) after failure of standard treatment3, and a phase I–II study with 
the PDGFRα antibody olaratumab led to an impressive but not yet understood overall 
survival improvement4. Possible explanations for the observed limited clinical effi cacy are: 
inclusion of a wide variety of sarcoma subtypes per study without incorporation of predictive 
biomarkers2,5, and use of single inhibitors rather than combinations, as numerous studies 
demonstrate that tumors often rely on multiple signaling pathways to maintain growth and 
progression1,2,6-8. Therefore, there is a critical need to defi ne, at a global level, the activated 
signaling networks that drive sarcoma progression, determine how they relate to currently 
defi ned sarcoma subtypes and whether they can provide a novel taxonomy for the disease, 
and identify targeted therapies and companion biomarkers for implementation of personalized 
treatment approaches.
So far, genetic screening underpins diagnosis of different sarcoma subtypes, yet targetable 
driver mutations are rarely found in non-GIST sarcomas. While disease-specifi c translocations 
such as EWS-ETS in Ewing sarcomas (ES) and SS18-SSX in synovial sarcomas (SyS) 
have been demonstrated9, the exact cellular functions of these fusions and their potential 
relationship to other oncogenic events is not fully understood, and targeting the translocation 
or associated activated pathways has not yet been successful. Therefore, mutation screening 
to select non-GIST sarcoma patients for targeted therapy has not led to clinical benefi t so 
far1,10,11. Regarding protein biomarkers, most studies to date have focused on total protein 
expression levels, while specifi c screening for phosphorylation status or other read-outs of 
activation state may provide more accurate information regarding the pathway dependency of 
tumor cells and likely therapeutic benefi t2,12-14. To this end, we characterized tyrosine kinase 
signaling networks in a large panel of sarcoma cell lines (n=20). We specifi cally chose to 
include sarcoma cell lines of both the bone sarcoma and STS subtypes, and sarcomas occurring 
in adults or at pediatric/adolescent or young adult (AYA) age (Table 7.1). Except for the GIST 
cell line, none of the included cell lines have been phosphoprofi led before, and this is the 
fi rst study to subject SyS and angiosarcoma (AS) cell lines to phosphoproteomic analysis6,15. 
This has enabled us to (i) characterize activated signaling networks in sarcoma, (ii) compare 
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activated signaling networks between and within sarcoma subtypes, and (iii) identify driver 
kinases. The results highlight potential strategies for future personalized sarcoma treatment.
Materials and Methods
CELL CULTURE: ES and RMS cell lines were kindly provided by Peter Houghton, SyS cell 
lines by Kazuyuki Itoh (Yamato-SS and Aska-SS), Akira Kawai (SYO-1) and Cinzia Lanzi 
(CME-1); AS cell lines by Mikio Masuzawa (MO-LAS-B and ISO-HAS-B) and the GIST 
cell line by Jonathan Fletcher (GIST882). All cell lines were obtained between 2010 and 
2015, authenticated in our laboratory upon arrival and routinely tested for mycoplasma (all 
negative). All translocation-associated cell lines (ES, SyS, and aRMS) were authenticated 
in our laboratory by confirming the presence of the characteristic EWS-FLI1 (ES), SS18-
SSX1/SSX2 (SyS), or PAX3-FKHR (aRMS) gene fusions as listed in Table 7.1 by RT-PCR. 
Fusion-negative eRMS cell lines were additionally tested for PAX3-FKHR gene fusions, 
which all proved to be fusion-negative, as expected. For the GIST882 cell line, mutation 
analysis confirmed its known KIT mutation (K642E; c.1924A>G=p.Lys642Glu). AS and 
eRMS cell lines were tested by IHC for the presence of subtype-specific protein markers, 
which included expression of CD31, CD34, and ERG for AS cell lines, and expression of 
desmin and myogenin for eRMS cell lines. Authentication methods and results of all cell lines 
were reviewed by an expert sarcoma pathologist (UE Flucke, Radboud UMC). Cells were 
cultured according to their recommended conditions to approximately 70% confluency for no 
longer than 25 passages in total for any experiment.
PHOSPHOPROTEOMIC PROFILING: Prior to profiling studies, cells were harvested and 
homogenized in 8 mol/L urea lysis buffer containing phosphatase inhibitors. Lysates were 
sonicated and centrifuged at 14,000 × g at 4°C for 20 minutes. For each cell line, 20 mg of protein 
was subjected to phosphoproteomic analysis. First, phosphopeptides were immunoprecipitated 
(details: Supplementary Methods). For nanoscale liquid chromatography coupled to tandem 
mass spectrometry (nano LC-MS/MS) analysis, pY-peptides were resuspended in MS-loading 
buffer (0.1% formic acid and 2% ACN). Peptides were separated over a 30 minutes gradient 
and MS was performed using a Thermo Fisher Scientific Orbitrap Plus. Up to the 10 most 
abundant ions (>5,000 counts) with charge states >+2 were sequentially isolated and further 
subjected to MS/MS fragmentation. MS data were analyzed using MaxQuant software 
(version 1.5.2.8.). Extracted peak lists were searched against the human UniProtKB/Swiss-
Prot database (version 2010_10), concatenated with a proportionally sized decoy database for 
false discovery rate (FDR) as well as the reversed sequences of all entries. Protein, peptide, 
and site FDRs were controlled at a maximum of 1%. Raw pY-peptide spectral intensities were 
extracted from the “Evidence” output files generated by Maxquant. These intensities were 
normalized against pY-peptide intensities for the heavy-labeled spiked-in peptide standards 
combined with GSK3B. The label-free intensity values of EFTU, MK14, and GSK3B heavy 
peptides in each cell line were averaged and a subsequent normalization factor generated. 
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MS intensity values of each pY-site quantifi ed in the dataset were divided by the appropriate 
normalization factor.
Raw MaxQuant output fi les were subjected to the following stringent fi ltering criteria prior 
to inclusion in bioinformatics analysis; (i) contaminants and reversed matches were removed, 
ensuring all identifi cations had a FDR of <1%, (ii) all non-pY sites (serine and threonine) 
were removed, (iii) pY-sites were fi ltered for a minimum localization probability confi dence 
of 0.75. All data was log2 transformed prior to bioinformatics analysis. Data analyses were 
performed using Microsoft Offi ce Excel and the bioinformatics platform Perseus (Max Planck 
Institute of Biochemistry) version 1.2.0.19. For hierarchical clustering, only pY sites with at 
least 10 valid values were included, according to standard Perseus fi ltering and clustering 
criteria.
PATHWAY AND NETWORK ANALYSIS: For pathway enrichment analysis, the KEGG 
Orthology Based Annotation System (KOBAS) was used16. The hypergeometric test was 
applied to test statistical enrichment of identifi ed KEGG and Reactome pathways, and the 
p-values were corrected for multiple comparisons using the Benjamini and Hochberg method17. 
Physical interactions among proteins of interest were retrieved from the Protein Interaction 
Network Analysis (PINA) platform18,19, and kinase–substrate relationships were downloaded 
from the PhosphoSitePlus database20. The networks were generated and visualized using 
PINA4MS, a Cytoscape plugin for PINA.
PROLIFERATION ASSAYS: The effects of small-molecule inhibitors (TAE684, crizotinib, 
ceritinib, and pazopanib) on cell viability was assessed by MTT proliferation assays as 
described previously (details: Supplementary Table 7.121,22).
PATIENT COHORT: Tumor samples from 43 patients diagnosed with SyS (all SS18-SSX 
translocation positive) between 1988 and 2015, were retrieved from the fi les of the Department 
of Pathology of the Radboud University Medical Centre (Radboud UMC). Patient follow-up 
data was retrieved from the clinical records. The study was performed in accordance with the 
Code of Conduct of the Federation of Medical Scientifi c Societies in the Netherlands. Patient 
characteristics are listed in Supplementary Table 7.2.
FISH: FISH was performed on 2-μm–thick formalin-fi xed paraffi n embedded (FFPE) tissue 
microarray (TMA) sections from the patient cohort described above, and an Aska-SS cytospin 
using an ALK (2p23) split-signal FISH DNA probe (Dako) as described previously21.
MUTATION ANALYSIS: RT-PCR and sequence analysis of the RTK domain of ALK and 
MET was performed on SyS cell lines as described previously21. SyS cells were additionally 
screened with the Cancer Hotspot Panel with a focus on potential PDGFRα and EGFR 
mutations23.
SEQUENCING LIBRARY PREPARATION AND CAPTURE: Sequencing libraries were 
prepared from 1 μg of Aska-SS RNA using the KAPA Stranded RNA-Seq Library Preparation 
Kit (Roche). Capture was performed using biotinylated probes complementary to the ALK 
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coding regions as previously described24 with addition of the double Capture process according 
to manufacturer’s instructions. Captured libraries were sequenced for standard depth 126-bp 
paired-end sequencing using the Illumina HiSeq 2500 System v4 (Illumina).
SEQUENCE ANALYSIS: Sequencing reads were deduplicated with Tally v15-065 and 
adaptor sequences removed with Cutadapt v1.8.1. Postfiltering, reads were mapped to human 
reference genome hg38 with STAR v2.4.2a and converted to UCSC genome browser tracks 
using the BEDTools v2.25.0 “genomecov” command. ALK exonic coverage was calculated 
from uniquely mapping reads using the BEDTools coverage tool (details: Supplementary 
Methods).
ALK RT-PCR: One micrograms of total RNA was reverse-transcribed to DNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR was performed using 
the primer sequences listed in the Supplementary Methods. Products were gel-purified using 
the Gel and PCR Clean-Up System (Promega) and were sequenced using the PCR primers.
WESTERN BLOT ANALYSIS: Western blot analysis was performed as previously described25 
(antibody details: see Supplementary Table online).
PATHSCAN ANALYSIS: PathScan signaling analysis was performed on Aska-SS cells 
treated with TAE684 (25 nmol/L), ceritinib (100 nmol/L), or crizotinib (750 nmol/L) and 
on Yamato-SS cells treated with pazopanib (10 μmol/L) and/or crizotinib (750 nmol/L), all 
for 24 hours, using the human PathScan RTK Signaling Antibody Array Kit (Cell Signaling 
Technology) according to the manufacturer’s protocol.
DEGLYCOSYLATION: Cells were lysed in 2% SDS and the lysates adjusted to 0.5% SDS, 40 
mmol/L DTT, and centrifuged at 12,000 × g for 10 minutes at room temperature. The supernatant 
was then heated at 96°C for 10 minutes and 10 μg of protein treated with O-Glycosidase, 
Endoglycosidase H, N-glycosidase F (all from NEB), following manufacturer’s protocols. 
Tunicamycin was obtained from Sigma. Cells were incubated with tunicamycin (2.5–20 μg/
mL) for 24 hours prior to preparation of cell lysates and Western blotting.
COMBINATION INDICES: To assess drug synergy between crizotinib and pazopanib, the 
combination index (CI) method was used22. Cells were treated with three designated doses 
of crizotinib (20, 50, and 100 nmol/L) and pazopanib (100, 1,000, and 10,000 nmol/L), and 
effects on cell viability were assessed by MTT assays. We next identified concentrations of 
each monotherapy necessary to obtain a similar reduction in cell viability as observed with 
combined treatments. Subsequently, CI for the combination treatments was calculated using 
the formula CI = [Ca,x/ICx,a] + [Cb,x/ICx,b]. Ca,x and Cb,x are the concentrations of drugs 
A and B used in combination to achieve x% drug effect, ICx,a and ICx,b are concentrations 
for single agents to achieve the same effects. A CI < 1 indicates synergy of the combination 
therapy. A CI equal to or higher than 1 indicates additivity or antagonism, respectively.
SOFT-AGAR COLONY-FORMING ASSAYS: Soft-agar colony forming assays were 
performed as previously described25.
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MOUSE XENOGRAFTS: Animal study protocols were performed in accordance with the 
guidelines of the Institutional Animal Welfare Committee of the Radboud University Nijmegen 
and Monash University. A total of 5 × 106–1 × 107 cells of Yamato-SS or Aska-SS cells were 
subcutaneously inoculated into 6–7-week-old female BALB/c mice (n = 6–9 per group). Drug 
administration was initiated when tumors were palpable. Crizotinib, ceritinib, and pazopanib 
were suspended in 0.5% hydroxypropylmethylcellulose (HPMC) + 0.5% Tween-80 to the 
necessary concentrations. For dose–response experiments, mice bearing Yamato-SS tumors 
were randomized into four groups receiving either crizotinib (0 mg/kg, 12.5 mg/kg, 25 mg/
kg, or 50 mg/kg) once daily or pazopanib (0 mg/kg, 10 mg/kg, 30 mg/kg or 100 mg/kg) twice 
daily, both orally. Mice bearing Aska-SS tumors were treated with either vehicle or 50 mg/kg 
Figure 7.1:  Tyrosine phosphorylation profi ling of sarcoma cell lines. A, Unsupervised 
hierarchical clustering of sarcoma cell lines based on tyrosine phosphorylation patterns. In 
general, the cells clustered into two major groups: 1, adult sarcomas (GIST and AS; Subgroup 
A); 2, pediatric/AYA sarcomas (SyS, RMS, and ES; further divided into subgroups B and C). 
Color bars indicate sarcoma subgroups as described in Table 7.1. B, Protein–protein network 
analysis of subgroup A revealing PTK2 (FAK) as key mediator. Red dots, hyperphosphorylated 
proteins found in subgroup A only. Direct protein–protein interactions are indicated by blue 
lines, while kinase–substrate relationships are indicated by magenta lines with arrows. C, 
Unsupervised hierarchical clustering using tyrosine kinase–derived phosphopeptides.
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of crizotinib or ceritinib once daily. Tumor growth was measured twice weekly with calipers. 
After 28 days of treatment, all mice were sacrificed and the resected tumors were fixed in 
formalin.
IMMUNOHISTOCHEMISTRY: IHC of MET, PDGFRα, and ALK on SyS patient TMAs and 
CD34 and Ki67 staining on SyS tumor xenografts was performed as previously described21,26 
(antibody details: see Supplementary Table online). Patient characteristics are listed in 
Supplementary Table 7.2.
AFFYMETRIX ANALYSIS: ALK, MET, and PDGFRα mRNA transcript levels were 
extracted from a publicly available Affymetrix dataset (accession number GDS2736) of 105 
clinical STS specimens (including 16 SyS) to compare mRNA transcript levels between 
sarcoma subgroups.
Results
PHOSPHOTYROSINE PROFLING OF HUMAN SARCOMA CELL LINES: Our cell line 
panel comprised 20 different sarcoma cell lines, including adult (AS and GIST) and pediatric/
AYA (ES, RMS and SyS) sarcomas (Table 7.1). Note that even though SyS can occur at 
all ages, all cell lines were derived from young adult patients. Tyrosine phosphorylation 
patterns were characterized by an immunoaffinity-coupled LC/MS-MS workflow, and after 
application of stringent filter criteria (see Materials and Methods), we identified 1,090 tyrosine 
phosphorylated peptides corresponding to 654 proteins. Of these 1,090 peptides, 334 met 
criteria for inclusion in subsequent hierarchical clustering analyses (Materials and Methods). 
Upon unsupervised hierarchical clustering of the different sarcoma cell lines based on their 
tyrosine phosphopeptide profile, the cell lines clustered into two major groups, being the 
adult sarcomas (GIST and AS; designated Subgroup A) and the pediatric/AYA sarcomas (SyS, 
RMS, and ES; Figure 7.1A). As the large pediatric/AYA cluster split into the ES4 cell line and 
two smaller clusters, we have designated the latter two pediatric/AYA clusters Subgroups B 
and C, respectively (Figure 7.1A). Note that in this subclassification, cell lines of particular 
sarcoma subtypes do not always cluster together. The majority of the ES cell lines are split 
between subgroups B and C. In addition, examples of RMS lines were also found in these 
two subgroups, and this subclassification was not explained by their aRMS (translocation-
positive; Table 7.1) or eRMS (translocation-negative) status. However, the SyS cell lines 
clustered together in subgroup B.
To identify signaling networks that exhibited differential activity across novel subgroups 
A–C, an ANOVA-based approach was applied to identify subgroup-enriched phosphosites, 
followed by bioinformatic determination of protein–protein interaction networks or pathways 
associated with these sites27. Subgroup A was characterized by hyperphosphorylation of 
48 phosphosites, with significant enrichment for the pathways associated with Fc gamma 
receptor (FCGR)-dependent phagocytosis, EPH-Ephrin signaling, adherens junctions, and 
cytoskeletal organization. Protein–protein interaction analysis for the proteins corresponding 
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to these phosphosites revealed a network with the key hubs PTK2 (focal adhesion kinase; 
FAK) and ACTB (β-actin; Figure 7.1B). Other kinases present within this network were FGR, 
MAPK3, TYRO3, and YES1. The only phosphosite significantly enriched in subgroup B 
versus the other two subgroups was PKP4 Y478, whereas subgroup C was characterized by 
significant hypophosphorylation of 48 sites compared with subgroups A and B. The protein–
protein interaction network corresponding to these hypophosphorylated sites exhibited major 
hubs associated with PI3K signaling (PIK3R1, PIK3R2), and this approach also emphasized 
the decreased phosphorylation of certain kinases (PDGFRα, EPHA2, and JAK2) in subgroup 
C versus the other subgroups (Supplementary Figure 7.1).
Next, tyrosine kinases (TK) were extracted from the original dataset, as these represent an 
important class of oncogenes and druggable targets14. This resulted in the identification of 132 
phosphotyrosine peptides belonging to 41 TKs, including 26 receptor tyrosine kinases (RTK) 
and 15 nonreceptor TKs. Unsupervised hierarchical clustering based on the tyrosine kinase–
derived phosphopeptides resulted in a more complex pattern than that generated using all 
phosphopeptides, but served to highlight ALK and KIT as highly-phosphorylated “outliers” 
in the Aska-SS and GIST882 cell lines, respectively, that may act as drivers (Figure 7.1C). To 
facilitate comparison between different (R)TKs, the total tyrosine phosphorylation count was 
calculated per protein (see Materials and Methods; Figure 7.2A). For RTKs, ALK, EPHA2, and 
KIT contributed the greatest proportion of phosphopeptide counts across the panel (although 
this reflects major contributions from individual cell lines for ALK and KIT, Figure 7.2B), 
while for nonreceptor TKs, FAK, LYN, SRC, and YES made the largest contributions (Figure 
7.2A). Considering the phosphorylation patterns across the panel, the nonreceptor TKs SRC/
LYN/YES, FAK1 and the RTK EPHA2 were phosphorylated at high levels in the majority of 
cell lines (Figure 7.2B). Some tyrosine kinases exhibited enhanced phosphorylation in subsets 
of cell lines without a clear preference toward a specific sarcoma subtype (e.g., EPHB3 in 
ES7, RH18, Rh36, and Aska-SS). Certain kinases appeared to be more sarcoma subtype-
specific, as exemplified by increased phosphorylation of DDR2 in ES cells, FGFR4 in RMS, 
EGFR, EPHA7, and PDGFRα in SyS and finally TIE1, VEGFR2, FGR, and BMX in AS. As 
expected, the GIST882 cell line exhibited an exceptionally high level of KIT phosphorylation 
(Figure 7.2B), reflecting its KIT-driven phenotype and imatinib sensitivity28. Interestingly, an 
extreme phosphotyrosine content was observed for ALK in the Aska-SS cell line, suggesting 
a novel and yet undescribed role for ALK as an oncogenic driver in SyS.
ALK REPRESENTS A NOVEL DRIVER IN SYS: In addition to the marked ALK tyrosine 
phosphorylation in Aska-SS, our MS analyses detected low ALK tyrosine phosphorylation 
on specific sites in ES2, EW8, Rh3 and Rh5. However, only Aska-SS cells demonstrated 
detectable phosphorylation on the ALK activation loop residues Y 1278, 1282, and 128329. 
Western blotting detected expression of full-length ALK (220 kDa) in several sarcoma cell 
lines, including ES7, EW8, Rh41, and Rh3 (Supplementary Figure 7.2), whereas Aska-SS 
expressed two predominant anti-ALK immunoreactive bands of approximately 110 and 80 
kDa (Figure 7.2C). Importantly, these aberrant ALK proteins in Aska-SS were detected using 
ALK-antibodies directed to pY1096, Y1507 and Y1282/1283, with highest phosphorylation 
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levels in the 110 kDa variant (Figure 7.2C). The latter observation particularly applied to 
activation loop phosphorylation. These data indicated that Aska-SS cells express truncated, 
activated ALK proteins, and suggested the 110-kDa variant represents the major driver. 
To determine the origin of these aberrant proteins, FISH analysis was undertaken, which 
identified heterozygous ALK breakage in Aska-SS cells (Figure 7.3A). RNAseq using an 
ALK Capture panel did not detect an ALK fusion partner, but instead revealed discontinuous 
coverage of ALK exons, with low expression from exon 1, absent expression from exons 
2-17, and the majority of expression from exon 18 onwards (Figure 7.3B). RT-PCR confirmed 
the presence of mRNA transcripts where exon 1 (containing the usual initiation codon) 
is spliced to exon 18 (Figure 7.3C and D). These would encode an aberrant ALK protein 
lacking the extracellular region encoded by exons 2–17, designated ALK Δ2-17 (Figure 7.3E; 
Supplementary Figure 7.3) with a predicted molecular weight of approximately 100 kDa. As 
the larger ALK immunoreactive band in Aska-SS was approximately 110 kDa, we determined 
whether the size difference between this and the predicted product was due to glycosylation. 
Treatment of Aska-SS lysate with endoglycosidase H, which targets high mannose-containing 
immature N-linked carbohydrates, resulted in partial conversion of the 110-kDa band to a 
100-kDa form (Supplementary Figure 7.4A), while incubation with O-Glycosidase resulted 
in a small but reproducible increase in mobility. However, treatment with N-glycosidase F, 
which removes almost all types of N-linked (Asn-linked) glycosylation, resulted in complete 
conversion to a 100-kDa form consistent with the predicted size for ALK Δ2–17. This also 
resulted in a shift of the 80-kDa ALK band to approximately 70 kDa. The 70-kDa form is 
consistent with use of initiation sites within exon 18, or alternatively this may represent a 
cleaved version of the larger variant. Treatment of cells with tunicamycin, an inhibitor of 
N-linked glycosylation, confirmed the impact of this modification on mobility of ALK Δ2–17 
(Supplementary Figure 7.4B). ALK mutation analysis in the other SyS cell lines demonstrated 
a previously reported ALK exon 23 deletion in Yamato-SS cells. This is known to also occur 
in RMS and ES, and has no effect on crizotinib sensitivity20,30,31.
To determine the functional role of ALK in SyS, the effect of a panel of ALK inhibitors 
including the clinically used compounds crizotinib (ALK/MET) and ceritinib (ALK), and 
the tool compound TAE684 (ALK), on cell proliferation was determined (Figure 7.4A; 
Supplementary Table 7.3). Aska-SS cells were extremely sensitive to all three inhibitors, 
with IC50 values ranging between 26 and 46 nmol/L. The other three SyS cell lines exhibited 
markedly lower sensitivity to TAE684 and ceritinib, reflecting their lack of ALK activation. 
Yamato-SS cells were also sensitive to crizotinib, likely explained by high levels of MET 
activation, consistent with their sensitivity to the MET/VEGFR2 inhibitor foretinib (Figure 
7.4A; Supplementary Figure 7.5). Crizotinib IC50 values were substantially higher for SYO-
1 and CME-1 cells, which exhibit undetectable or very low levels of ALK/MET tyrosine 
phosphorylation (Figure 7.2B). Western Blot and PathScan analysis determined that the ALK 
inhibitors decreased ALK phosphorylation in Aska-SS cells and in general, significantly 
reduced activation of Erk, Akt, S6RP, STAT3, and STAT1 (Figure 7.4B and C). Prolonged 
treatment resulted in decreased expression of cyclin A, Rb hypophosphorylation and 
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PARP cleavage, consistent with increased cell-cycle arrest in G1 and enhanced apoptosis 
(Supplementary Figure 7.6). Importantly, treatment of mice bearing subcutaneous Aska-SS 
xenografts with either crizotinib or ceritinib demonstrated a remarkable dependency on ALK 
for tumor growth and maintenance, with drug treatment resulting in robust and durable tumor 
regressions (Figure 7.4D and E). Histopathology analyses demonstrated that these regressions 
were associated with a signifi cant decrease in the number and size of tumor blood vessels, 
as well as less proliferative cells (Supplementary Figure 7.7). Overall these data demonstrate 
that ALK Δ2–17 activates multiple proliferative and survival pathways, resulting in ALK 
addiction both in vitro and in vivo.
Figure 7.3:  Characterization of the novel ALK driver in Aska-SS cells. A, FISH analysis 
demonstrating ALK breakage in the Aska-SS cell line. The arrows highlight single red signals 
indicating the presence of a breakpoint, whereas the other signals comprise both green and red label 
indicating full-length ALK. Image is at ×630 magnifi cation. B, Discontinuous expression of ALK 
coding exons in Aska-SS. RNAseq was undertaken following capture of transcripts corresponding 
to ALK-coding regions. Note low expression of exon 1, absent expression of exons 2–17, and then 
high expression from exon 18 onwards. The black and blue bars represent the mean expression 
levels for exons 1–17 and 18–29, respectively. C, Confi rmation of exon 1-exon 18 splicing in Aska-
SS. RT-PCR was undertaken on total RNA from Aska-SS and EW8 (harboring full-length ALK). For 
Aska-SS, lanes 1, 2, 3, and 4 contain products generated from primers specifi c for exons 1 (forward) 
and 18 (reverse; predicted size for ALK variant: 317 bp), exons 1 and 21 (predicted size for ALK 
variant: 784 bp), exon 18 and 21 (predicted size for ALK-variant: 415 bp), and exon 1-C-terminal 
end of coding region (predicted size for ALK-variant: 2,098 bp), respectively. The same reactions 
were undertaken for EW8, but only the exon 18 and 21 primers generate a detectable product as 
the other fragment sizes are too large in the context of full-length ALK. D, Confi rmation of exon 
1-exon 18 splicing by DNA sequencing. The 317-bp product generated by RT-PCR was subjected 
to DNA sequencing. The nature of other products in C was also confi rmed by this approach. E, 
Schematic representation of the truncated form of ALK in Aska-SS (ALK Δ2–17). The extracellular 
domain of full-length ALK comprises two MAM (meprin, A5 protein and receptor protein tyrosine 
phosphatase mu) domains (aa 264–427 and 480–626), one low-density lipoprotein class A (LDLa) 
motif (aa 453–471), and a glycine-rich region (aa 816–940; ref. 50). Because exons 2–17 of ALK 
encode the aa 223–971 region, the deletion results in a truncated form of ALK (ALK Δ2–17) lacking 
these four domains. TM, transmembrane; PTK, protein tyrosine kinase.
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Figure 7.4: Validation of ALK as a potential actionable target in SyS. A, Effect of ALK inhibitors on SyS cell 
line proliferation in vitro. The graphs indicate dose–response curves of SyS cell lines to crizotinib, ceritinib, and 
TAE-684 monotherapies. Error bars, SDs. B, Effect of crizotinib on key signaling pathways in the Aska-SS cell 
line. Cells were treated with the indicated concentrations of crizotinib for 1 hour. Cell lysates were prepared and 
Western blotted with the indicated antibodies. Data are representative of duplicate experiments. C, Pathscan 
signaling pathway analysis for Aska-SS cells treated with ALK inhibitors. Cells were treated with TAE684 (25 
nmol/L), ceritinib (100 nmol/L), or crizotinib (750 nmol/L) for 24 hours. All signals were significantly different 
from control (p< 0.05), apart from the trends observed for ceritinib on pAkt Ser473 (p=0.0561), TAE684 on 
pAkt Thr308 (p=0.0728), TAE684 on pSTAT3 Tyr705 (p=0.0636), and no significant difference for crizotinib on 
pSTAT1 Tyr701 (p=0.1563). D and E, Effect of ALK inhibitors on Aska-SS xenograft growth. Mice were treated 
with crizotinib (50 mg/kg; D) or ceritinib (50 mg/kg; E). Values are presented as mean relative tumor volume ± SD. 
P values were assessed by Student t test. F, Expression of ALK in human SyS. Examples of patient SyS sections 
with positive (left) and negative (right) ALK expression, as determined by IHC. Images are ×200 magnification; 
insets are ×400 magnification. G, IHC staining of ALK in Aska-SS (positive control for F). Image is at ×200 
magnification. H, FISH analysis demonstrating ALK breakage in a SyS patient. The arrows highlight single colored 
signals indicating a breakpoint. Image is at ×100 magnification.
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Figure 7.5:  Targeting of MET and PDGFRα in in vitro and in vivo SyS models. A, Effect of pazopanib on SyS cell 
line proliferation in vitro. The graph indicates dose–response curves for the different cell lines. Error bars, SDs. B, 
Expression of total MET and PDGFRα RTKs in the four SyS cell lines. For MET, the 145-kDa band represents 
mature, processed MET; the upper band seen in Yamato-SS is pro-MET. C, Synergism between pazopanib and 
crizotinib treatment in the Yamato-SS cell line in vitro. The x-axis and y-axis, respectively, show the relative 
concentration of pazopanib and crizotinib in synergy compared with the concentrations required in monotherapy 
to obtain a similar effect on SyS cell viability (concentration combination/concentration monotherapy; details in 
Materials and Methods). The bold line represents a combination index of 1. Dots below, on, or above the bold line 
represent synergy, additivity, or antagonism, respectively. Numbers next to the dots indicate the concentrations 
of pazopanib (nmol/L; left) and crizotinib (nmol/L; right) used in the combinations. D, Effect of pazopanib and 
crizotinib, alone and in combination, on key signaling pathways in Yamato-SS cells. Cells were treated with the 
indicated concentrations of pazopanib and crizotinib for 1 hour. Cell lysates were prepared and Western blotted with 
the indicated antibodies. Data are representative of duplicate experiments. E, Pathscan signaling pathway analysis 
for Yamato-SS cells treated with pazopanib and/or crizotinib. Cells were treated with crizotinib (250 nmol/L) 
and/or pazopanib (10 μmol/L) for 24 hours. All signals were signifi cantly different (p<0.05) versus control, apart 
from combination treatment on pAkt Thr308 (p=0.102) and pazopanib pStat3 Tyr705 (p=0.0825). With combined 
treatment, the reduction in pAkt Ser473 and STAT1 Tyr701 was signifi cant compared with both monotherapies and 
control (all p<0.01; Student t test). F, Effect of pazopanib and crizotinib, alone and in combination, on anchorage-
independent growth of Yamato-SS cells. Error bars, SD; p-values were obtained with Student t test. G, Effect 
of crizotinib on Yamato-SS xenograft growth. Mice were treated with the indicated concentrations of crizotinib. 
Values are presented as mean relative tumor volume ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001 as assessed by 
Student t test. H, Effect of pazopanib on Yamato-SS xenograft growth. Values are presented as in G. *, p<0.05; **, 
p<0.01 as assessed by Student t test. I, Effect of pazopanib on angiogenesis. CD34 expression in Yamato-SS tumors 
from the pazopanib treatment group (100 mg/kg; top) and control group (bottom). Images are ×100 magnifi cation.
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To confirm the clinical relevance of these findings, we first interrogated a publicly available 
Affymetrix dataset of 105 clinical STS specimens (including 16 SyS) and compared ALK 
mRNA transcript levels between sarcoma subgroups. This determined that ALK mRNA was 
significantly more highly expressed in SyS as compared with other STS, suggesting a unique 
and specific role for ALK in SyS versus other STS subtypes (Supplementary Figure 7.8). 
In addition, we assessed protein expression of ALK in 43 primary SyS patient specimens. 
ALK immunopositivity was observed in 6 of 43 (14%) of the patients (Figure 7.4F and G; 
Supplementary Figure 7.9). No significant correlation was found between ALK expression 
levels and patient outcome. The ALK-expressing samples were also evaluated by FISH. 
Interestingly, one of the six ALK-positive patients showed ALK rearrangement in 23% of 
the cells (100 cells counted; Figure 7.4H). This prompted us to evaluate an additional four 
metastatic lesions from the same patient. All lesions were positive for ALK expression. FISH 
analysis reported translocations in 10%–15.3% of cells in three of the lesions (50–150 cells 
counted per lesion, depending on lesion size). The fourth lesion showed ALK gain of up to 6 
copies. These data validate our cell line–based in vitro and in vivo studies and highlight ALK 
as an important therapeutic target in a subset of SyS.
Figure 7.6: MET and PDGFRα expression in SyS patient tumors. A and B, Examples of patient 
SyS sections with positive (left) and negative (right) MET and PDGFRα expression, respectively. 
C, Example of a patient with a biphasic, primary SyS. Expression of MET in the epithelial 
cells (left) and PDGFRα in the mesenchymal cells (middle) is evident. General morphology is 
demonstrated by hematoxylin and eosin staining (right). Images are ×200 magnification; insets 
are ×400 magnification.
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KINASE ACTIVATION PROFILES AND RATIONAL DESIGN OF COMBINATION 
THERAPIES: Although the phosphoproteomic analysis identifi ed driver kinases in Aska-SS 
and GIST882 cell lines, the other sarcoma cell lines often exhibited more than one TK with 
high levels of activation (Figure 7.1A and 2B). One way to overcome the problem of network 
“robustness” conferred by multiple activated kinases is implementation of combination 
treatments or use of appropriate multikinase inhibitors25. Again, we focused on the SyS cell 
lines to further test this hypothesis. In addition to aberrant ALK activation in Aska-SS, these 
lines were characterized by high MET (in Yamato), and PDGFRα and EGFR phosphorylation 
in all of the lines (Figure 7.2B). No mutations were found in MET, PDGFRα, or EGFR in 
any of the SyS cell lines. PDGFR- or EGFR-targeted monotherapies proved ineffective in 
vitro, with at best modest growth suppression with the VEGF/PDGFR inhibitor pazopanib in 
SYO-1 cells (Figure 7.5A; Supplementary Figure 7.5; Supplementary Table 7.3). Therefore, 
we determined whether simultaneous targeting of one of these kinases might enhance the 
observed sensitivity of Yamato-SS cells to the ALK/MET inhibitor crizotinib (Figure 7.4A). 
Given the robust expression of PDGFRα in Yamato-SS cells (Figure 7.5B), and the fact that 
pazopanib is clinically approved for SyS treatment, this was undertaken with pazopanib. 
Interestingly, synergistic effects (CI<0.8) were observed upon combined treatment with 
pazopanib and crizotinib (Figure 7.5C), indicating that targeting PDGFRα is effective but only 
in the context of MET inhibition. Western blot and PathScan signaling analysis revealed that 
Erk activation was sensitive to crizotinib but not pazopanib, and determined that combination 
treatment signifi cantly reduced Akt S473 and STAT1 Y701 phosphorylation compared with 
each monotherapy and control, providing potential mechanisms for the observed drug synergy 
(Figure 7.5D and E). Combination treatment also resulted in enhanced apoptosis, as indicated 
by the appearance of cleaved PARP at 48 hours posttreatment (Supplementary Figure 7.10). 
Combined treatment with crizotinib and pazopanib was also signifi cantly more effective than 
either monotherapy in soft-agar colony-forming assays (Figure 7.5F).
However, in mice bearing subcutaneous Yamato-SS xenografts, we observed a dose-dependent 
tumor growth retardation with each compound individually, which was more pronounced with 
crizotinib (Figure 7.5G and H). Crizotinib-treated tumors were characterized by signifi cant 
reductions in blood vessel size (mean CD34+ vessel surface for vehicle, 176.8 mm2/vessel 
vs. crizotinib 50 mg/kg, 129.3 mm2/vessel, p=0.0261) and tumor cell mitotic count (vehicle, 
3.1 ± 0.9 vs. crizotinib 50 mg/kg, 0.8 ± 0.3, p=0.0057). Therefore, Yamato-SS cells exhibit 
a dependency on MET for tumor growth in vivo. In pazopanib-treated tumors, there were 
signifi cantly fewer CD34+ blood vessels compared with controls (vehicle, 189.7/mm2 vs. 
pazopanib 100 mg/kg, 122.2/mm2; p=0.0073; Figure 7.5I). This effect on angiogenesis, likely 
mediated by VEGFR inhibition, probably underpins the contrasting sensitivity of Yamato-SS 
cells to pazopanib treatment in vitro and in vivo. Overall, these data demonstrate that MET 
represents a potential therapeutic target in a subset of SyS, indicate that pazopanib may also 
be of benefi t for specifi c SyS patients, and highlight the potential clinical utility of crizotinib/
pazopanib combination treatment.
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MET AND PDGFRα EXPRESSION IN SYS PATIENTS: To interrogate MET and PDGFRα 
expression in SyS patients, we utilized publicly available Affymetrix gene expression data 
and also assayed our own cohort of clinical SyS specimens by IHC. There was no significant 
difference for MET mRNA expression in SyS compared with the other sarcoma histologies, 
but there was a trend for higher PDGFRα mRNA expression in SyS (Supplementary Figure 
7.8). Immunopositivity for MET or PDGFRα was detected in 58% (25/43) and 84% (36/43) 
of SyS patients, respectively (Figure 7.6A and B). In 56% (24/43) of SyS patients, the two 
proteins were coexpressed, but the highest scores for PDGFRα and MET were mutually 
exclusive. Interestingly, two of the patients presenting with the histologic biphasic SyS 
subtype showed a remarkable differential MET/PDGFRα coexpression pattern, with MET 
and PDGFRα expressed mutually exclusively in distinct areas of the tumor resembling the 
epithelial and spindle cell components characteristic of this subtype (Figure 7.6C). These data 
confirm that MET and PDGFRα represent potential therapeutic targets in SyS, either alone or 
in combination.
Discussion
In this study, we utilized mass spectrometry–based phosphoproteomics to profile the largest 
and most heterogeneous set of sarcoma cell lines screened to date to identify perturbed 
signaling networks characteristic of existing or novel subtypes, and driver kinases that may 
represent candidate therapeutic targets. Importantly, this has identified several potential 
therapeutic strategies for specific subsets of SyS patients, highlighting opportunities for 
personalized treatment of this sarcoma subtype.
Our study identified ALK as a novel driver in the Aska-SS cell line, with exceptionally high 
ALK tyrosine phosphorylation levels similar to those of the driver kinase KIT in the imatinib-
sensitive GIST882 cell line28. We determined that the ALK sensitivity in Aska-SS was 
underpinned by expression of a novel truncated ALK variant lacking a significant proportion 
of the extracellular domain (ALK Δ2–17). Other activated ALK variants with extracellular 
domain deletions have been described in neuroblastoma and melanoma, where the deletions 
encompass regions encoded by exons 2–3, and all of the extracellular domain, respectively32,33. 
Consequently our data add to growing evidence that extracellular domain deletions unleash 
the oncogenic potential of ALK, and represent a significant mechanism for ALK deregulation 
in human cancers, in addition to mutation, fusion and gene amplification/overexpression29.
Although all SyS tumors harbor SS18-SSX fusion genes, there is a wide variety in clinical 
behavior and response to chemotherapy or targeted treatment within these tumors, emphasizing 
the role of additional factors in orchestrating SyS progression34. Our detection of ALK Δ2–17 
in the Aska-SS cell line, and an ALK rearrangement in an ALK-immunopositive SyS patient 
specimen, highlight ALK alterations as one such factor. Because the ALK aberration was 
detected in 1 of 4 SyS cell lines and 1 of 43 SyS patients, yet all of our SyS samples and cell 
lines harbored the characteristic SS18-SSX translocation, ALK is likely not associated with 
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the characteristic SS18-SSX fusion gene. In addition, as the Aska-SS cell line harbors SS18-
SSX1, while the patient specimen contained SS18-SSX2, ALK aberrations are not associated 
with expression of a specifi c SS18-SSX fusion. As ALK activation in STS has been linked to 
the presence of metastatic lesions35, Aska-SS is derived from a pulmonary metastatic lesion, 
and the ALK breakage–positive SyS patient demonstrated breakage-positive metastases, 
ALK aberration in SyS may be required for metastatic progression. However, it is clear from 
our comprehensive functional analyses in Aska-SS that ALK signaling is required for cell 
proliferation and survival in vitro, and tumor growth and maintenance in vivo. Consequently, 
once ALK activation occurs, the cancer cells can become dependent on this driver, despite the 
presence of a SS18-SSX fusion.
We acknowledge that ALK-targeted treatment will likely not be applicable to SyS tumors 
in general, but the dependency of a subset of these tumors on ALK signaling offers great 
potential for personalized treatment within this sarcoma subtype. In this regard, ALK protein 
expression was detected in 14% of primary SyS tumors and 1 of 6 of the ALK immunopositive-
tumors exhibited ALK rearrangement, with the percentage of breakage-positive cells meeting 
diagnostic criteria for designation as ALK aberration-positive. The presence of a small 
subpopulation of SyS patients exhibiting these characteristics is similar to non–small cell 
lung cancer (NSCLC), where ALK rearrangements are found in 2%–7% of cases36. In the 
latter setting, oncogenic ALK fusions are an established companion biomarker for crizotinib 
sensitivity. In addition, IC50 values for crizotinib in Aska-SS cells were similar to those of 
ALK-rearranged lymphoma cells, where ALK is an established clinical target37. Consequently 
our work highlights ALK as an oncogenic driver and highly promising therapeutic target in a 
subset of SyS.
ALK has also been assessed as a therapeutic target in other sarcoma subtypes. A phase I dose-
escalation study of crizotinib for pediatric cancer patients, including a variety of sarcoma 
subtypes, reported enriched antitumor activity in patients with infl ammatory myofi broblastic 
tumors (IMT). Here, the impressive response rate in this subtype was attributed to the presence 
of activating ALK aberrations. No ALK aberrations or objective responses to crizotinib were 
reported in other sarcoma subtypes, although no SyS patients were included38. In addition to 
IMT, RMS have been subject to clinical evaluation of crizotinib effi cacy based on reported 
ALK protein expression and gene amplifi cation31 (NCT01548926, NCT02034981, and 
NCT01742286). However, no objective responses have been reported in RMS patients39,40. 
These data may refl ect a failure to detect genomic ALK rearrangements in this subtype. 
Furthermore, while we could detect ALK expression in certain RMS cell lines, this was 
not accompanied by relevant levels of ALK phosphorylation, indicating that ALK protein 
overexpression in RMS may not be accompanied by receptor activation.
Three other RTKs demonstrated enhanced activation in SyS cell lines, MET in Yamato-
SS, and PDGFRα and EGFR in all SyS lines. Importantly, Yamato-SS cells were sensitive 
to crizotinib in vitro and in vivo, and over half of primary SyS tumors demonstrated MET 
expression, highlighting MET as a potential therapeutic target in this sarcoma subtype. In the 
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case of PDGFRα and EGFR, treatment of SyS cells with pazopanib, gefitinib, or erlotinib 
was without effect in vitro, indicating that these RTKs do not act as sole drivers. However, 
pazopanib exhibited efficacy against Yamato-SS xenografts, likely reflecting an additional 
effect on VEGFRs leading to reduced angiogenesis. The latter data are consistent with 
pazopanib monotherapy demonstrating clinical benefit in a subset of SyS patients, with 49% 
of the patients having stable disease at 3 months41. Also, in the extended phase III trial, there 
was a trend for SyS patients to have superior responses on pazopanib, though this was not 
significant, possibly due to the relatively small size of this subgroup3. Clearly, our data and 
recent clinical studies highlight the therapeutic potential for pazopanib in SyS, but further 
work is required to identify biomarkers of therapeutic response that allow administration in a 
personalized fashion.
Two additional aspects of our study are worthy of comment. First, we determined that a high 
proportion of clinical SyS specimens coexpress both MET and PDGFRα, with a subset of 
biphasic tumors exhibiting differential localization of these receptors to the epithelial and 
spindle cell components of the tumor, respectively. Although at this point we could not assess 
phosphorylated protein expression status with IHC on our clinical dataset, these data validate 
the presence of high levels of these receptors in subsets of SyS patients. Second, combined 
treatment of Yamato-SS cells with pazopanib and crizotinib demonstrated synergistic effects 
in vitro and in anchorage-independent growth assays, consistent with the high expression and 
activation of both MET and PDGFRα. Although the expression of MET has been described 
previously in SyS, explicitly in the epithelial part42,43, its combination with PDGFRα 
expression in spindle cell parts in biphasic tumors is novel, as is the combination of MET and 
PDGFRα targeting. Consequently, our work highlights a potential combination therapy that 
could be used for SyS tumors that coexpress MET and PDGFRα, either in the same tumor 
region, or in a biphasic fashion. In this context, it is worth noting that two phase I studies in 
other advanced cancers are running: NCT01468922, combining the MET-inhibitor ARQ197 
with pazopanib; and NCT01548144, combining pazopanib with crizotinib. A preliminary case 
report of the latter study reported a therapeutic response and good tolerability of the combined 
treatment at the lowest doses44 (200 mg pazopanib with 250 mg crizotinib), emphasizing its 
clinical potential.
Beyond SyS, the global and unbiased nature of our phosphoproteomic profiling approach 
enabled us to identify potential therapeutic targets for other sarcoma subtypes, including 
DDR2 in ES and FGFR4 in RMS. In addition, molecular subclassification based on tyrosine 
phosphorylation patterns led to a novel taxonomy, with the pediatric/AYA sarcomas clustering 
away from adult sarcomas and subdivided into two subgroups. In this subclassification, cell 
line models of the ES and RMS sarcoma subtypes do not cluster together in their designated 
ES and RMS histologic classifications, respectively, highlighting how knowledge of histologic 
subtype is insufficient for assigning targeted treatments, and further molecular interrogation 
is required to design more personalized approaches. To this end, detailed signaling network 
analyses identified hyper- and hypophosphorylation signatures characteristic of each of 
the novel subgroups, revealing that the hyperphosphorylation pattern in subgroup A (adult 
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sarcomas) is built around a network with PTK2 (FAK) as a key component, potentially 
identifying FAK as a specifi c, and actionable vulnerability in these tumors. Importantly, a 
number of small-molecule FAK tyrosine kinase inhibitors are currently undergoing preclinical 
and clinical testing. In particular, PF-00562271, VS-4718 and VS-6063 demonstrated 
promising clinical activity in patients with selected solid cancers, emphasizing their potential 
utility for sarcoma treatment45,46.
Of note, the potential of phosphoproteomic screening of sarcomas in the clinic is underlined 
by recent studies: in a clinical (not further specifi ed) sarcoma sample, phosphoproteomics 
was capable of detecting an ALK-rearrangement47, as we did in the Aska-SS cell line, and this 
technique has also enabled patient stratifi cation in RMS48. For clinical samples, the use of 
reverse-phase protein arrays (RPPA) or NanoString technology may offer a practical approach 
for interrogating phosphorylation status when limited amounts of tissue are available48. The 
coupling of phosphoproteomic approaches with other established techniques in clinical trial 
design and accompanying translational studies may therefore be of great value in design of 
personalized sarcoma treatments49. The potential power of a phosphoproteomics approach 
over genomic analyses in SyS is exemplifi ed by the study of Ishibashi and colleagues, in 
which pALK expression was detected in SyS cases without underlying genomic aberrations35.
In conclusion, our study has provided detailed insights into the signaling network 
characteristics of particular sarcoma subtypes and identifi ed potential therapeutic targets that 
have been validated using both in vitro and in vivo models and patient specimens. This work 
has identifi ed protein and phosphoprotein markers that, following further validation, could 
be incorporated into pathologic characterization of sarcomas, leading to improved patient 
stratifi cation for targeted treatment approaches.
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Supplementary methods
SAMPLE PREPARATION FOR PHOSPHOPROTEOMIC ANALYSIS: For each cell line, 
20 mg of protein was subjected to phosphoproteomic analysis. First, lysates were reduced 
with TCEP for 15 min at RT, followed by a 30 min incubation at RT with iodacetamide 
(IAA) to alkylate the samples. Then samples were pre-digested with Lys-C for 4h at RT after 
which samples were diluted to 0.8M Urea and CaCl2 was added to boost trypsin efficacy. 
Samples were digested overnight in trypsin at RT. The next day, trifluoroacetic acid (TFA) 
was added to a final concentration of 1% for 15 min at RT. Two “spike-in” standardized 
heavy peptides (EFTU and MAPK14; Mimotopes, Notting Hill, Australia) with alanine were 
added to enable normalization for quantification. Samples were spun for 4000 rpm for 15 
min prior to loading the sup on tC-18 desalting and concentration columns (Sep-Pak, Waters, 
Milford, MA, USA). Purified and concentrated peptides were lyophilized for 1-2 days and 
dissolved in immunoaffinity purification (IAP) buffer (50mM MOPS with 10mM sodium 
phosphate dibasic, 130mM sodium chloride and 0.5% NP40) and added to sepharose 4B 
beads pre-conjugated to 100ug of PY100 antibody (Cell Signalling Technology) and 100 μg 
of pY20 antibody (BD) in a 1:4 bead:antibody ratio. Peptides were incubated with antibodies 
overnight at 4°C with rotation. Non-specific binding peptides were removed by three washes 
with IAP buffer and three washes with milliQ. pY peptides were eluted with 0.1% TFA in 
40% acetonitrile (ACN) and the pY enriched peptides were dried using a vacuum centrifuge 
and stored at -80°C prior to nanoscale liquid chromatography coupled to tandem mass 
spectrometry (nano LC-MS/MS) analysis.
PHOSPHOPROTEOMIC ANALYSIS: For nano LC-MS/MS analysis, pY peptides were 
resuspended in MS loading buffer (0.1% formic acid and 2% ACN). Peptides were separated 
over a 30 min. gradient and mass spectrometry was performed using a Thermo Fisher Scientific 
(San Jose, CA, USA) Orbitrap Plus. Up to the 10 most abundant ions (>5,000 counts) with 
charge states > +2 were sequentially isolated and further subjected to MS/MS fragmentation. 
MS data were analyzed using MaxQuant software 16 (version 1.5.2.8.). Extracted peak 
lists were searched against the human UniProtKB/Swiss-Prot database (version 2010_10), 
concatenated with a proportionally sized decoy database for false discovery rate (FDR) as well 
as the reversed sequences of all entries. The following search parameters were selected for the 
pY data; fixed cysteine carbamidomethylation modification; variable methionine oxidation 
modification, variable protein N-acetylation, variable phosphorylation of serine, threonine 
and tyrosine, minimum peptide length of 6 amino acids and up to 2 missed cleavages were 
allowed. Match between run was enabled with default settings and label-free quantitation 
enabled where appropriate. For identification of the standard peptides, an additional variable 
modification of heavy alanine (+4 Da) was enabled. Protein, peptide, and site FDRs were 
controlled at a maximum of 1%.
PHOSPHOTYROSINE PEPTIDE QUANTITATION AND NORMALIZATION: Raw pY-
peptide spectral intensities were extracted from the ‘Evidence’ output files generated by 
Maxquant. These intensities were then normalised against pY peptide intensities for the 
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heavy labelled spiked in peptide standards combined with GSK3B. The label-free intensity 
values of EFTU, MK14 and GSK3B heavy peptides in each cell line were averaged and a 
subsequent normalization factor generated. MS intensity values of each pY site quantifi ed in 
the dataset were divided by the appropriate normalization factor. Raw MaxQuant output fi les 
were subjected to the following stringent fi ltering criteria prior to their inclusion in further 
bioinformatics analysis; 1) contaminants and reversed matches were removed, ensuring all 
identifi cations were reported with an FDR of <1%, 2) all non-pY-sites (serine and threonine) 
were removed, 3) pY-sites were fi ltered for a minimum localization probability confi dence 
of 0.75. All data was log2 transformed prior to bioinformatics analysis. Data analyses were 
performed using Microsoft Offi ce Excel and the bioinformatics platform Perseus (Max Planck 
Institute of Biochemistry, Munich) version 1.2.0.19.
SEQUENCE ANALYSIS: Sequencing reads were deduplicated with Tally v15-0657 and 
adaptor sequences removed with Cutadapt v1.8.18. Post-fi ltering, reads were mapped to human 
reference genome hg38 with STAR v2.4.2a9 and converted to UCSC genome browser tracks 
using the BEDTools v2.25.010 ‘genomecov’ command. ALK exonic coverage was calculated 
from uniquely-mapping reads using the BEDTools coverage tool.
ALK RT-PCR: 1 μg of total RNA was reverse-transcribed to DNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR was performed 
using the following primer sequences: Exon1-18-F1: 5ʹ-CGATCTTGGAGGGTTGCGTC-
3ʹ and Exon1-18-R1: 5ʹ-CTTGTGGCTTTCAGGGTCCA-3ʹ; Exon1-21-F1: 
GTCCAGGGTGCTGAAGGG and Exon1-21-R1: GCCTTCATACACCTCCCCAA; Exon18-
21-F1: TCACATGGACCCTGAAAGCC; 3’-end: GTAGCGGCTTCTAAGGGCAA. PCR 
products were gel-purifi ed using the Gel and PCR Clean-Up System (Promega) and were 
sequenced using the PCR primers.
Supplementary Table 7.1:  Specifi c information for MTT cell viability assays with single 
agents. Number of seeded cells per well was based on previously performed pilot experiments. 
Treatment duration was at least two times the doubling time, which was cell line dependent.
Cell line Number of cells/well Doubling time Treatment duration
Yamato-SS 5000 40 hours 4 days
Aska-SS 10000 65 hours 6 days
SYO-1 3000 58 hours 6 days
CME-1 4000 29 hours 3 days
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Supplementary Table 7.2: Patient characteristics of synovial sarcoma cohort. * Patients 
without a proven SS18-SSX translocation are not included in our cohort.
Total patients (n= 43) 
Gender Male
Female
Missing
: 27 (62.8%)
: 15 (34.9%)
: 1 (2.3%)
Follow-up Median
Mean
Range
Missing
: 39 months
: 65 months
: 5 - 240 months
: 12
Age at diagnosis Median
Mean
Range
: 32 years
: 34 years
: 10 – 76 years
Localization Extremity
Head/neck
Other
Missing
: 27 (62.8%)
: 6 (14.0%)
: 5 (11.6%)
: 5 (11.6%)
Histology Monophasic
Biphasic
Missing
: 17 (39.5%)
: 13 (30.2%)
: 13 (30.2%)
Translocation* SS18-SSX1
SS18-SSX2
SSX not further specified
Missing
: 21 (48.8%)
: 8 (18.6%)
: 5 (11.6%)
: 9 (20.9%)
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Supplementary Table 7.3:  Summary of SyS cell line sensitivity to specifi c tyrosine kinase 
inhibitors. IC50 values are presented in nM ±SD. 1TAE684 potentially also inhibits IGF-
1R. However, since no phosphorylated IGF-1R was demonstrated in the SyS cell lines, we 
considered TAE684 a specifi c ALK inhibitor in the SyS cell lines. 2Phosphorylated VEGFR was 
not detected in the SyS cell lines. *Foretinib, gefi tinib and erlotinib were tested at concentrations 
up to 1000 nM. All other compounds were tested up to a concentration of 10,000 nM.
Targets Yamato-SS Aska-SS SYO-1 CME-1
TAE684 ALK, IGF-1R1 811±126 26±3 354±81 201±32
Crizotinib ALK, MET 82±18 46±5 920±156 3132±596
Ceritinib ALK 1669±135 37±12 1476±56 1881±287
Foretinib* MET, VEGFR22 61±6 396±6 173±8 >1000
Pazopanib VEGFR2, PDGFR, KIT >10000 >10000 578±130 2999±197
Gefi tinib* EGFR >1000 >1000 >1000 >1000
Erlotinib* EGFR >1000 >1000 >1000 >1000
Supplementary Figure 7.1:  Integrated protein-protein interaction network for all sarcoma 
subgroups. Integrated network analysis of sarcoma Subgroups A, B and C. Red shading 
indicates proteins only hyperphosphorylated in subgroup A, while green indicates proteins 
only hypophosphorylated in subgroup C. The blue shading highlights WEE1 which is only 
hypophosphorylated in subgroup A, and the yellow shading indicates hyperphosphorylation 
in subgroup B. Direct protein-protein interactions are indicated by blue lines, while kinase-
substrate relationships are indicated by magenta lines with arrows.
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Supplementary Figure 7.2:  ALK expression and phosphorylation in ES and RMS cell lines. 
Lysates were Western blotted with antibodies specifi c for total ALK and pALK (pY1096, 
activation loop residues pY1282/pY1283, and pY1507). Normal ALK has a mobility of 220 
kDa, as indicated with the green arrows on all blots. Orange arrow indicates cleaved ALK and/
or cross-reacting bands of approximately 140 kDa. The asterisk indicates a cross-reacting band 
of approximately 120 kDa.
Supplementary Figure 7.3:  Schematic representation of ALK exon 2-17 deletion in Aska-
SS cells. Mapping of ALK exons to the extracellular, transmembrane (TMD) and intracellular 
(kinase) domains.
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Supplementary Figure 7.4:  Deglycosylation of ALK in Aska-SS cells. A. Treatment of Aska-
SS cell lysates with Endo H, O-Glycosidase and N-glycosidase F enzymes. Buffer 1 is used 
for Endo H, buffer 2 for O-Glycosidase and N-glycosidase F. Following the deglycosylation 
reactions the lysates were subjected to Western blot analysis. Data are representative of triplicate 
experiments. B. Treatment of Aska-SS cells with tunicamycin. Following 24 h treatment cell 
lysates were prepared and Western blotted for ALK. Blotting for 14-3-3 was used as a loading 
control. Data are representative of duplicate experiments. For A and B, positions of size markers 
(in kDa) are indicated on the left. Arrows on the right indicate 100 kDa band consistent with 
ALK Δ2-17.
Supplementary Figure 7.5:  SyS cell line sensitivity to foretinib, gefi tinib and erlotinib. SyS 
cells were seeded in 384 well plates, and treated with concentrations of drug up to 1000 nM. 
Cell viability was determined in a 5-day proliferation assay with Cell Titre Glo as readout. Error 
bars represent standard deviation.
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Aska-SS cells . Cells were treated with crizotinib (1 mM) for 24 or 48 h. Cell lysates were 
prepared and Western blotted as indicated. Data are representative of duplicate experiments.
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Supplementary Figure 7.7:  Effects of ALK inhibition on Aska-SS in vivo tumors. Effects 
of ceritinib on Aska-SS xenografts are shown. A. Ki67 (top panels) and CD34 (lower panels) 
expression in Aska-SS tumors from mice from the control group (vehicle; left) or from the 
ceritinib treatment group (50 mg/kg; right). Images are x200 magnifi cation. B. Quantifi cation of 
Ki67 staining as shown in (A). 6 fi elds (200x) per slide were scored for control tumors; 2-6 fi elds 
per slide were scored for ceritinib-treated tumors due to tumor regressions (less tissue available). 
Only viable sections were used for scoring. Values are presented as the mean percentage of 
positive cells as proportion of all counted cells per section (200x) ± SD. C. Quantifi cation of 
mitotic tumor cells. Values are presented as the mean number of mitotic cells counted per 400x 
section ± SD. D. Quantifi cation of CD34 staining as shown in (A), demonstrating the number of 
blood vessels (mean vessel count per mm2; left) and blood vessel size (vessel surface in mm2; 
right). 15 fi elds per slide were scored for control tumors; 3-12 fi elds per slide were scored for 
ceritinib-treated tumors due to tumor regressions (less tissue available). Only viable sections 
were used for scoring. Error bars represent standard deviation. *p < 0.05 as assessed by Student’s 
t-test. ****p < 0.0001 as assessed by Student’s t-test.
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Supplementary Figure 7.8:  ALK, MET and PDGFRα mRNA expression in SyS versus other 
STS . A-C. mRNA transcript expression levels for ALK (A; 2 probes), MET (B; 4 probes) 
and PDGFRα (C; 3 probes) in clinical SyS (n=16) and other soft-tissue sarcoma (STS; n=89) 
tumor specimens as assessed by an Affymetrix array. Data was extracted from the NCBI 
Gene Expression Omnibus (GEO) as published by Nakayama et al 200711. Figures illustrate 
signifi cantly increased ALK mRNA signal intensity in clinical SyS samples compared to clinical 
non-SyS STS samples (both probes p<0.01; Student’s T-test). No signifi cant differences were 
found for any of the MET probes. There was a trend for PDGFRα mRNA expression to be higher 
in SyS versus other STS histologies, which was signifi cant with probe 3. RNA signal intensity 
represents GCOS-calculated signal intensity. Values represent mean ± SEM. All p-values were 
calculated with a Student’s T-test. SyS: Synovial sarcoma; STS: soft-tissue sarcoma (no SyS).
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Supplementary Figure 7.9:  ALK IHC and patient characteristics of ALK-positive SyS tumors 
. Patient characteristics of ALK positive tumors. All tumors included are primary tumors before 
treatment. All images are displayed at a 200x magnifi cation. PFS = progression-free survival; 
OS = overall survival. *The percentage of positive cells are given, including the intensity of the 
staining defi ned as: none (-), low (+/-), moderate (+) or strong (++). **Patient no. 2 harbored 
the ALK-fusion.
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Supplementary Figure 7.10:  Effect of PDGFR and MET inhibition on apoptosis in Yamato-SS 
cells . Cells were treated with pazopanib and/or crizotinib for 48 h. Cell lysates were prepared 
and Western blotted as indicated. Data are representative of duplicate experiments.
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Abstract
For solid tumours, quantitative analysis of [18F]-fluorodeoxyglucose positron emission 
tomography with integrated computed tomography potentially can have significant value in 
early response assessment and thereby discrimination between responders and nonresponders 
at an early stage of treatment. Standardised strategies for this analysis have been proposed, 
and the positron emission tomography response criteria in solid tumours (PERCIST) criteria 
can be regarded as the current standard to perform quantitative analysis in a research setting, 
yet is not implemented in daily practice. However, several exceptions and limitations limit 
the feasibility of PERCIST criteria. In this article, we point out dilemmas that arise when 
applying proposed criteria like PERCIST on an expansive set of patients with metastasised 
solid tumours. Clinicians and scientists should be aware of these limitations to prevent that 
methodological issues impede successful introduction of research data into clinical practice. 
Therefore, to deliver on the high potential of quantitative imaging, consensus should be reached 
on a standardised, feasible and clinically useful analysis methodology. This methodology 
should be applicable in the majority of patients, tumour types and treatments. 
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Introduction 
Despite continuing advances in oncology, response rates to anticancer treatments are still 
not optimal. If a treatment is ineffective, the patient is unnecessarily exposed to potential 
toxicity and avoidable costs are made. To reduce the number of patients that are exposed to 
a treatment without benefi t, early identifi cation of treatment failure is essential. Functional 
(e.g. multi-parametric magnetic resonance imaging) and molecular (e.g. positron emission 
tomography) imaging modalities have special merit to determine treatment response, as 
these can visualise biological changes at an early stage, whereas much more time is needed 
before morphological changes, such as a decrease in size, become apparent on anatomical 
imaging. Additionally, functional and molecular imaging techniques can distinguish between 
active and inactive disease, whereas with anatomical imaging, discrimination between viable 
tumour and treatment-induced fi brosis or necrosis may be diffi cult. [18F]-fl uorodeoxyglucose 
positron emission tomography with integrated computed tomography (18F-FDG-PET/CT) is 
nowadays the most widely used molecular imaging technique in oncology for assessment 
of treatment response. The analysis of 18F-FDG-PET/CT data, however, is very complex 
due to the multitude of information and technical challenges, such as partial volume effects, 
physiological variations, acquisition errors and suboptimal signal-to-noise ratio. In clinical 
practice, assessment of 18F-FDG-PET/CT scans is performed visually. While this is often 
suffi cient in the diagnosis and staging of tumours, quantitative analysis is required in the 
detection of more subtle changes in response assessment. Quantitative analysis is one of the 
assets of 18F-FDG-PET for objective measurement of tumour metabolism and its changes 
induced by therapy. For lymphomas, recently the Deauville classifi cation, a semi-quantitative 
analysis for treatment response, has been introduced into routine clinical practice1. However, 
for solid tumours so far no (semi-)quantitative analyses have been implemented in the clinic. 
Several studies in different solid tumours, including those in non-small cell lung cancer2-6, 
breast cancer7,8, gastro-intestinal stromal tumours9, oesophageal squamous cell carcinoma10, 
colorectal cancer11, thymic epithelial tumours12, and head and neck cancer13, have shown the 
potential value of quantitative analysis of 18F-FDG-PET/CT in early prediction of treatment 
response. Remarkably, a plethora of different methods is used in these studies, including 
change in maximum standardised uptake value (SUVmax)
3, SUVmean in a circular region of 
interest10, SUVpeak to mediastinum ratio
12, SUV at several isocontours5, total lesion glycolysis 
(TLG)8, as well as a personalised interpretation of the positron emission tomography response 
criteria in solid tumours (PERCIST) criteria, described as ‘modifi ed PERCIST’6. In order 
to apply quantitative analysis of 18F-FDG-PET/CT for monitoring treatment response in 
clinical practice, robust and non-laborious operator-friendly standardised methods that 
produce reliable and reproducible results are of great importance. In a research setting, such 
standardised strategies have been proposed. Several guidelines for quantitative analysis have 
been suggested by European Organisation for Research and Treatment of Cancer (EORTC)14, 
the Cancer Imaging Program of the National Cancer Institute15 and the Netherlands Society of 
Nuclear Medicine16. In 2009, the PERCIST criteria were described, in analogy to the generally 
accepted response evaluation criteria in solid tumours (RECIST) criteria for tumour response 
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assessment using CT17. With a more detailed description of target lesion and measurement 
choice, this has brought significant progress in standardising quantitative analysis. Both the 
EORTC and PERCIST criteria were suggested as quantitative analysis techniques by the most 
recent European Association of Nuclear Medicine (EANM) procedure guideline for tumour 
imaging with 18F-FDG-PET/CT18. When comparing PERCIST and EORTC criteria, these two 
methods led to similar responses and overall survival outcomes19. The preferable method is 
PERCIST, as it describes in more detail how lesions should be assessed and as such leads to 
more reproducible results. The application of PERCIST, however, has limitations. PERCIST 
is time-consuming, cannot be applied in all cases and puts high demands on acquisition of 
18F-FDG- PET/CT, (e.g. time between scanning and injection, comparable background activity 
and normoglycaemia). Meeting these acquisition criteria is a prerequisite for obtaining reliable 
data, as has been shown previously20. Moreover, other issues arise when one is trying to apply 
the PERCIST criteria, which hinder the application of PERCIST in daily routine This explains 
why although RECIST is ubiquitously used in studies, the use of PERCIST is still limited. 
In this article, we will discuss the practical problems in applying PERCIST. Additionally, we 
emphasise the need for uniformity in analysing 18F-FDG-PET/CT scans to be able to succeed 
in early prediction of treatment (non)response.
Analysing metabolic response 
PERCIST is of value as it describes methods of analysis in much detail, including several 
relevant aspects: (1) the lesions to include (2) the measurements to use, and (3) quantification 
of a lesion with complete response. When applying these PERCIST criteria however, several 
practical problems arise. 
1. The lesions to include 
Analogous to RECIST 1.1, PERCIST includes five target lesions, with a maximum of two 
target lesions per organ. To qualify as a possible target lesion, PERCIST sets two criteria: 
size and FDG-activity. Size of the lesion is relevant, as it is related to the potential partial 
volume effect. This can be defined as the loss of apparent activity in small lesions because of 
the limited resolution of the constructed images of the FDG-PET scanner. PERCIST advises 
to only include lesions with a minimal size of 1.5 cm diameter volume. However, the size 
measured on CT is not directly related to the metabolic volume of a lesion, which can be much 
smaller. In addition, FDG-avid lesions cannot always be reliably assessed on CT. For example, 
bone metastases in the vertebrae can be highly FDG-avid, but cannot be measured on CT. It 
is, therefore, not always possible to meet this criterion. The second inclusion criterion is the 
avidity of a lesion. This criterion intends to warrant evaluation of lesions with a sufficiently 
high uptake to be able to show a substantial decrease. In order to do this, the SUV corrected 
for lean body mass (also referred to as SUVLBM) in a 1 cm
3 spherical volume of interest (VOI), 
called SULpeak, is determined. It is defined that lesions should have a SULpeak at least 1.5-fold 
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greater than liver SULmean ± 2 standard deviations (SDs). When the liver is diseased, which 
is not uncommon in oncology, it is advised to take two times the SUVmean of the descending 
thoracic aorta blood pool as a lower boundary. Unfortunately, this criterion leaves out most 
lung lesions, which are generally only mildly FDG-avid, because there is almost no additional 
background activity. Due to this low background activity, however, there is more than a fair 
chance that these lung lesions show a substantial decrease in activity (Figure 8.1A). This 
means that when applying this criterion, pulmonary lesions will often be disregarded for 
PERCIST analysis. As PERCIST includes the fi ve hottest lesions in each follow-up scan, fi ve 
different lesions can be considered at each follow-up scan. Liver lesions will usually have a 
higher FDG-uptake due to a higher background value, and will therefore be preferred over 
lesions that have low background activity. This criterion, however, is more related to organ 
localisation than to the aggressiveness of the lesion. 
Figure 8.1:  A: Pulmonary metastasis of sarcoma patient at baseline (A.1) and after 8 weeks 
of anti-angiogenesis treatment (A.2): this particular lesion cannot be included according to 
PERCIST, as its FDG-avidity is too low at baseline, although response during follow-up seems 
overt. B: Bone metastasis of breast cancer patient at baseline (left) and after 14 days of treatment 
with everolimus and exemestane (right): strong decrease in SUVmax, but blue delineation shows 
strong increase in TLG based on isocontour of 70% of SUVmax. FDG, fl uorodeoxyglucose; 
SUVmax, maximum standardised uptake value.
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2. The measurements to use 
PEAK STANDARDISED UPTAKE VALUE: The primary outcome measurement of 
PERCIST is the SULpeak of five target lesions. This however, may represent only a small 
percentage of the total tumour burden, and information about the rest of the tumour is lost. 
Accordingly, a large necrotic area developed under treatment is not taken into consideration 
if there is still a small part with high FDG-avidity. If a tumour lesion shows a decrease in 
metabolism in most parts of the tumour, but an unchanged high metabolism in a small part of 
this lesion, it yet remains debatable which part of the tumour is the best predictor of tumour 
response and as such which measurement should be used. 
MAXIMMUM STANDARDISED UPTAKE VALUE: Measuring SUVmax is an easier and 
quicker method for measuring response than the SUVpeak, and is thought to overlap partly with 
the SUVpeak. However, SUVmax only reflects the hottest voxel of a tumour and leaves out large 
changes in the rest of the tumour. Unfortunately, SUVmax is influenced by the voxel size of the 
PET scanner, and a larger VOI as used in PERCIST is preferred to reduce the noise effects on 
a single voxel17. 
TOTAL LESION GLYCOLYSIS: PERCIST advises that TLG is obtained as a secondary, 
explorative, outcome measurement. TLG is the product of the tumour VOI and the mean 
activity of this VOI. As such, TLG includes more information. The difficulty with TLG 
however, lies in adequate tumour delineation. Ideally, with TLG, the whole tumour is 
included in the VOI, without including normal tissue. Several threshold approaches have been 
suggested to obtain appropriate tumour delineation. PERCIST suggests using an absolute 
threshold: 2 SD above mean activity of normal liver. This absolute threshold however, often 
results in either a threshold too low to correctly exclude normal tissue, or a threshold too high 
to include tumour lesions with lower overall uptake, such as lung lesions. Another possibility 
to delineate tumour from background is to subtract ‘normal background’ FDG-uptake from 
the tumour lesion. However, as this background varies drastically throughout an organ, this 
uptake is not reproducible and therefore not feasible as a measurement. The most recent 
EANM guideline proposes a proportional threshold (e.g. 41% of SUVmax) when determining 
TLG18. A proportional TLG based on the SUVmax, however, results in a wide variety in TLG 
follow-up. With this proportional threshold, in general only a part of the tumour is included 
in the VOI. When subsequently SUVmax decreases during treatment this threshold decreases, 
thereby including a larger part of the tumour in the VOI, leading to a higher TLG. Especially 
in large tumours with an intense hotspot resulting in a high SUVmax, which decreases at follow 
up, this paradoxically may result in an overall larger TLG, despite evident response (Figure 
8.1B). Theoretically, (semi)automatically defined TLG would result in a high repeatability, 
however, in reality, repeatability appeared to be low, comparable to manual definition of the 
TLG21,22. 
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3. Quantiﬁ cation of a lesion with complete response
If FDG-uptake of a lesion does not exceed background activity, it can be considered a 
complete response, as no VOI can be drawn separating normal tissue from tumour tissue. 
Next, either the information of this lesion can be left out (avidity considered zero), or the 
baseline VOI can be copied in the scan positioned as closely to the original tumour lesion 
as possible, resulting in a organ-dependent background FDG-uptake23. Both methods result 
in very different numbers, resulting in a huge impact on the sum of the lesions and with that 
in percentage of response. PERCIST suggests subtracting liver background SUL from the 
original lesion to come to a 100% decline17.
Conclusions and recommendations
Quantitative analysis of 18F-FDG-PET/CT potentially can have great value for discriminating 
between responders and non-responders at an early stage of treatment. This can be of great 
importance for patients’ treatment outcomes, and can help to reduce health care costs. 
However, it is crucial to be aware of the current limitations. Firstly, strict adherence to 
acquisition demands is needed in order to get reliable data. Highly reproducible data are 
needed for sensitive assessment of changes in tumour metabolism. As small deviations from 
acquisition protocol already can create substantial differences in tumour uptake, this is a sine 
qua non. Secondly, quantitative analysis has to be done according to a standardised method. 
PERCIST can be considered as a good starting point for a standardising technique, but needs 
to address the exceptions and limitations in order to increase feasibility. Additionally, TLG 
can be a promising measurement for response assessment, but when processing heterogeneous 
tumours with metastases located in different body parts, the VOI for TLG should be 
based on organ-specifi c background cut-off values, as was also suggested previously20. In 
conclusion, we argue that the current guidelines are insuffi cient to produce results that are 
generally applicable. As such, in order to realise the high potential of quantitative imaging, 
fi rst consensus should be reached on a feasible analysis methodology. Until this consensus 
is reached, prudence is advised in applying quantitative analysis of 18F-FDG-PET/CT for 
treatment response assessment in metastasised solid tumours. 
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Abstract
INTRODUCTION: Pazopanib is the first approved targeted treatment for non-GIST soft 
tissue sarcoma (STS) patients. Unfortunately, responses are only observed in a limited subset 
of STS patients. Data on early response prediction is sparse. We aimed to correlate early 
metabolic response on FDG-PET/CT to treatment outcome. 
PATIENTS AND METHODS: 20 STS patients underwent FDG-PET/CT at baseline, 2 and 8 
weeks after start of pazopanib. In addition, blood samples were collected for pharmacokinetic 
(PK) assessment (Ctrough levels and AUC0-24h). The relation between early metabolic response 
evaluation after 2 weeks of therapy and pazopanib exposure at two weeks or treatment 
response defined by RECIST 1.1 evaluated after 8 weeks was explored. 
RESULTS: After 8 weeks of therapy, 14 out of 20 patients had discontinued pazopanib due 
to tumor progression (‘non-responders’ n=12) or toxicity (n=2). Quantitative scoring at two 
weeks identified 25% (3 of 12) of all non-responders, whereas visual response analysis by 
an independent evaluation from a nuclear medicine physician identified 42% (5 of 12) of 
all non-responders. Importantly, no patient was incorrectly labeled by FDG-PET/CT as non-
responder. PK results were not related to early metabolic response. 
DISCUSSION: This study shows that FDG-PET/CT can potentially be used as an early 
biomarker to identify pazopanib non-responders by RECIST. The results of this hypothesis-
generating study emphasize the need to set up a larger study, which could facilitate future 
early and cost-effective decision making in STS patients treated with pazopanib.
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Introduction  
Soft-tissue sarcomas (STS) represent a group of rare mesenchymal cancers that encompasses 
more than 70 histological subtypes1. Patients with metastatic STS have a median overall 
survival (OS) of approximately 19 months, ranging from 12-24 months in clinical practice2, 
which is dependent of histological subtype3. The conventional fi rst-line treatment for 
advanced STS other than gastrointestinal stromal tumors (GIST) is doxorubicin or, in well-
defi ned cases, the combination of doxorubicin and ifosfamide4. In the past decade, there has 
been some progress in the development of new systemic treatment options for soft tissue 
sarcomas. In recent years, trabectedin has been approved as second line chemotherapy 
for lipo- and leiomyosarcoma5, and eribulin as second line chemotherapy for advanced 
liposarcoma6. Recently, the addition of the Platelet Derived Growth Factor Receptor 
(PDGFR) antibody olaratumab to doxorubicin has shown survival benefi t in a randomized 
phase 2 study compared to single agent doxorubicin in advanced STS patients, leading to 
FDA approval and conditional approval by EMA7. The fi rst oral targeted therapy for STS 
patients with proven effi cacy is the receptor tyrosine kinase inhibitor pazopanib, which targets 
Vascular Endothelial Growth Factor Receptor (VEGFR)-1, -2 and -3, PDGFR- and - and stem 
cellfactor receptor (c-KIT). Based on the outcome of the PALETTE trial, the FDA and EMA 
approved pazopanib for non-GIST, non-adipocytic STS patients in second line and beyond8. 
Patients treated with pazopanib showed a progression free survival (PFS) benefi t of 3 months 
compared to placebo. Unfortunately, 23% of patients had progressive disease as best response 
and they should be considered as de novo resistant to pazopanib therapy (non-responders). 
In addition, about 10-30% of the STS patients treated with pazopanib develop grade 3-4 
toxicity8,9. It is therefore evident that easily assessable biomarkers to predict response early 
after the start of treatment are required to identify those patients who will ultimately not 
benefi t from therapy. This is particularly important to avoid treatment of patients with an 
ineffective, potentially toxic, and expensive drug over a prolonged period of time. Molecular 
imaging with the glucose analogue [18F]-Fluorodeoxyglucose-Positron Emission Tomography 
/ Computed Tomography (FDG-PET/CT) has shown clinical relevance in sarcoma patients 
for diagnosing grade and staging10; refl ecting outcome after (neoadjuvant) chemotherapy11,12; 
and for predicting the anti-tumor effect of imatinib in GIST patients13,14 at an earlier stage 
than is currently possible with conventional radiological imaging that solely depicts tumor 
morphology (CT/MRI). In addition, FDG-PET/CT has been successful in predicting the 
effects of angiogenesis inhibitors in metastatic renal cell carcinoma (mRCC)15. 
Until now, metabolic response depicted by FDG-PET/CT has not been related to drug 
pharmacokinetics (PK) while drug exposure is recognized to be important for optimization 
of antitumor activity of several targeted therapies16. Pazopanib is administered orally without 
food at a fi xed dose of 800 mg once daily (OD). Pazopanib pharmacokinetics show large 
interpatient variability when given regardless of patients’ size or clinical condition, with many 
yet unknown factors infl uencing exposure17-19. Studies providing further insight in potential 
early pharmacodynamic and pharmacokinetic biomarkers are essential to optimize pazopanib 
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treatment for the individual patient with STS and to select those patients who are de novo 
resistant or sub-optimally treated. Although exposure to pazopanib might affect treatment 
outcome as has been demonstrated for mRCC20, this relation is less clear for STS patients21,22. 
Previously, a side study of the PALETTE study attempted to evaluate the value of FDG-PET/
CT for early response measurement in STS patients treated with pazopanib. Unfortunately, 
this multicenter imaging side study did not render adequate results due to many protocol 
violations23. Therefore, the current study was designed to analyze the value of FDG-PET/
CT imaging for early evaluation of non-response to pazopanib in STS patients. In addition 
to early response monitoring with FDG-PET/CT, this study explores the relation between 
pazopanib pharmacokinetics and early metabolic response.
Patients and Methods
PATIENTS: Patients with a histological diagnosis of an STS for whom pazopanib is approved 
and indicated as judged by the treating physician were included. Inclusion and exclusion 
criteria were similar to those used in the PALETTE trial8. In addition, patients were required 
to have a positive baseline FDG-PET scan for continuation in the study, and diabetic 
patients were only eligible if well controlled. The trial was approved by the regional medical 
ethics committee. All patients gave written informed consent. The study was registered at 
ClinicalTrials.gov (NCT01995981).
STUDY DESIGN:  The study was designed as a prospective observational feasibility study. In 
this study two hypotheses were explored: (1.) FDG-PET/CT can be used for early monitoring 
of response to pazopanib treatment in STS patients, and (2.) There is a relation between FDG-
PET/CT response and pazopanib exposure. 
A baseline FDG-PET/CT was performed 0-2 weeks before start of pazopanib therapy. All 
patients were instructed to take pazopanib during this study in a standardized manner: 800mg 
pazopanib OD, at 8:00AM with a glass of water, one hour before using a standardized 
continental breakfast. Evaluation was performed at 2 weeks and 8 weeks after start of treatment 
with pazopanib (the latter is at the time of conventional RECIST response evaluation). At both 
time points, blood samples were collected at 0, 1, 2, 3, 4, 6, 8, 10, and 24 hours after ingestion 
of pazopanib and an FDG-PET/CT scan was performed. At 8 weeks, a standard contrast-
enhanced CT scan for tumor evaluation was incorporated in the FDG-PET/CT, and PFS was 
scored according to RECIST 1.124. Patients showing stable disease or response by RECIST 
were defined as responders to pazopanib, whereas patients showing progressive disease were 
defined as non-responders. Additionally, adverse events during the study were graded by 
CTCAE v4.025.
FDG-PET ANALYSIS: FDG-PET/CT-scans were acquired approximately one hour after 
injection of 1.6MBq/kg FDG according to the European Association of Nuclear Medicine 
(EANM) standardized guidelines26. Patients had been fasting for at least 6 hours before 
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injection. Whole body FDG-PET images were acquired using a Biograph 40 mCT PET/
CT scanner (Radboud UMC: Siemens Healthcare, Knoxville, TN, USA; AVL-NCI: Philips 
Medical Systems, GEMINI ToF Big Bore, Cleveland, OH, USA). The PET scanner was 
accredited by the research 4 life (EARL) initiative for quantitative multicenter PET/CT 
studies. PERCIST requirements in patient preparation, FDG-PET acquisition, evaluation and 
assessment were followed27. This includes obtaining the baseline PET scan at 50–70 min after 
tracer injection, and obtaining the follow-up scan within 15 min (but always 50 min or later) 
of the baseline scan. All scans had to be performed with the same injected dose ±20% of 
FDG. FDG accumulation was registered in Bq/mL, which was then corrected for the injected 
dose, time elapsed between the injection and scanning, and gender specifi c lean body mass 
to obtain the standardized uptake value (SUL)28. For the purpose of response monitoring, the 
peak standardized uptake value corrected for lean body mass (SULpeak) was determined in (a 
maximum of) 5 of the most metabolically active tumor lesions, with a maximum of two lesions 
per organ, on sequential FDG-PET/CT images. The SULpeak was calculated using a customized 
Matlab script (Matlab 2014b, Natick, Massachusetts, USA). This script automatically searched 
for the metabolically most active part of the tumor using a three-dimensional (3D) spherical 
volume of interest (VOI) of 1 mL. As STS patients frequently have metastatic disease in the 
liver, uptake in the descending thoracic aorta was used as a control instead of uptake in normal 
liver. No minimal uptake was required, as long as lesions could be clearly distinguished from 
background uptake. Adjacent lesions within a single organ (e.g. lymph node or bone lesions) 
that could not be measured separately were considered as one single target lesion. If necessary, 
adjacent normal tissue uptake in the bladder or myocardium was manually excluded from the 
VOI. Metabolic changes were defi ned as fractional change (ΔSULpeak), comparing the second 
or third scan with the baseline scan. Quantitative metabolic partial response (qM-PR) was 
defi ned as ≥30% decrease in ΔSULpeak, quantitative metabolic progressive disease (qM-PD) 
is defi ned as ≥20% increase in ΔSULpeak or new lesions according to PERCIST defi nitions
27. 
The remainder is defi ned as quantitative metabolically stable disease (qM-SD). Furthermore, 
the FDG-PET/CT images were visually scored in a blinded, independent central review by 
one experienced nuclear medicine physician. The categories of visual response assessment 
included metabolic partial response, stable disease, or progressive disease (visual-PR, SD, 
and PD, respectively). Additionally, metabolic response was analyzed per metastatic subtype 
tissue: lymph nodes, bone, abdominal organs, lung and others (consisting of subcutaneous 
tissue, muscle and perineum). If there was more than one lesion per tissue subtype in a patient, 
the mean was taken. If a patient had multiple lesions at one site, the average response for that 
metastatic site was calculated.
PHARMACOKINETCS: Blood samples were centrifuged at 3000g for 5 minutes at room 
temperature; plasma was collected and split into 2 aliquots and stored at -40˚C until the 
day of analysis. Pazopanib plasma concentrations were determined using a validated ultra-
performance liquid chromatography–tandem mass spectrometric method (LC-MS/MS) 
comparable to the earlier described bioanalytical method29. The Area Under the Concentration 
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Time Curve (AUC0-24h) for pazopanib was calculated using a noncompartmental trapezoidal 
approach (Phoenix WinNonlin v6.3). 
STATISTICS AND DATA ANALYSIS: The overall survival (OS) and progression free 
survival (PFS) were calculated using Kaplan-Meier estimates with a Log Rank test to identify 
significant differences between variables. A Spearman’s rho test was used to determine 
correlations between AUC0-24h, Ctrough levels and FDG-response. An independent t-test was 
used on log transformed continuous variables, while the chi2-test was used for categorical 
variables.
Statistical tests were based on a two-sided significance level. The level of significance was 
set at 0.05. Since this was an exploratory feasibility study the sample size of 20 was chosen, 
and no corrections for multiple testing were done. The analyses were performed using SPSS 
Statistics version 22.
Figure 9.1: Study design. A: Study protocol timeline; OD = once daily. B: study profile 
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Results 
PATIENT CHARACTERISTICS: Patients were included from 2013-2017 at two sites in 
the Netherlands (the Radboud University Medical Center in Nijmegen and the Antoni van 
Leeuwenhoek – Netherlands Cancer Institute in Amsterdam). The baseline characteristics are 
shown in Table 9.1. Patients with eight different STS subtypes were included. The majority 
of patients had received one line of chemotherapy prior to pazopanib treatment (11 of 20 pts, 
55%). Of these, six had received doxorubicin and three the combination of doxorubicin and 
ifosfamide. In total, 23 patients were included, of whom three dropped out before study start 
(Figure 9.1). The remaining twenty patients had paired FDG-PET/CT scans at baseline and 
after two weeks of pazopanib treatment. Seven patients discontinued the study prematurely 
(before 8 weeks of therapy) due to serious pazopanib toxicity (n=3) or rapid tumor progression 
(n=4), and therefore had no FDG-PET/CT and PK assessment after 8 weeks of treatment. Of 
the three patients that experienced serious toxicity, two discontinued pazopanib (one gastric 
bleeding, one hepatotoxicity), the third patient also developed hepatotoxicity but could 
continue pazopanib at a lower dosage (600mg) and was therefore included in the survival 
analyses of this study. After eight weeks of therapy (fi rst clinical evaluation moment) an 
additional 8 patients showed progressive disease on CT. This means that in total 12 patients 
(60%) (excluding the two patients who stopped due to toxicity and therefore response 
remains unknown) discontinued pazopanib due to tumor progression, our defi nition for ‘non-
responders’. The 6 patients (30%) who experienced clinical benefi t (all scored as stable disease 
by RECIST 1.1) continued pazopanib for 5-18 months until disease progression occurred. 
Patients who responded to pazopanib had a synovial sarcoma (n=2), myxofi brosarcoma (n=1), 
unclassifi ed spindle cell sarcoma (n=1), pleiomorphic undifferentiated high grade sarcoma 
(n=1) and epithelioid hemangioendothelioma (n=1). The median overall survival was 9.3 
months and at the end of the study three patients were still alive. 
FDG-PET: In total, 53 FDG-PET/CT scans were performed in 20 patients. Four scans (7.5%) 
showed a variation of >0.3 SUL difference in the descending aorta, which is considered 
undesirable when comparing two FDG-PET/CT scans quantitatively27. Nonetheless, all FDG-
PET/CT scans were included in the analysis of this study as this refl ects the limitations in 
daily clinical practice. Maximum uptake at baseline varied from SULpeak 1.92 – 24.40, which 
refl ects the metabolic heterogeneity of the sarcoma subtypes.
At two weeks, based on the PERCIST guidelines, 4 of the 18 patients showed a quantitative 
metabolic (qM)-PR, and 3 patients showed qM-PD (2 due to metabolic increase ≥20%, and 
1 based on new lesions (in calculations scored as +20%)). The remainder 11 patients had 
qM-SD. All patients who showed any degree of increase in metabolic activity (n=10, 0.25% 
- 46.47%) at two weeks, excluding the two who stopped prematurely due to toxicity, were all 
radiologically confi rmed non-responders after 8 weeks of therapy (Figure 9.2).
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Table 9.1: Baseline patient characteristics. # 3 patients are still alive at study closure, of 1 
patient OS data is unknown.
Variable Total n=20 (%)
Age (yrs)
 ◦ Range (yrs)
 ◦ Median (yrs)
40-78
60
Sex (male) 9 (45)
STS subtypes
 ◦ Leiomyosarcoma
 ◦ Synovial sarcoma
 ◦ Angiosarcoma
 ◦ Myxofibrosarcoma
 ◦ Pleiomorphic rhabdomyosarcoma
 ◦ Epithelioid hemangioendothelioma
 ◦ Solitary Fibrous Tumor
 ◦ Unclassified spindle cell sarcoma
 ◦ Epithelioid sarcoma
 ◦ Desmoplastic small blue round cell tumor
 ◦ Pleiomorphic undifferentiated high grade sarcoma
7 (35)
2 (10)
2 (10)
2 (10)
1 (5)
1 (5)
1 (5)
1 (5)
1 (5)
1 (5)
1 (5)
ECOG
 ◦ 0
 ◦ 1
 ◦ 2
4 (20)
13 (65)
3 (15)
Duration of disease from diagnosis until pazopanib start
 ◦ Range (months) 1-248
Lines of chemotherapy before pazopanib, range 0-4
Progressive disease at 8 weeks:
 ◦ Yes
 ◦ No
 ◦ Missing
Progressive disease median (months)
Progressive disease range (months)
12 (60)
6 (30)
2 (10)
2
1-18
Overall survival median (months) #
Overall survival range (months)
8
1-24
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In addition to the FDG-PET/CT at two weeks, also an FDG-PET/CT was performed at 8 weeks 
in combination with the CT for clinical evaluation. 13 patients completed this FDG-PET/
CT at 8 weeks, of whom 3 (23%) showed qM-PR and 3 (23%) qM-PD. In these 6 patients, 
contrast-enhanced CT evaluation according to RECIST 1.1 corresponded with the FDG-PET/
CT scan results and therefore, the patients continued and discontinued pazopanib accordingly. 
Of the 7 patients with metabolic stable disease (-13% to +15% versus baseline) after eight 
weeks of therapy, 5 had radiological progressive disease and discontinued pazopanib while 2 
had a clinical response and continued pazopanib.
Besides the quantitative analysis (PERCIST analysis), which is currently considered too time 
consuming for general clinical practice, an independent visual response analysis at two weeks 
(non-quantitative) was performed and compared to baseline. This evaluation was executed by 
one experienced, independent nuclear medicine physician who was blinded for other results. 
FDG-PET/CT scans were scored as visual-PR (n=9), visual-SD (n=4), or visual-PD (n=5). 
All patients with FDG-PET scans scored as visual-PD at two weeks did show radiological 
progressive disease at eight weeks and discontinued pazopanib. Therefore, visual scoring 
identifi ed more non-responders (42%) than the quantitative scoring (25%). In addition, of 
the patients with visual stable metabolic disease, all but 1 patient showed radiological disease 
progression. 
Figure 9.2:  FDG-PET response compared to clinical outcome
168
Chapter 9
9
When dividing the patients according to the median SULpeak on the baseline FDG-PET/CT 
(5.3), a high or low maximum SULpeak at baseline did no correlate to a difference in PFS. Due 
to the size of the group no relation could be made between tumor histology.
Of note, it is important to be aware of FDG response differences between the various tissues. 
Although the group size is small, bone lesions in general showed an early increase in FDG 
uptake whereas the other tissue sites showed an early decrease in FDG uptake after two 
weeks of therapy (Figure 9.3). Of the 8 patients with bone lesions 5 were non-responders, 1 
responded to pazopanib treatment, and 2 patients discontinued pazopanib prematurely due to 
toxicity. 
PHARMACOKINETICS: All 20 patients completed the PK assessment after two weeks of 
pazopanib therapy, and 13 patients completed the second PK assessment after eight weeks 
(which are the same patients who completed the FDG-PET/CT at eight weeks). Both the 
AUC0-24h and Ctrough levels were considered in the analysis. A geometric mean AUC0-24h (range) 
of 847µg.h/mL (477-1654) was found after two weeks, and 732µg.h/mL (206-1264) after 
eight weeks. The median Ctrough level was 26.3 (range: 16.6-56.5) and 33.2 (range: 8.0-45.4) 
µg/mL at 2 and 8 weeks, respectively. AUC0-24h data were significantly correlated with Ctrough 
levels at both assessments (Spearman rho 0.96 and 0.97, p<0.001). Early metabolic response 
at two weeks was compared to pazopanib exposure at two weeks (Figure 9.4). There was no 
significant correlation between the quantitative FDG response and AUC0-24h or Ctrough levels 
(Spearman rho -0.16, p = 0.5, and -0.14 p = 0.6 respectively). 
Discussion
Metastatic STS is a rare group of tumors for which there are few therapeutic options, resulting 
in poor patient survival rates. Pazopanib is the first available oral targeted drug for this patient 
group. Unfortunately, a large proportion of the STS patients treated with pazopanib will 
not respond to therapy, but may experience serious toxicity8,9. This underpins the need for 
a biomarker to identify non-responders in an early stage. This study evaluates the value of 
metabolic response assessment by FDG-PET/CT for determining pazopanib treatment efficacy 
Figure 9.3: Geometric mean of the ∆SUL per metastatic site at FDG-PET at two weeks versus 
baseline
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in STS patients and showed promising results. The two weeks’ time point for evaluation was 
chosen as pazopanib has reached steady state by then and thereby hypothetically represents 
the optimal metabolic response. Early metabolic progression at two weeks was only seen 
in RECIST non-responders at eight weeks, and is therefore a potential indication for early 
discontinuation of pazopanib treatment. As FDG-PET/CT scanning is widely accessible, non-
invasive, and the costs are easily covered when pazopanib administration could be reduced 
by several weeks, the benefi t of this early biomarker potentially is of much interest and value. 
Overall, metabolic progressive disease at 2 weeks was a very good predictor of non-response 
to pazopanib according to RECIST criteria at 8 weeks (Figure 9.5). When using the criterion 
for metabolic progressive disease at two weeks as criterion to identify non-responders, this 
would correctly reduce continued treatment beyond 2 weeks in 25% of the patients (3 of 12) 
by quantitative analysis and 42% (5 of 12) by visual analysis. No patient was incorrectly 
labeled by FDG-PET/CT as non-responder. As visual analysis of FDG-PET/CT identifi ed 
more non-responders than the laborious quantitative analysis and is much easier to perform 
in a routine clinical practice, visual analysis might be the preferable way forward30. Another 
disadvantage of the quantitative analysis was the large number of patients showing stable 
disease according to PERCIST criteria, as uptake differences often not exceeded the threshold 
of <30% or >20% difference compared to the baseline FDG-uptake. The metabolic differences 
were more pronounced for the FDG-PET/CT scans at eight weeks. Evidently, postponing 
FDG-PET/CT evaluation means that FDG-PET/CT can no longer be used for early response 
assessment. Therefore, when quantitative analysis is applied in future studies with pazopanib, 
the applicability of the PERCIST criteria of ≥30% decrease and ≥20% increase needs re-
assessment to establish whether the cut-off criteria for response may be related to tumor type, 
tumor localization, tumor grading or treatment. Of note, the sample size of this study was not 
Figure 9.4:  Relationships between pazopanib pharmacokinetics and FDG response at two 
weeks.
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calculated to provide statistically significant results, but to generate exploratory information 
about the potential of FDG-PET/CT for early response assessment.
In addition to the studies with FDG-PET/CT, potential pharmacokinetic influences on FDG-
PET/CT response were studied. Particularly, we studied the relation between FDG uptake 
and pazopanib exposure. FDG seems to be an independent biomarker of pazopanib treatment 
response, as in this study no influence of pharmacokinetic variability on FDG response was 
identified. 
Importantly, in this study population bone lesions had the largest increase in FDG uptake two 
weeks after treatment start compared to baseline. A possible explanation could be the flare 
response phenomenon, which may be explained by e.g. activation of inflammatory cells or an 
increase in osteoblastic activity at the site of metastatic bone lesions due to the rapid repair, 
and thus represents response to treatment rather than disease progression. The flare response 
is a well-known phenomenon and has been described in the literature for various treatments, 
including anti-angiogenic therapy for bone metastases in, among others, NSCLC33. However, 
the hypothesis of limited pazopanib exposure due to an impaired blood circulation in bone 
lesions could suggest the exact opposite. When analyzing bone lesions it is important to be 
aware of this unexplained phenomenon, especially as radiological response in bone lesions 
without clear soft tissue component is difficult by RECIST34. 
As this is an exploratory study, some limitations need to be addressed. Firstly, our study 
population had a relatively high number of non-responders (60%, 12 of 20), when compared 
to the 23% non-responders in the phase 3 study8. As we used similar inclusion and exclusion 
criteria this is most likely explained by variation due to our small sample size. Secondly, as 
tumors can be very small at the moment of diagnosis and some STS subtypes are known for 
their indolent growth and relatively low metabolism, FDG-PET/CT evaluation may be less 
suitable in those STS patients. 
Finally, although both recruiting hospitals are considered to have high-standard nuclear 
medicine facilities, there were some FDG-PET/CT scans not fully performed according to the 
PERCIST acquisition guidelines, although in most cases this did not result in large differences 
in baseline FDG uptake in the descending aorta. As this reflects clinical practice, all FDG-
PET/CT were included in the analysis of the study. However, it does emphasize awareness 
of the logistic difficulties encountered, which was also the cause of the failure of the original 
PALETTE side study. 
In conclusion, this study successfully evaluated the clinically relevant hypothesis of using 
FDG-PET/CT as early biomarker of pazopanib in STS patients. We demonstrated that 
metabolic progression on FDG-PET/CT two weeks after start of pazopanib can predict 
RECIST progression of disease, assessed 6 weeks later. There was no relation between 
pazopanib exposure and FDG response, suggesting that FDG could be an independent early 
biomarker of pazopanib failure. A larger study needs to validate our findings to implement 
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FDG-PET/CT in the early response evaluation of pazopanib in STS patients, also taking cost-
effectiveness into account.
Figure 9.5:  Typical example of the  metabolic response seen in a patient with a partial 
response.
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Introduction
Pazopanib (VotrientTM GlaxoSmithKline) is approved by the FDA and EMA for treatment of 
patients with advanced renal cell cancer (mRCC) and patients with non-adipocytic advanced 
soft tissue sarcoma (STS) who received prior chemotherapy for metastatic disease or who 
have progressed within 12 months after (neo)adjuvant therapy1, 2. Unfortunately, 7–9% of the 
patients develop grade 3 or 4 liver toxicity and even fatal hepatotoxicity has been reported3. 
Manufacturer guideline states that patients with elevated transaminases of >8× upper limit 
of normal (ULN) should interrupt pazopanib until they return to ≤3× ULN. Subsequently, 
pazopanib can be reintroduced at a reduced dose of 600mg once daily (OD). If transaminase 
elevations of >3× ULN recur, pazopanib should be permanently discontinued4. Patients with 
mRCC can switch to other equipotent angiogenesis inhibitors with different toxicity profiles5. 
Unfortunately for STS patients no other angiogenesis inhibitors are available. Pazopanib 
is often the last resort and discontinuation has large clinical consequences. The underlying 
mechanism of pazopanib-induced hepatotoxicity is not yet unraveled, however, limited clinical 
information suggests that it might be immune mediated6. If autoimmune inflammation indeed 
underlies pazopanib-induced hepatotoxicity, corticosteroids could potentially overcome this 
problem. Based on this hypothesis, we treated two STS patients with prednisolone after re-
elevation of transaminase when pazopanib was restarted at a reduced dose of 600mg OD. 
Case reports
Case one is a 47-year-old male patient with advanced synovial sarcoma since 2010. He was 
previously treated with doxorubicin followed by ifosfamide. Metastases were located in the 
lungs only. He used no co-medication. He started pazopanib 800mg OD with normal ALT, 
AST, and bilirubin levels at baseline. After seven weeks he developed hepatotoxicity with 
transaminases of >8× ULN. No physical adverse events or hypersensitivity symptoms were 
reported. Case two is a 55-year-old female patient with advanced synovial sarcoma since 
February 2014. She was previously treated with combination chemotherapy consisting of 
doxorubicin and ifosfamide. She had multiple lung lesions and one metastasis in the adrenal 
gland, with normal ALT, AST, and bilirubin levels at baseline and three weeks after start with 
pazopanib treatment (800mg OD). In week 5 she suddenly developed hepatotoxicity with 
transaminase values of >8× ULN. Similarly, no clinical symptoms were reported. In both 
cases no indications of liver metastases were present. Both patients interrupted pazopanib, 
and liver enzymes were monitored once weekly. After recovering to ≤3× ULN, pazopanib 
was restarted at a reduced dose of 600 mg OD according to the drug label. Both patients 
developed recurrent hepatotoxicity, with transaminases of >8× ULN within one week which 
implied discontinuing pazopanib. Instead we started prednisolone orally at 30mg OD while 
continuing pazopanib at the reduced dose of 600mg OD. The patients were well informed 
about the risks and gave consent for this experimental closely monitored continuation of 
pazopanib. Liver enzymes were monitored 3–5 days after starting prednisolone, showing a 
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rapid decrease. After one week prednisolone was reduced to 15mg OD. Transaminase levels 
continued to decrease and prednisolone was diminished to 10mg, and later 5mg OD as toxicity 
had returned to ≤3× ULN. No adverse events were experienced from prednisolone. Both 
patients continued pazopanib at 600mg OD with confi rmed stable disease during 38 weeks 
for Patient 1, and 18 weeks for Patient 2. Serum trough levels of pazopanib were measured 
under prednisolone treatment to confi rm adequate exposure. Patients 1 and 2 had pazopanib 
levels of 26 mg/l and 22 mg/l, respectively. The target pazopanib exposure in patients with 
mRCC is 20.5 mg/l, which both patients met7. However, the target exposure in patients with 
STS needs to be defi ned yet. Liver serology for hepatitis B and C tested negative in both cases. 
In conclusion, both patients showed rapid decrease of transaminases, sustaining after reducing 
the dose of prednisolone, and consequently pazopanib could be continued (Figure 10.1).
Discussion
In patients with advanced STS therapeutic options are scarce. Pazopanib is the only licensed 
oral tyrosine kinase inhibitor for non-adipocytic soft tissue sarcoma. Therefore pazopanib 
discontinuation due to toxicity has major impact. Although our observations have to be 
explored further, we believe that management as described could be applied under close 
monitoring of liver enzymes to patients with pazopanib-induced hepatotoxicity, in particular 
when no therapeutic alternatives exist.
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Figure 10.1: Liver enzymes. ALT (range male: <45 U/l, range female: <35 U/l); AST (range 
male: <35 U/l; range female: <30 U/l); bilirubin total (range (fe)male: <17U/l). A: start pazopanib 
at 800mg OD; B: liver toxicity of >8× ULN (CTCAE grade 3) therefore stop pazopanib; C: 
toxicity reduced to ≤3× ULN (CTCAE grade 0) therefore restart at reduced dose of 600mg 
pazopanib OD; D: recurrent toxicity >10× ULN (CTCAE grade 3) therefore start prednisolone 
30mg OD + continue pazopanib 600mg OD; E: decreasing transaminases therefore continue 
prednisolone at 15mg OD + pazopanib 600mg OD; F: decreasing transaminases therefore 
continue prednisolone at 10mg OD + pazopanib 600mg OD; G: decreasing transaminases 
therefore continue prednisolone at 5mg OD + pazopanib 600mg OD.
181
Management of pazopanib-induced liver toxicity
10
References
1. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic 
renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-8, 
2010.
2. van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue 
sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. 
Lancet 379(9829): 1879-86, 2012.
3. Kapadia S, Hapani S, Choueiri TK, et al: Risk of liver toxicity with the angiogenesis 
inhibitor pazopanib in cancer patients. Acta Oncol 52(6): 1202-12, 2013.
4. UK GlaxoSmithKline: Votrient 200 mg and 400 mg fi lm coated tablets – Summary of Product 
Characteristics (SPC), electronic Medicines Compendium. http://www.medicines.org.uk/
emc/medicine/23148/SPC/Votrient+200+mg+and+400+mg+fi lm+coated+tablets/.
5. Westgeest HM, van Erp NP, Honeywell RJ, et al: Successful treatment of renal cell 
carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol 
31(6): e83-6, 2013.
6. Klempner SJ, Choueiri TK, Yee E, et al. Severe pazopanib-induced hepatotoxicity: 
clinical and histologic course in two patients. J Clin Oncol 30(27): e264-8, 2012.
7. Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and 
clinical safety and effi cacy in patients with advanced renal cell carcinoma. Br J Cancer 
111(10): 1909–1916, 2014.

Discussion and appendices

Chapter 11
11
 Summarizing discussion and future perspectives
Nederlandse samenvatting
186
Chapter 11
11
Summarizing discussion and future perspectives
Synovial sarcoma is a distinct soft tissue sarcoma (STS) subtype that accounts for 
approximately 6% of all STS1 and the only STS that can be diagnosed at 0-100 years of age, 
with a peak age in the late thirties. Its name originates from the former belief that tumors had 
their origin in the synovial lining of the joints. In clinical practice however, synovial sarcomas 
occur everywhere throughout the body, with a predilection for the extremities, and the cell of 
origin is still unknown. In 1987 the first report about a chromosomal translocation between 
chromosome X and 18 in synovial sarcomas was published2. Subsequently, researchers 
discovered the two most common fusion genes SYT-SSX1 and SYT-SSX2, and that most, 
if not all, synovial sarcomas harbor this unique translocation3,4. In the following decades 
functional studies showed an effect of this translocation/fusion genes on several intracellular 
pathways, however its mechanism remained uncertain. Twenty-five years after the first report 
of this translocation, a landmark study by Kadoch et al., showed that the oncogenic SS18-SSX 
fusion proteins compete with the wildtype SS18 in binding to the BAF (SWI/SNF) chromatin 
remodeling complex, thereby altering the composition of this essential epigenetic regulating 
complex. It was shown that in addition to ejection of the wildtype SS18, these oncogenic 
fusions also eject the tumor suppressor SMARCB1 (BAF47) from the complex, and are both 
subsequently degraded via the proteasome. The altered composition of the BAF complex 
furthermore causes aberrant chromatin remodeling within the genome by binding to the SOX2 
gene promotor, where it removes the repressive histone H3K27 trimethylation which leads 
to increased SOX2 transcript expression. As SOX2 drives proliferation, this event is thought 
to be critical for synovial sarcoma pathogenesis5,6. With this universal genetic signature, a 
generally homogeneous tumor behavior and a corresponding uniform therapeutic response 
in affected patients would be expected. Unfortunately, this is not the case. Tumors arise in an 
undefined population, they show indolent to highly aggressive clinical behavior, and systemic 
treatments show inconsistent tumor responses. Moreover, besides being helpful in diagnostics, 
the translocation has not shown to be a successful therapeutic target yet. Studies with peptide 
vaccinations targeting the breakpoint did not reveal positive results7,8. A phase 2 clinical trial 
(NCT02601950) investigated the antitumor activity of inhibiting PRC2-mediated deposition 
of H3K27me3 by targeting the EZH2 subunit in BAF47-deficient tumors. This trial included 
33 synovial sarcoma patients, yet results to date reported no objective responses9. 
In this thesis I explored prognostic factors and current treatments in both primary and 
advanced synovial sarcomas (part I). Next, I investigated new potential therapeutic options for 
synovial sarcomas in preclinical studies (both in vitro and in vivo, part II). Finally, I looked at 
pharmacodynamics and pharmacokinetics of pazopanib, a clinically approved targeted therapy 
for STS patients with a trend to superior effects in synovial sarcoma patients. I evaluated 
an early response biomarker and looked at overcoming pazopanib-induced hepatotoxicity, a 
well-known side effect of pazopanib (part III). 
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Part I: Epidemiology and current treatment options in synovial sarcoma patients
Currently, patients with localized disease are treated primarily with surgery, and on indication, 
(neo)adjuvant radiotherapy. Even though the role of chemotherapy in the primary setting in 
adults remains questionable10,11, pediatric patients tended to receive additional (neo)adjuvant 
chemotherapy in the past. Recently a clinical trial selected low, intermediate and high risk 
pediatric synovial sarcoma patients based on clinical prognostic factors. Chemotherapy was 
omitted in the low risk pediatric patients (free margins after resection, small size, and low 
grading), which resulted in similar survival rates12. This shows that identifi cation of clinical 
risk factors has added value to the treatment of pediatric synovial sarcoma. 
In chapter 3 a cohort of primary synovial sarcoma patients was explored for prognostic 
variables. In total, 461 patients were retrieved from the Netherlands Cancer Registry, with a 
median age of 38.0 years (range 2–89). Patients who were not treated according to standard 
care (i.e., did not receive surgery as part of their primary treatment) were excluded from the 
analyses, as they were considered unrepresentative. Overall, patients had a 5- and 10-year 
overall survival rate of 63.5±2.4% and 53.8±2.6%, respectively. For analysis, patients were 
divided into the following age categories at diagnosis: <18 years, 18-34 years, 35-64 years 
and ≥65 years, refl ecting pediatric, Adolescent and Young Adult (AYA), adult, and geriatric 
age, respectively. The most distinct prognostic factor for survival in non-primary metastatic 
patients was age at onset. Children who develop synovial sarcoma have signifi cantly better 
survival rates. Survival decreased gradually with tumors diagnosed at older onset. The effect 
remained when correcting for expected higher age-related mortality in older patients and the 
better survival rates were irrespective of the adjuvant chemotherapy given in children. Other 
tumor characteristics that were related to worse overall survival in our study were larger 
tumor size and tumors located in other places than head and neck or extremities. As both 
characteristics occurred randomly in all age groups, this could not explain the age effect. A 
possible explanation for the better survival rates at younger age can be found in the results of 
the study by Lagarde et al., who showed that development of synovial sarcoma metastases 
is associated with genome complexity of the primary tumor and that the adult tumor genome 
was more frequently rearranged compared to the genomic profi les of pediatric synovial 
sarcomas14. Chromosomal complexity was classifi ed according to the Genomic Index (GI), 
which integrates the number and type of DNA copy number alterations. Its score is based 
on the number of total alterations (segmental gains and losses) and the number of involved 
chromosomes. 
Once patients develop advanced disease, systemic treatment consists of chemotherapy 
(doxorubicin, with or without ifosfamide) or (at higher lines of treatment) the angiogenesis 
inhibitor pazopanib or alternative chemotherapeutic schedules. Unfortunately, although 
sometimes durable remissions are observed, cure at this stage based on systemic treatment only, 
is hardly ever achieved15. In chapter 4 an analysis on prognostic variables was performed on 
a cohort of patients with locally advanced and metastatic synovial sarcomas treated with fi rst 
line chemotherapy within studies of the European Organisation for Research and Treatment 
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of Cancer Soft Tissue and Bone Sarcoma Groups (EORTC STBSG) (n=313). In this analysis, 
factors that were related to poor overall survival were low performance status of the patient 
and presence of metastases. Age could not be studied in depth as this cohort study included 
no pediatric patients and only 4% of the patients were older than 65 years of age. In addition, 
this cohort of synovial sarcoma patients was compared to the overall group of “other” STS 
subtype within the context of first line chemotherapy studies in locally advanced and metastatic 
disease. Synovial sarcoma patients were significantly younger, had their primary tumors more 
often in an extremity and had a better performance status compared to other STS patients. 
Most patients (71%) were treated with anthracyclines or a combination of doxorubicin with 
ifosfamide, which are the standard first line chemotherapy schedules for STS patients. When 
compared to other STS patients, synovial sarcoma patients had a significantly better response 
to chemotherapy and better survival rates. Again, it emphasizes that synovial sarcoma has a 
distinct behavior compared to other STS subtypes. This is important as, due to its rarity, in 
phase 3 trials synovial sarcomas are often lumped together with other STS subtypes in clinical 
trials. This makes subtype specific results difficult to interpret, also because the group of 
synovial sarcomas as a whole comprises only about 8-10% of all STS. 
Part II: Exploring new targets in synovial sarcoma
The essential translocation and the relation of the genomic complexity with its clinical 
aggressiveness, emphasize the importance of understanding underlying genetic alterations in 
synovial sarcomas. In 2012 little was known about the mutation status of synovial sarcomas. 
Previous studies reported diversely about mutations in different oncogenes and most studies 
did not verify the mutations in corresponding healthy tissue17-26. We, therefore, sequenced a 
panel of synovial sarcomas, including both pediatric and adult tumors. In a subset of 26 tumors 
of 22 patients, next generation sequencing of over 400 cancer-related genes was executed 
(chapter 5). All variations found were also evaluated in corresponding normal DNA, and 
if variations were also detected in corresponding normal tissue they were considered to be 
polymorphisms. The cohort included a variety of primary tumors, recurrences and metastasis. 
In total, eight somatic mutations were found, one in each of the following genes: KRAS, 
CCND1, RNF213, KDR, SEPT9, CSMD3, MLH1, and ERBB4. Mutations were found more 
often in adult than in pediatric tumors, however this was not significant in our relatively 
small cohort. Lower survival rates were seen in patients harboring a mutation. Mutation status 
turned out to be very heterogeneous, and there was no repetitive occurrence of mutations or 
mutated pathways. In total, eight somatic mutations were detected, with a maximum of one 
mutation per sample. Two of the discovered mutations, in the KRAS and the CCND1 gene, 
represent known oncogenic mutations in other malignancies. This highlights that oncogenic 
events are shared across cancer types, and are not restricted to histological tumor types. 
Besides mutation status, we also assessed copy number variation. This was performed in six 
tumors, including two sets of two tumors from the same patient. An interesting outcome of the 
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sequencing study was the discovery of loss of chromosome 6q in a metastasis that developed 
resistance to pazopanib. This loss of chromosome 6q was not seen in a simultaneously existing 
metastasis from the same patient that continued to respond to pazopanib. Even though this 
has only been found in one patient, activity of pazopanib might be related to the genes on this 
part of the genome. As 6q comprises multiple genes, it is yet unknown which gene could be 
involved in this mechanism.
Ultimately, the idea behind understanding tumor biology is to fi nd new therapeutic targets. 
Especially more specifi c treatment options with less toxicity would be favorable such as 
specifi c antibodies or tyrosine kinase inhibitors. In vitro studies are a fast and cost-effi cient 
way to test multiple potential targeted therapies. We used in vitro studies to evaluate both 
a cell cycle inhibitor and receptor tyrosine kinase inhibitors as potential treatment options 
for synovial sarcoma patients. Of the reported mutations described in the previous chapter, 
only the CCND1 mutation is currently druggable. Since other synovial sarcoma studies also 
reported about excessive activity of the cyclin D1 pathway19,27-37, we explored the possibility 
of targeting this pathway in synovial sarcomas (chapter 6). First, we extensively examined 
alterations of proteins involved in the cyclin D1 pathway. This showed that nuclear pRb 
expression was related to worse overall survival, and overexpression of β-catenin showed a 
similar tendency. Additionally, four synovial sarcoma cell lines were screened for mutations 
in genes involved in the cyclin D1 pathway, revealing a CCND1 amplifi cation with a p53 
mutation in one, and a β-catenin mutation in another cell line. Next, the cyclin D1 pathway 
was targeted with the CDK4/6 inhibitor palbociclib, a therapy which has shown limited toxic 
effects in breast cancer patients38,39. Inhibitory effects with clinically relevant concentrations 
of palbociclib were seen in 3 out of 4 synovial sarcoma cell lines, leading to a decreased pRb 
and a G1 cell cycle arrest. Unfortunately, clinically relevant doses did not result in a 100% 
growth inhibition. Analogous to the combination treatment of palbociclib and anti-hormone 
therapy in advanced breast cancer patients40, combination treatment of palbociclib with other 
therapies need to be searched for in future studies to enhance this preclinical potential for 
synovial sarcoma patients.
Nonetheless, in most synovial sarcomas no mutation or copy number alteration was 
discovered, which was recently confi rmed in a large STS cohort, including a subset of 
synovial sarcomas41. Therefore, we were encouraged to analyze oncogenic patterns in 
synovial sarcomas using other methods. To discover activated pathways in synovial sarcomas, 
mass-spectometry was used to identify phosphorylation profi les of sarcoma cell lines42. This 
analysis identifi es activated (phosphorylated) proteins, which is often diffi cult to explore 
by immunohistochemistry. This multi-center study analyzed 20 different STS cell lines, 
including 4 synovial sarcoma cell lines. All four synovial sarcoma cell lines tested showed 
heterogeneous expression patterns, with either focus on one leading single receptor tyrosine 
kinase (RTK) or expression of multiple RTKs (chapter 7). Based on the results of the mass-
spectometry analysis, the effect of clinically available RTK inhibitors on potential targets 
were explored. Some tyrosine kinases exhibited enhanced phosphorylation in subsets of cell 
lines without a clear preference towards a specifi c sarcoma subtype (e.g. EPHB3 in a Ewing 
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sarcoma, rhabdomyosarcoma and synovial sarcoma cell line). Whereas other kinases appeared 
to be more sarcoma subtype-specific, as exemplified by increased phosphorylation of DDR2 
in Ewing sarcoma cells, FGFR4 in rhabdomyosarcoma, EGFR, EPHA7 and PDGFRα in 
synovial sarcoma and lastly TIE1, VEGFR2, FGR, and BMX in angiosarcoma cell lines. As 
expected, a gastro-intestinal stromal tumor cell line (GIST882) exhibited an exceptionally 
high level of KIT phosphorylation reflecting its KIT-driven phenotype and imatinib sensitivity. 
Similarly, an extreme phosphorylated tyrosine kinase content was observed for ALK in one 
synovial sarcoma cell line (ASKA-SS). This indicated sole ALK addiction, and we discovered 
an underlying newly reported ALK breakage in that cell line. This breakage has not been 
reported before, and occurrence in other (synovial) sarcomas will be part of further research. 
The ALK addiction was confirmed and described in literature with a high sensitivity for ALK 
inhibitory therapies, with IC50 values that correspond to the sensitivity in ALK-dependent 
lymphomas with crizotinib and non small cell lung cancer with ceritinib (NSCLC)43,44. In 
addition, xenografts of this Aska-SS cell line demonstrated a remarkable dependency on 
ALK for tumor growth and maintenance, with drug treatment resulting in robust and durable 
tumor regressions. The clinical relevance of ALK in synovial sarcomas was explored by 
immunohistochemistry. ALK immunopositivity was detected in 6 of 43 (14%) synovial 
sarcoma patient specimens, one of which exhibited an underlying ALK breakage. 
The other three synovial sarcoma cell lines we studied by mass spectrometry showed a more 
diverse signaling network, without one explicit oncogenic driver. One way to overcome 
multiple activated kinases is implementation of combination treatments or the use of 
appropriate multikinase inhibitors. This was tested in a synovial sarcoma cell line which 
expressed high levels of MET, PDGFRα and EGFR, with no underlying mutations in these 
genes. Interestingly, monotherapy of pazopanib as a PDGFRα-inhibitor had no inhibitory 
effects in vitro, whereas synergistic effects were observed upon combined treatment of 
pazopanib and crizotinib (a combined MET/ALK inhibitor). Again, clinical relevance was 
tested by immunohistochemistry, with 56% (24/43) of synovial sarcoma tumor tissues co-
expressing the two proteins, with the highest scores for PDGFRα and MET being mutually 
exclusive. Important to note that monotherapy of pazopanib did show in vivo effects. In 
pazopanib-treated tumors, significantly fewer CD34+ blood vessels were observed compared 
to untreated tumors, which is an effect that cannot be measured in vitro. 
MET targeting in synovial sarcomas has also been investigated by other study groups, who 
recently confirmed MET as a potential target45,46. The synergistic results of the combination 
of crizotinib and pazopanib observed in vitro, would be interesting to test in vivo, although 
this combination of tyrosine kinase inhibitors could be challenging in terms of toxicity. 
Consequently, the integrated approach of this study has led to the identification of ALK and 
MET as promising therapeutic targets in synovial sarcoma.
191
Summerizing discussion and future perspectives
11
Part III: Pharmacodynamics and pharmacokinetics of pazopanib in metastatic STS
Besides identifying new targets for treatment of synovial sarcoma patients, optimizing current 
treatments can also lead to improved patient care. One of the two currently available targeted 
therapies for STS patients, including synovial sarcoma patients, is pazopanib. Pazopanib is an 
orally administered multi-kinase inhibitor, and was originally developed as an angiogenesis 
inhibitor targeting vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, and 
VEGFR3. In addition, it inhibits the activity of platelet-derived growth factor receptor α 
(PDGFR-α), PDGFR-β, and c-Kit. The phase III study PALETTE investigated the effect 
of pazopanib on progression-free survival in patients with metastatic non-adipocytic STS 
after failure of standard chemotherapy. It showed progression-free survival benefi t in STS 
patients. Unfortunately, 23% of the patients had progressive disease as best response, and 
reported grade 3-4 toxicity included fatigue (13%), hypertension (7%), anorexia (6%), and 
diarrhea (5%). Interestingly, potentially better results were seen in synovial sarcoma patients, 
however, this was not signifi cant47. In the previous phase II study of Sleijfer et al. in advanced 
STS patients with a maximum of two previous chemotherapies, the progression-free rate 
at 12 weeks was 49% in the synovial sarcomas, versus 44% in leiomyosarcomas and 39% 
in the other STS subtypes48. Altogether, it would be of benefi t to identify non-responders 
at an early stage, to avoid treatment of patients with an ineffective, potentially toxic, and 
expensive drug over a prolonged period of time. FDG-PET/CT has been evaluated as early 
response monitor for several treatments in various malignancies, although standardizing the 
quantitative analysis remains diffi cult. Experts in the fi eld have introduced guidelines, known 
as “PERCIST”, to quantitatively analyze FDG response. Chapter 8 describes the potentials 
and pitfalls of using the PERCIST guidelines for analyzing FDG response of solid tumors. 
Awareness of these limitations is essential to prevent that methodological issues impede 
successful introduction of research data into clinical practice. To investigate if FDG-PET/CT 
is applicable for early pazopanib treatment response monitoring in STS patients, the PREDICT 
study was developed as reported in chapter 9. In this pilot study change in glucose metabolism 
depicted by FDG-PET/CT was evaluated as a biomarker for assessment of early treatment 
response. Pharmacokinetic evaluation was included in the analysis to explore the relation 
between pharmacokinetics and metabolic response. Including this potential confounder in 
the analysis is important as pazopanib shows large interpatient pharmacokinetic variability, 
and previous pharmacokinetic studies in STS have shown that trough concentrations of 
>20 mg/L are related to better progression free survival rates49. In total, 20 patients were 
included who showed FDG-uptake on their baseline FDG-PET/CT before pazopanib start. 
After eight weeks two patients had to discontinue pazopanib treatment due to toxicity and 
twelve patients had stopped due to disease progression. Six patients showed stable disease 
and continued pazopanib. The key fi nding of this study was that peak standardized uptake 
value corrected for lean body mass (SULpeak) derived from FDG-PET/CT images, acquired 
two weeks after start of treatment, was a moderate predictor of treatment failure after 8 weeks 
(non-responders according to RECIST criteria). Quantitative FDG-PET scoring at two weeks 
identifi ed 25% (3 of 12) of all non-responders. The visual response analysis (VRA) by an 
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experienced nuclear medicine physician, which is easier to apply in daily clinical practice, 
showed to be a better predictor of treatment failure than quantification of SULpeak of FDG-
PET/CT images, identifying 42% (5 of the 12 non-responders). In both analyses, no patient 
was incorrectly labeled as non-responder. Pazopanib pharmacokinetics showed no relation to 
metabolic response. Before implementing metabolic response on FDG-PET/CT as an early 
biomarker these results need to be confirmed in a larger cohort study. 
The last topic of this thesis is focused on hepatotoxicity caused by pazopanib treatment. 
Elevated liver enzymes (transaminases) usually develop shortly after pazopanib initiation. 
Discontinuation of pazopanib therapy due to this hepatotoxicity has large clinical 
consequences for patients with STS as after pazopanib only limited therapeutic options are 
available. Chapter 10 reports about two synovial sarcoma patients who developed elevated 
transaminases within two months after treatment start. The underlying mechanism of pazopanib-
induced hepatotoxicity is not yet unraveled, however, limited information in the literature 
suggests that it might be immune mediated as liver biopsies of two patients with pazopanib 
hepatotoxicity showed inflammation50. In addition, Xu et al. showed that HLA-B*57:01 
carriage confers higher risk of ALT elevation in patients receiving pazopanib, which also 
implicates an immune-mediated mechanism for pazopanib-associated hepatotoxicity51. If 
autoimmune inflammation indeed underlies pazopanib-induced hepatotoxicity, corticosteroids 
could potentially overcome this problem. Based on this hypothesis, we studied two STS 
patients who interrupted pazopanib based on liver toxicity. Liver enzymes normalized after 
interrupting pazopanib, and both patients restarted pazopanib at a lower dose. As re-elevation 
of transaminase occurred, they received prednisolone while continuing pazopanib. These 
patients were followed carefully and indeed, simultaneous intake of prednisolone resulted in 
a significant decrease in transaminases. The two patients could continue pazopanib treatment 
until disease progression, without signs of relapsed hepatotoxicity, while in the meantime the 
dose of prednisolone was slowly decreased. This lead to the conclusion that an inflammatory 
response seems to be present and concomitant treatment with prednisolone can be done in 
case a patient profits from pazopanib and the liver function can be closely monitored.
General conclusion
Synovial sarcoma is an intriguing soft tissue sarcoma subtype, with many uncertainties about 
its etiology, pathogenesis and medical treatment response. This thesis provides evidence for 
the heterogeneity within the synovial sarcoma subtype, on clinical, genetic and proteomic 
level and in treatment response to chemotherapy and pazopanib. Besides exploring synovial 
sarcoma behavior, we provide strong preclinical evidence for several treatment options, 
including a cell cycle inhibitor and the RTK inhibitors (ALK and MET). 
In addition, we suggest measures to optimize pazopanib treatment in STS patients, by 
exploring FDG-PET/CT as an early metabolic response biomarker and have described 
positive experiences with prednisolone rescue in case of pazopanib induced hepatotoxicity.
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Future perspectives
The results obtained in this thesis will have a role in the design of future clinical trials for 
synovial sarcoma patients. 
The relation between age and survival is a factor that needs to be considered in the design of 
future studies in primary synovial sarcoma. It may well be that the Genomic Index, the for this 
fi nding most probable underlying factor, will be part of future risk classifi cation systems in 
primary synovial sarcoma. In addition, it is essential to be aware of the distinctive clinical and 
genetic characteristics of synovial sarcomas when it comes to the design of clinical studies 
for STS in the metastatic setting. Predefi ned subanalyses for the cohort of synovial sarcoma 
patients in unselected STS trials or trials stratifi ed per subtypes, such as the phase 2 trial with 
pazopanib by Sleijfer et al.48, could overcome the need for large clinical trials with solely 
synovial sarcoma patients. 
As next generation sequencing (NGS) is more widely accessible and costs have decreased 
tremendously over the last decade, NGS screening has become more and more part of daily 
clinical practice. Unfortunately, as our next generation sequencing study also showed, 
frequent druggable mutations in synovial sarcomas are uncommon. It is questionable whether 
NGS is the most practical method to determine these druggable mutations for this patient 
group. Especially, as the ALK rearrangement we found with phosphoproteomics testing 
is more easily detected by FISH techniques than by next generation sequencing. So far, 
sequencing of large panels including numerous genes has not proven to be of clinical benefi t 
in synovial sarcoma patients. Based on our fi ndings, ALK rearrangement warrants further 
evaluation in a larger subset of synovial sarcomas to explore the frequency of this ALK driven 
phenotype, which can be identifi ed by phosphorylation profi ling or screening for genetic 
rearrangements by means of FISH. Potentially even immunohistochemistry screening can 
be used as fi rst selection method for further screening by FISH. Ultimately, whether positive 
immunohistochemistry or FISH rearrangements are indeed of clinical relevance needs to be 
verifi ed with clinical response to ALK inhibitors in synovial sarcoma patients. Importantly, as 
this ALK rearrangement is uncommon in this rare tumor type, a clinical study with suffi cient 
patients is probably unrealistic. To overcome this practical issue, a study could be designed 
that selects patients based on this ALK driven phenotype, ignorant of the type of tumor. The 
ALK-inhibitor crizotinib has been studied in several tumor types, including some very rare 
subtypes of sarcomas, in the CREATE trial52. In a current study entrectenib is being given 
to patients with ALK/ROS/NTRK mutations in several tumor types including sarcomas 
(NCT02568267). This study evaluates treatment effects for several specifi c genetic alterations. 
To ultimately facilitate care for rare tumor types, including sarcomas, the European Reference 
Network has set up a European network for Rare adult solid Cancers (EURACAN). In 
addition, the SPECTA (Screening cancer Patients for Effi cient Clinical Trial Access) platform, 
a collaborative European platform that helps deliver high-quality, translational research 
across (rare) tumor types and molecular alterations, provides rapid access to patient data and 
biological samples to enable the quick implementation of new clinical trials. This platform is 
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linked to the European Organisation for Research and Treatment of Cancer (EORTC) and has 
been set up to facilitate the translation of research as described. The use of other treatment 
options and combinations of targeted therapies described in this thesis (palbociclib and the 
combination of pazopanib with crizotinib) warrants further (pre)clinical investigation for their 
potency to be used in the treatment of synovial sarcomas. 
Besides these targeted therapies, also the potency of immunotherapy is currently evaluated, 
in which NY-ESO-1 is a potential target of interest in synovial sarcomas. Several studies, 
including a study with autologous T cells transduced with a T-cell receptor (TCR) directed 
against NY-ESO-153 and a case report in which treatment with dendritic cells targeted with 
Lentiviral Vector-expressing NY-ESO-154, showed promising results. Combinations of 
immunotherapy with targeted therapies, which might be better tolerable than combining 
targeted agents, also deserve attention in future research. 
Finally, there are still many details unclarified about the position of pazopanib as treatment 
in many different STS subtypes, with a large number of patients unresponsive to treatment. 
Other studies have suggested pazopanib-resistance in synovial sarcoma being related to miR-
761 in extracellular vesicles55, or through DUSP6 downregulation56. Therefore, further studies 
are needed to explore the mechanistic effects behind these pazopanib-resistance hypotheses. 
If this can be clarified, pazopanib-resistant patients can be selected beforehand and potentially 
the resistance mechanism can be circumvented. As long as the mechanism of pazopanib 
resistance is not clarified, early biomarkers evaluating response are a solution to save valuable 
time, spare toxicities, and decrease treatment costs. A larger study is needed to confirm 
our finding that FDG-PET/CT can serve as an early biomarker to identify non-responders. 
Sufficient patient numbers are essential to evaluate if the identification of non-responders 
is specific enough to be cost-effective and deprives no patient of an effective treatment. 
One of the challenges of these studies is financial support, as pharmaceutical industries are 
usually not interested in identifying early response markers that will lead to early treatment 
discontinuation. However, when cost-effectiveness is the primary objective, health assurance 
companies, research organizations, and cancer charities could potentially be interested. On 
the contrary, approaches to overcome pazopanib-related liver toxicity are of interest to all 
parties involved and are of interest to a broader, and thus numerical larger, group of patients 
for whom pazopanib is part of standard treatment, namely patients with renal cell carcinoma 
and STS. This makes the feasibility of a further study to explore the value of prednisolone to 
overcome pazopanib induced hepatotoxicity more likely.
In conclusion, the results described in thesis contribute to the understanding of distinct features 
of synovial sarcomas. Furthermore, they aim to direct further research in this area leading to 
smarter and more personalized treatments, which ultimately lead to improved survival of 
synovial sarcomas patients.
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Nederlandse samenvatting
Weke delen sarcomen zijn tumoren die ontstaan vanuit het steun- en bindweefsel. Het 
synoviosarcoom is een van de subtypes van het weke delen sarcoom en kan, als enig subtype, 
gediagnosticeerd worden op alle leeftijden met een piekincidentie rond de 35-38 jaar. De naam 
is ontstaan met de gedachte dat deze tumoren ontstonden in het synoviaal weefsel rondom 
de gewrichten. Deze opvatting is echter allang verlaten aangezien de tumoren overal in het 
lichaam kunnen voorkomen, weliswaar met een voorkeur voor de extremiteiten. Dat maakt 
dat het nog altijd onduidelijk is vanuit welk celtype deze tumoren ontstaan. In 1987 werd voor 
het eerst beschreven dat synoviosarcomen een translocatie laten zien tussen chromosoom X 
en 18, waardoor de fusiegenen SYT-SSX1 of SYT-SSX2 ontstaan. Deze translocatie is uniek 
voor het synoviosarcoom en komt in (vrijwel) alle tumoren voor. In de decennia hierna zijn 
verschillende interacties tussen de translocatie en intracellulaire signaalpaden bestudeerd, 
maar de exacte relatie is tot op heden niet opgehelderd. Ondanks deze unieke genetische 
afwijking laat het synoviosarcoom in de kliniek een allesbehalve consistent patroon zien 
wat zich uit in het vóórkomen in een erg heterogene patiënten populatie wat betreft leeftijd, 
een mild tot erg agressief beloop, een grote verscheidenheid aan primaire tumorlocaties en 
een wisselende respons op chemotherapie (hoofdstuk 2). Tot nu toe heeft de karakteristieke 
translocatie en de daarbij passende fusiegenen echter alleen waarde in de diagnostiek, maar is 
deze nog niet nuttig gebleken als aangrijpingspunt voor therapie. 
In dit proefschrift worden prognostische factoren en huidige behandelmogelijkheden verkent 
van synoviosarcoom patiënten met zowel primaire als gemetastaseerde tumoren (deel I). 
Daarna worden nieuwe therapeutische mogelijkheden onderzocht in synoviosarcomen 
met behulp van preklinisch onderzoek (deel II). Als laatste wordt de farmacodynamiek en 
-kinetiek van pazopanib onderzocht, een doelgerichte therapie welke in de kliniek wordt 
toegepast in weke delen sarcomen met een superieur effect in synoviosarcoom patiënten. 
De mogelijkheden om de FDG-PET/CT scan als vroege biomarker van therapie respons 
op pazopanib te gebruiken zijn onderzocht. Tevens is een strategie om levertoxiciteit van 
pazopanib te behandelen getest (deel III).
Deel I: epidemiologie en huidige behandelmogelijkheden in patiënten met een 
synoviosarcoom
Patiënten met een primair synoviosarcoom krijgen een chirurgische behandeling waarbij de 
tumor wordt verwijderd, eventueel in combinatie met (neo)adjuvante radiotherapie. In de 
kinderoncologie wordt hier vaak nog (neo)adjuvante chemotherapie aan toegevoegd, terwijl 
de toegevoegde waarde bij volwassen patiënten twijfelachtig is. Middels studies wordt 
geprobeerd hier meer inzicht in te krijgen. Een recente klinische studie in kinderen met 
een synoviosarcoom liet zien dat chemotherapie in laag risico patiënten veilig achterwege 
gelaten kon worden. Een retrospectieve studie in volwassen patiënten laat juist effect zien van 
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adjuvante chemotherapie in hoog risico patiënten. Dit benadrukt tevens het belang van het 
bepalen van valide prognostische risicofactoren.
In hoofdstuk 3 wordt een cohort van primaire synoviosarcoom patiënten beschreven met als 
doel prognostische factoren te evalueren. Hiervoor zijn data verzameld van 461 patiënten die 
geregistreerd zijn door de Nederlandse Kankerregistratie tussen 1989 en 2013. De mediane 
leeftijd van de patiënten was 38 jaar (bereik 2-89). Patiënten die niet volgens de huidige 
standaard therapie waren behandeld, welke bestaat uit minimaal chirurgie, werden beschouwd 
als niet representatief en derhalve geëxcludeerd. Patiënten in deze studie hadden een 
respectievelijke 5- en 10-jaars overleving van 63,5±2,4% en 53,8±2,6%. Voor analyse werden 
patiënten verdeeld in 4 groepen gebaseerd op de leeftijd ten tijde van diagnose; kinderen (<18 
jaar), adolescenten en jong volwassenen (18-34 jaar), volwassenen (35-64 jaar) en ouderen (≥65 
jaar). Leeftijd was de meest opvallende prognostische factor. Jongeren die gediagnosticeerd 
werden met een synoviosarcoom hadden signifi cant betere overlevingskansen. Deze werden 
slechter naarmate de patiënten ouder waren op het moment van diagnose. Het verschil in 
overleving per leeftijdsgroep bleef aanwezig na correctie voor de normale levensverwachting 
in de betreffende leeftijdscategorie. Ook de frequentere toediening van chemotherapie op 
kinderleeftijd speelde geen rol bij de betere overleving, al was de groep van kinderen eigenlijk 
te klein om daar harde uitspraken over te doen. Andere factoren die gerelateerd waren aan 
slechtere overleving waren grotere tumoren en tumoren die ontstaan zijn op andere plekken 
dan het hoofd-hals gebied of de ledematen. Deze twee laatstgenoemde factoren waren 
gelijkmatig verdeeld over alle leeftijdsgroepen en gaven dus geen goede verklaring voor het 
leeftijdseffect. Een mogelijke verklaring voor het leeftijdsverschil kan gevonden worden in 
de resultaten van de Franse studiegroep (Lagarde, et al) die in een cohort van synoviosarcoom 
patiënten de genomic index ten opzicht van leeftijd heeft geëvalueerd. De genomic index 
geeft aan in welke mate er chromosomale aberraties zijn, waarbij de score wordt bepaalt aan 
de hand van de hoeveelheid aberraties (segmentele deleties of vermeervoudigingen) en de 
hoeveelheid aangedane chromosomen. Zij rapporteerden dat patiënten met een verhoogde 
genomic index sneller metastasen vormden met een slechtere overleving, waarbij tumoren 
ontstaan op volwassen leeftijd signifi cant vaker een verhoogde genomic index hadden ten 
opzicht van tumoren die zich op kinderleeftijd hebben ontwikkeld. 
Wanneer er sprake is van een irresectabele tumor of metastasen kan systeemtherapie 
gegeven worden bestaande uit chemotherapie (doxorubicine eventueel gecombineerd met 
ifosfamide) en als volgende lijn de angiogenese remmer pazopanib of andere alternatieve 
chemotherapeutica. Met deze systeemtherapie wordt geprobeerd om langdurig verdere 
tumorgroei tegen te gaan, maar genezing in dit stadium is vrijwel niet meer mogelijk. Er 
wordt in deze gemetastaseerde setting bij synoviosarcoom patiënten dus gesproken over een 
palliatieve behandeling. In hoofdstuk 4 is een analyse gedaan naar prognostische factoren 
in patiënten in deze palliatieve setting. Het betrof patiënten met een lokaal recidief van de 
tumor die anderszins niet te behandelen was, of –en dat was de grootste groep– patiënten met 
metastasen op afstand, veelal in de longen. De gegevens van 313 synoviosarcoom patiënten 
die eerste lijns chemotherapie kregen in studies uitgevoerd door de European Organisation for 
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Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC STBSG) 
zijn meegenomen in deze analyse. Prognostische factoren in deze groep patiënten waren een 
slechte performance status van de patiënt en de aanwezigheid van metastasen op afstand. 
Leeftijd op het moment van diagnose was geen prognostische factor. Het is echter belangrijk 
om te noemen dat aan deze studies geen kinderen hadden deelgenomen en slechts 4% van 
de patiënten ouder was dan 65 jaar. Dit toont meteen aan dat patiënten die participeren in 
studies over het algemeen jonger zijn dan van de totale populatie van (synovio)sarcoom 
patiënten. In deze analyse hebben we tevens een vergelijking gemaakt tussen synoviosarcoom 
patiënten en patiënten met andere weke delen sarcoom subtypes in de palliatieve fase. Deze 
analyse liet zien dat synoviosarcoom patiënten in vergelijking met de andere weke delen 
sarcoom patiënten een betere performance status hadden, jonger waren en vaker de primaire 
tumor in een ledemaat hadden. Daarnaast hadden synoviosarcoom patiënten een significant 
betere respons op chemotherapie en een betere overleving. Het belang van het aantonen van 
verschillen tussen deze groepen is dat patiënten met allerlei verschillende weke delen sarcoom 
subtypes in fase 3 klinische studies vaak worden samengevoegd tot één patiëntengroep, terwijl 
er evidente verschillen in tumorgedrag zijn tussen de verschillende subtypes. Aangezien 
synoviosarcomen slechts 8-10% van de totale groep weke delen sarcomen bevatten, is de 
beste oplossing om dit probleem te ondervangen een subgroep stratificatie, al vraagt dit wel 
deelname van voldoende patiënten. 
Deel II: het verkennen van nieuwe behandelopties in synoviosarcomen
In 2012 was er nog weinig onderzoek gedaan naar de mutatiestatus van synoviosarcomen. 
Eerdere studies hadden wel verschillende gen variaties in synoviosarcomen beschreven, 
maar de meeste waren niet gecontroleerd in het gezonde weefsel van de patiënt. Hierdoor 
is het onduidelijk of het tumor specifieke mutaties zijn of natuurlijke variaties van het gen 
(polymorfismes) of kiembaanmutaties. In hoofdstuk 5 hebben we daarom gekeken naar de 
mutatiestatus van het synoviosarcoom in zowel tumoren van kinderen als volwassenen. In 
26 tumoren van 22 patiënten zijn meer dan 400 aan kanker gerelateerde genen onderzocht 
met behulp van next generation sequencing. Zowel primaire tumoren als tumor recidieven 
en metastasen zijn geanalyseerd. Alle gevonden variaties werden gecontroleerd in gezond 
weefsel van de patiënten. Als ze in gezond weefsel werden terug gevonden werden ze 
beschouwd als polymorfismes, wanneer ze enkel in tumor weefsel voorkwamen dan werden 
het somatische mutaties genoemd. In totaal zijn er 8 somatische mutaties gevonden, die 
elk slechts éénmaal voorkwamen, in de genen: KRAS, CCND1, RNF213, KDR, SEPT9, 
CSMD3, MLH1, en ERBB4. Mutaties werden vaker gevonden in tumoren van volwassenen in 
vergelijking met tumoren van kinderen, maar gezien de beperkte grootte van deze studie was 
dit niet een significant verschil. Tevens werd een slechtere overleving gezien in patiënten die 
een tumor met een mutatie hadden. Het patroon van de mutaties was erg heterogeen, waarbij 
mutaties niet geclusterd konden worden binnen bijvoorbeeld één signaalpad. Twee van de 
gevonden mutaties, in het KRAS en het CCND1 gen, zijn bekende oncogene mutaties die 
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al eerder beschreven zijn in andere maligniteiten. Naast de mutatie status is er ook gekeken 
naar chromosomale afwijkingen (aberraties). Dit is gedaan in zes synoviosarcomen uit vier 
patiënten, waarbij van twee patiënten elk twee verschillende metastasen zijn meegenomen. 
Hierbij werd een verlies van chromosoom 6q gevonden in een metastase van een patiënt 
die progressief was onder pazopanib gebruik. Dit in tegenstelling tot de op pazopanib 
reagerende metastase van dezelfde patiënt, waar dit verlies niet zichtbaar was. Aangezien het 
chromosoomdeel 6q veel genen bevat is het vooralsnog niet te voorspellen welk gen mogelijk 
betrokken is bij deze verworven pazopanib resistentie. 
Het uiteindelijke doel van deze studie dat zich focust op het begrijpen van de tumorbiologie 
van synoviosarcomen in het bijzonder, is het vinden van nieuwe aangrijpingspunten voor 
therapie. Deze nieuwe therapieën kunnen verder onderzocht worden middels preklinisch 
onderzoek welke bestaat uit in vitro onderzoek en in vivo experimenten voordat deze in 
de kliniek worden getest. Van alle mutaties die gevonden zijn in de studie beschreven in 
hoofdstuk 5, is op dit moment alleen medicatie beschikbaar die de activerende mutatie in het 
CCND1 gen remt, namelijk de selectieve CDK4 en -6 remmer palbociclib. In hoofdstuk 6 
is het cycline D1 signaalpad in synoviosarcomen dan ook verder geanalyseerd. Eerst zijn de 
verschillende eiwitten die betrokken zijn bij dit signaalpad beoordeeld op mate van expressie. 
Hieruit bleek dat nucleaire pRb expressie gerelateerd is aan een slechtere overleving. 
Ditzelfde leek ook te gelden voor overexpressie van β-catenine, maar dit was niet signifi cant. 
Ook zijn vier synoviosarcoom cellijnen gescreend op mutaties in genen die betrokken zijn 
bij het cycline D1 signaalpad. Een CCND1 amplifi catie met een p53 mutatie is gezien in één 
cellijn, terwijl een andere cellijn een β-catenine mutatie liet zien. Naast de mate van expressie 
binnen dit signaalpad is er ook gekeken naar het effect van het remmen van dit signaalpad. 
Er is gebruik gemaakt van palbociclib, een CDK4/6-remmer, welke reeds gebruikt wordt in 
patiënten met gemetastaseerd borstkanker. De remmer is getest op de vier synoviosarcoom 
cellijnen. In drie van deze cellijnen was er een effect te zien van palbociclib bij klinisch 
relevante concentraties. De hoeveelheid pRb gaat omlaag en er is een toename van cellen in 
G1-arrest. Er werd echter geen 100% groeiremming gezien. De volgende stap moet zijn om 
deze therapie te combineren met een andere therapie om volledige celremming te kunnen 
bewerkstelligen, zoals ook in borstkanker patiënten waarbij palbociclib gecombineerd wordt 
met hormoontherapie. 
Aangezien de meeste synoviosarcomen geen mutaties lieten zien besloten we ook op een andere 
manier het onderliggende oncogene werkingsmechanisme van deze sarcomen te onderzoeken. 
In een internationale samenwerking zijn geactiveerde signaalpaden onderzocht op basis van 
fosforylatie profi elen. In hoofdstuk 7 is middels massaspectrometrie een groot panel van 
sarcoom cellijnen, inclusief de vier synoviosarcoom cellijnen die ook zijn gebruikt voor het 
onderzoek dat is beschreven in hoofdstuk 6, gescreend voor de fosforylering van hun tyrosine 
kinase peptides. Interessant om op te merken was de fosforylering van sommige eiwitten 
in meerdere subtypes (bijvoorbeeld EPHB3 in een Ewing sarcoom, rhabdomyosarcoom en 
synoviosarcoom cellijn), terwijl andere kinases juist subtype specifi ek waren (bijvoorbeeld 
DDR2 in Ewing sarcomen, FGFR4 in rhabdomyosarcomen, EGFR, EPHA7 en PDGFRα 
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in synoviosarcomen, en TIE1, VEGFR2, FGR, en BMX in angiosarcoom cellijnen). Zoals 
verwacht liet de GIST cellijn (GIST882) een uitzonderlijk hoge fosforylering zien van 
het tyrosine kinase KIT, passende bij zijn KIT gedreven fenotype en sterke gevoeligheid 
voor imatinib (een KIT-remmer). Onverwachts liet één synoviosarcoom cellijn (Aska-SS) 
eenzelfde hoge fosforylering zien van het ALK eiwit. Nader onderzoek naar deze cellijn 
liet ook een ALK-aberratie zien die de verhoogde gefosforyleerde expressie mogelijk kan 
verklaren. Hieraan gecorreleerd laat de cellijn een sterke gevoeligheid zien voor twee op 
ALK aangrijpende therapieën (ceretinib en crizotinib). Deze ALK-gerichte therapieën 
worden momenteel toegepast bij onder andere ALK-afhankelijke lymfomen en niet 
kleincellig longcarcinomen. Deze ALK gevoeligheid in de Aska-SS cellijn werd bevestigd 
met een in vivo experiment waarbij een sterke en langdurige groeireductie werd gezien in 
muizen met tumoren ontstaan uit deze Aska-SS cellijn. ALK als potentieel aangrijpingspunt 
van therapie werd tevens getest in tumoren van patiënten. Middels FISH (Fluorescentie-In-
SituHybridisatie) werd een ALK-aberratie gezien in de tumor van één patiënt, daarnaast werd 
ALK positiviteit bij immunokleuringen gezien in 14% (6/43) van de synoviosarcomen. 
De andere drie synoviosarcoom cellijnen lieten daarentegen activiteit zien in meerdere 
verschillende signaalpaden. Er leek bij deze cellijnen niet één specifieke aansturing. De gedachte 
is dat cellijnen met meerdere actieve signaalpaden behandeld zouden moeten worden met een 
combinatie van remmers of met een multi-target remmer. Hierdoor kunnen doelgericht de 
verschillende signaalpaden geblokkeerd worden, wat uiteindelijk hetzelfde remmende effect 
zou kunnen veroorzaken. Om dit te testen werd de synoviosarcoom cellijn gebruikt die expressie 
laat zien van pMET, pPDGFRα en pEGFR zonder onderliggende mutaties in deze genen (de 
Yamato-SS cellijn). Het middel pazopanib (remt onder andere PDGFRα en VEGFR) liet in 
vitro geen effect zien, terwijl in vivo een anti-angiogenese effect kon worden waargenomen in 
het Yamato-SS muis model met afname van CD34+ bloedvaten in de behandelde tumoren. De 
ALK/MET-remmer crizotinib daarentegen liet zowel een remmend effect zien in vitro als in 
vivo. In in vitro studies werd pazopanib gecombineerd met crizotinib. Deze combinatie liet in 
de Yamato-SS synoviosarcoom cellijn inderdaad een synergistisch effect zien. Ook hier werd 
de klinische relevantie bestudeerd door een immunokleuring voor PFDGRα en MET, waarbij 
co-expressie gezien werd in 56% (24/43) van de synoviosarcomen. De volgende stap is om de 
ALK gerichte behandeling in studieverband in patiënten met ALK positieve synoviosarcomen 
te testen, alsmede de combinatie behandeling van crizotinib en pazopanib, waarbij er eerst 
uit fase 1 onderzoek zal moeten blijken of de middelen veilig gecombineerd kunnen worden. 
Fase 1 onderzoek waarbij deze middelen worden gecombineerd worden reeds uitgevoerd 
(NCT01548144; clinicaltrials.gov).
Deel III: farmacodynamiek en farmacokinetiek van pazopanib in patiënten met een 
gemetastaseerd weke delen sarcoom
Behalve het ontwikkelen van nieuwe therapieën liggen er ook verbetermogelijkheden bij 
huidige therapieën. Op dit moment zijn er twee doelgerichte therapieën beschikbaar voor 
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weke delen sarcoom patiënten: pazopanib en olaratumab. Olaratumab wordt, gebaseerd 
op resultaten van een recente gerandomiseerde fase 2 studie, gegeven in combinatie met 
doxorubicine als eerste lijns behandeling in de palliatieve setting. Resultaten van de fase 3 
studie zullen bepalen of dit middel zal worden opgenomen in het standaard arsenaal voor de 
behandeling van patiënten met weke delen sarcomen.
Pazopanib is een orale angiogenese remmer, welke bewezen effectief bleek in de fase 3 
PALETTE studie. Helaas werd bij 23% van de patiënten in deze studie met een weke delen 
sarcoom geen enkele respons op therapie gezien en werd graad III-IV toxiciteit regelmatig 
gerapporteerd (vermoeidheid 13%, hypertensie 7%, anorexia 6% en diarree 5%). Daarbij werd 
in een eerdere fase 2 studie gezien dat pazopanib mogelijk effectiever is in synoviosarcoom 
patiënten in vergelijking met andere weke delen sarcoom patiënten. Een vroege screening 
om te bepalen bij wie dit middel niet effectief is, is daarom essentieel. Voor andere kanker-
gerichte therapieën blijkt de FDG-PET/CT scan een techniek te zijn om in een vroeg stadium 
te kunnen voorspellen bij wie de behandeling niet aanslaat. In hoofdstuk 8 zijn verschillende 
methodes uiteengezet die gebruikt kunnen worden om de metabole respons op de FDG-PET/
CT scan te analyseren. Er wordt in het bijzonder ingegaan op de PERCIST criteria die op dit 
moment de meest gebruikte criteria zijn voor de kwantitatieve beoordeling van FDG-PET/
CT scans in studieverband. Deze informatie is vervolgens gebruikt om een pilot studie op 
te zetten (hoofdstuk 9). In deze studie werd bestudeerd of het mogelijk is om al na 2 weken 
te kunnen evalueren of pazopanib effectief is op basis van een glucosemetabolisme effect. 
Hiervoor werden 20 patiënten met een gemetastaseerd weke delen sarcoom geïncludeerd die 
zouden gaan starten met pazopanib. De biomarker glucosemetabolisme werd gemeten met 
behulp van een FDG-PET/CT scan. Patiënten kregen voor start van therapie een FDG-PET/
CT scan, die twee weken nadat met pazopanib was gestart herhaald werd. De FDG opname 
in de tumoren werd voor en na start van pazopanib vergeleken, zowel middels kwantitatieve 
meting als ook subjectief door een ervaren geblindeerde nucleair geneeskundige. De offi ciële 
evaluatie was na 8 weken met een standaard CT scan volgens de huidige klinische praktijk 
(RECIST criteria). Naast de FDG-PET/CT scans werd ook farmacokinetisch onderzoek 
uitgevoerd waarbij pazopanib bloedspiegels werden afgenomen. Hiermee kon de blootstelling 
aan pazopanib worden bepaald op hetzelfde moment als FDG-PET evaluatie. Gezien de 
bekende grote farmacokinetische variatie van pazopanib, kon zo worden onderzocht of er een 
relatie was tussen beschikbaarheid van pazopanib en pazopanib geïnduceerde tumor respons 
op een FDG-PET/CT scan. Van de 20 geïncludeerde patiënten waren er na acht weken 14 
patiënten gestopt met pazopanib (twee vanwege onacceptabele toxiciteit en 12 vanwege 
ziekteprogressie). Zes patiënten lieten stabiele ziekte zien en konden na deze acht weken de 
pazopanib behandeling continueren. Het bleek dat patiënten die een toename lieten zien in 
metabole FDG opname twee weken na start therapie allen patiënten waren bij wie pazopanib 
na 8 weken niet effectief bleek te zijn. Deze toename is zowel kwantitatief beoordeeld als 
ook visueel door een ervaren nucleair geneeskundige. De visuele beoordeling kon meer 
patiënten identifi ceren bij wie de pazopanib niet effectief bleek (42%, 5 van de 12) dan de 
meer tijdrovende kwantitatieve beoordeling (25%, 3 van de 12). Daarnaast is gekeken of de 
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blootstelling aan pazopanib van invloed was op deze metabole respons. Dit bleek echter niet 
zo te zijn en blootstelling kon daarmee worden uitgesloten als variabele die van invloed zou 
zijn op metabole/klinische respons. Daarmee laat deze studie positieve resultaten zien voor 
het gebruik van de FDG-PET/CT scan als vroege biomarker om pazopanib resistentie aan te 
tonen in patiënten met een weke delen sarcoom, waarbij de beste resultaten worden bereikt 
met de visuele beoordeling door een nucleair geneeskundige. Alvorens echter de FDG-PET/
CT scan kan worden geïmplementeerd als vroege biomarker voor pazopanib effectiviteit bij 
de behandeling van gemetastaseerde weke delen sarcomen, zal een studie moeten worden 
uitgevoerd met een groter patiëntaantal om de huidige resultaten te bevestigen.
Het laatste hoofdstuk richt zich op een frequent voorkomende bijwerking van pazopanib, de 
toename van leverenzymen (transaminasen) in het bloed, welke regelmatig optreedt kort na 
start van de behandeling. In patiënten met een weke delen sarcoom is er geen alternatieve anti-
angiogene therapie wanneer deze bijwerking optreedt. Dat betekent dat wanneer weke delen 
sarcoompatiënten gedwongen worden vanwege deze bijwerking te stoppen met pazopanib, 
dit grote klinische gevolgen voor ze heeft. Dit is anders bij bijvoorbeeld patiënten met 
niercelcarcinoom, voor wie verschillende alternatieve therapieën met angiogeneseremmers 
beschikbaar zijn. Het onderliggende mechanisme van deze toxiciteit is nog niet bekend, 
maar beperkte beschikbare informatie lijkt te wijzen op een immuun gemedieerd 
mechanisme. In hoofdstuk 10 beschrijven we twee synoviosarcoom patiënten die verhoogde 
transaminasen ontwikkelen binnen acht weken na start van de behandeling met pazopanib 
waardoor pazopanib gestaakt moest stoppen. Bij normalisatie van de leverwaarden werd de 
pazopanib herstart waarna opnieuw verhoging van de transaminasen optrad. Gebaseerd op 
de immuungemedieerde pathofysiologische hypothese werd anti-inflammatoire medicatie 
gestart. Beide patiënten hebben de pazopanib gecontinueerd en zijn gelijktijdig met een 
afbouwschema prednisolon behandeld. De leverenzymwaarden werden nauwlettend in de 
gaten gehouden gedurende deze behandeling. Er werd een normalisatie van de transaminasen 
gezien, waardoor de behandeling met pazopanib voortgezet kon worden tot ziekte progressie. 
Op basis van deze bevindingen kan geconcludeerd worden dat combinatiebehandeling met 
prednisolon een mogelijke oplossing biedt voor patiënten met klinisch voordeel van pazopanib 
bij wie de behandeling beperkt wordt door levertoxiciteit. Dit kan echter alleen toegepast 
worden onder nauwlettende controle van lever enzymwaardes.
Conclusie
Met de studies beschreven in dit proefschrift is geprobeerd de presentatie en biologie van 
het synoviosarcoom, alsmede de gevoeligheid voor diverse behandelingen, beter in kaart te 
brengen. De resultaten geven een beeld van een zeer heterogene tumor op zowel klinisch, 
genetisch als therapeutisch vlak. Verschillende nieuwe therapieën voor synoviosarcomen 
zijn in een preklinische setting getest met veelbelovende resultaten. Verder werd het gebruik 
van een FDG-PET/CT scan als vroege biomarker onderzocht om patiënten met een weke 
delen sarcoom die niet reageren op pazopanib al in een vroeg stadium te kunnen identificeren. 
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Tenslotte zijn er eerste aanwijzingen voor een positief effect van predisolon in patiënten met 
pazopanib geïnduceerde levertoxiciteit.
De data gepresenteerd in dit proefschrift kunnen worden gebruikt bij de opzet van toekomstige 
studies waarbij leeftijd, of de hier mogelijk aan gekoppelde genomic index, als prognostische 
factor meegenomen moet worden in de studie opzet. Ook is het belang benadrukt van het 
synoviosarcoom subtype als een aparte identiteit binnen de weke delen tumoren in grotere 
fase 3 studies. Hierdoor kunnen mogelijk subgroep stratifi caties worden meegenomen in 
de onderzoeksopzet. De klinische gevolgen van next generation sequencing lijken voor 
synoviosarcomen tot dusver beperkt. Wel is het belangrijk dat screening voor ALK middels 
bijvoorbeeld FISH, immunohistochemie of fosforyleringsprofi elen meegenomen wordt als 
nieuw therapeutisch aangrijpingspunt. Ook palbociclib lijkt een potentiële therapie waarbij 
de nadruk gelegd moet worden op het vinden van een goede combinatie behandeling om 
langdurig klinisch effect te bewerkstelligen. Bovendien zullen deze bevindingen uit de 
prekliniek eerst nog in een klinische studie uitgezocht moeten worden. Ook de combinatie 
behandelingen met tyrosinekinaseremmers die aangrijpen op MET en PDGFRα verdient 
nader onderzoek in patiënten. Als laatste zullen de resultaten van de studies uit hoofdstuk 9 en 
10 gevalideerd moeten worden in grotere studies. 
Uiteindelijk moeten deze resultaten bijdragen aan een meer tumorgerichte benadering van 
patiënten met een weke delen sarcoom, waarbij dit proefschrift zich voornamelijk richt op 
patiënten met synoviosarcomen. Door deze specifi ekere behandeling zal hopelijk de kwaliteit 
van leven en de overleving van deze patiënten verbeteren.
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Dankwoord
Nu ik vol trots mijn ‘boekje’ kan overhandigen, wil ik ook graag de vele mensen bedanken 
met wie ik samen heb mogen werken om dit resultaat te bereiken, of die me op andere vlakken 
ondersteuning hebben gegeven in de afgelopen jaren. Het was een bijzondere samenwerking 
met verschillende afdelingen binnen het Radboud, maar ook met verschillende instanties 
nationaal en internationaal.
Nu kan veel onderzoek naar kanker niet gedaan worden zonder het grote aandeel van de 
patiënten zelf. Patiënten die in een vreselijk moeilijke periode van hun leven nog hun 
medewerking willen geven voor de verbetering van de behandeling van kanker. Ik heb 
ongelooflijk veel respect voor jullie dappere en inspirerende houding die de aanmoediging 
geeft om verder te gaan met (onderzoek naar) de behandeling van kanker. 
Buiten patiënten is ook financiële steun onmisbaar om onderzoek uit te kunnen voeren. Ik wil 
dan ook Koen Jansen & Susan van Dijk bedanken voor hun inzet. Jullie steun heeft dit project 
mogelijk gemaakt. Met alle onderzoeken heb ik geprobeerd een steentje te kunnen bijdragen 
aan het begrijpen van het synoviosarcoom en het aanzetten tot verbetering van de prognose 
van synoviosarcoom patiënten. Ik hoop dat jullie trots zijn op het eindresultaat! 
Prof. dr. Winette van der Graaf, beste Winette, al tijdens de eerste jaren van mijn studie 
geneeskunde had jij door dat de oncologie en ik wel eens een goede match zouden kunnen zijn. 
Vanaf het begin heb jij alles mogelijk gemaakt om mijn eerste stappen binnen de oncologie 
te kunnen uitvoeren; van het schrijven van mijn eerste case-report, een onderzoeksstage in 
Australië, of het creëren van mijn eerste oncologische baan. Ik waardeer het ontzettend hoe 
je toch altijd weer tijd maakte om mij te begeleiden bij de patiëntenzorg, om te luisteren naar 
mijn ervaringen en die van jezelf te delen, mee te denken in het doen van onderzoek, artikelen 
van feedback te voorzien en mij in contact te brengen met de mensen in het veld. Ongelooflijk 
bedankt voor alles wat je voor mij betekend en gedaan hebt!
Dr. Yvonne Versleijen-Jonkers, beste Yvonne, als dagelijkse supervisor van mijn preklinische 
onderzoek, maar vooral als kamergenootje, heb jij al mijn beginstappen binnen zowel het 
onderzoek als de patiëntenzorg van dichtbij meegemaakt. Door het luisteren naar mijn 
verhalen over bijzondere ervaringen van de patiëntenzorg en tegelijkertijd mee te denken over 
de onderzoeksplanning, het corrigeren van artikelen en begeleiden van experimenten was het 
hartstikke fijn om je als copromotor te hebben de afgelopen jaren. 
Dr. Nielka van Erp, beste Nielka, wat een enthousiasme straal jij toch altijd uit. Je hebt me 
hartstikke veel geholpen met het opzetten van mijn eerste patiëntenstudie, die zonder jou toch 
een stuk minder soepel zou zijn gelopen. Daarnaast is jou meedenken met de patiëntenzorg 
uniek. Jij brengt de werelden van farmacie, onderzoek en kliniek bij elkaar! 
De leden van de manuscriptcommissie, prof. dr. Kiemeney, prof. dr. Ligtenberg en prof. dr. 
Sleijfer wil ik hartelijk danken voor het lezen en beoordelen van dit proefschrift. Ook de leden 
van de promotiecommissie, bedankt voor jullie tijd en aanwezigheid bij de verdediging. 
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Dear David Thomas, thank you for the opportunity of exploring the life of a researcher in the 
fi eld of oncology. I enjoyed learing so much during my time at your lab. This experience made 
me continue performing sarcoma research, as shown with this thesis. 
Emmy & Melissa, als dokter beginnende in een onderzoekslab voelt het soms toch een beetje 
als een vis op het droge. Gelukkig stonden jullie altijd paraat om met geduld uit te leggen 
hoe je nu eigenlijk een PCR, western blot of immunokleuring uitvoert. Zonder jullie was 
ik waarschijnlijk nog steeds bezig met uitvogelen hoe ik de crizotinib opgelost krijg. Veel 
dank voor de gezelligheid, wijze raad en hulp die ik heel hard nodig heb gehad om dit boekje 
te kunnen volbrengen. Daarmee ook gelijk heel veel succes aan de twee opvolgers in ons 
groepje: Anke & Marije! You go girls! 
Amy van de Ven, Esther Schaars & Sabri Cebeci, jullie hebben tijdens je (afstudeer)stage alle 
drie bijgedragen aan de stukken die terug te vinden zijn in dit boekje. Ondanks mijn soms wat 
chaotische rooster was het leuk om met jullie te mogen samenwerken. Ik hoop dat ik jullie 
interesse binnen de oncologie heb kunnen opwekken. Bedankt voor jullie inzet, tijd en hulp! 
Ook alle co-auteurs die ieder voor zich een bijdrage hebben geleverd aan de hoofdstukken 
van dit boekje, waaronder Vincent Ho van het IKNL, de collega’s uit het NKI-AVL, de leden 
van de EORTC, Roger Daly en collega’s van de Monash University in Australië en anderen, 
zonder jullie was het boekje een stuk dunner geweest!
Mijn promotietraject was een unieke baan waarbij ik de mogelijkheid kreeg om onderzoek te 
combineren met de klinische praktijk. Deze combinatie-baan was niet alleen veelzijdig, het 
vroeg ook om een bijzondere samenwerking tussen onderzoek en patiëntenzorg. In de eerste 
plaats dank aan de collega’s van de afdeling Medische Oncologie: zowel de secretaresses, 
de poli-assistentes en de (research) verpleegkundigen, iedereen staat altijd klaar om iets 
te regelen en te helpen om de patiëntenzorg en patiëntenstudies in goede banen te leiden. 
Daarnaast de vele fellow’s oncologie, mede-onderzoekers en de oncologen met wie ik de 
interesse voor dit bijzondere vak deel. In het bijzonder mijn twee sarcoom collega’s Suzanne 
Kaal & Ingrid Desar die altijd klaar stonden om mee te denken, ervaringen te delen en in te 
vallen als supervisor op de dagen dat Winette van huis was. 
Daaropvolgend wil ik mijn collega’s van de sarcoom tumorwerkgroep bedanken voor jullie 
samenwerking! Ondanks de grootte van het Radboud, voelde dit team persoonlijk, betrokken 
en behulpzaam met als gezamenlijk doel de beste zorg te kunnen leveren aan de aan ons 
toevertrouwde patiënten. 
Ondanks dat ik tijdens mijn promotietraject verbonden zat aan de afdeling Medisch Oncologie 
was mijn kantoor gevestigd op de afdeling Pathologie, waardoor ik ook hier met velen heb 
kunnen samenwerken. In de eerste plaats, Han van Krieken (toenmalig hoofd van de afdeling 
pathologie), bedankt voor de gastvrijheid. Bastiaan Tops, Patricia Groenen en Ad Geurts van 
Kessel en de afdeling genetica, bedankt voor de hulp bij het sequencen, dat was niet gelukt 
zonder gebruik te kunnen maken van jullie expertise. William Leenders, Anneke Navis & 
Sanne van Lith, bedankt voor het delen van jullie adviezen bij verschillende experimenten. 
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En uiteraard Uta Flucke, ik mis het om een patholoog onder speeddial te hebben die altijd tijd 
maakt voor klinische of onderzoeksvragen! 
Ook de collega’s op het CDL, bedankt voor jullie ondersteuning bij de muizenstudies. Dat zou 
ik zeker niet zonder jullie gekund hebben! 
Als laatste de twee afdelingen die ontzettend veel geholpen hebben met het volbrengen van 
de PREDICT studie: de afdeling Farmacie (o.a. Angela Colbers, Monique Roukens en Bo van 
den Heuvel) en de afdeling Radiologie en Nucleaire Geneeskunde (o.a. Wim Oyen, Willem 
Grootjans, Erik Aarntzen, Lioe-Fee de Geus-Oei en Michel de Groot). Veel dank voor het 
delen van jullie expertise, hulp en adviezen! 
Inmiddels zijn mijn onderzoeksjaren al weer een tijdje geleden en ben ik begonnen als AIOS 
Interne met opnieuw fijne mensen om mij heen. Beste Doetinchem collega’s, de afgelopen 
jaren heb ik mogen vertoeven in jullie midden. In het begin moest ik even wennen aan het idee 
dat niet elk bultje een sarcoom inhield, maar al snel voelde ik mij hartstikke thuis daar in de 
Achterhoek. Als klein perifeer ziekenhuis zijn we groot in sfeer, collegialiteit en gezelligheid 
(en Rodin quizzen)! 
Naast collega’s zijn de mensen buiten het werk van onschatbare waarde. Ik heb me de 
afgelopen jaren des te meer gerealiseerd hoe waardevol het is om neer te kunnen ploffen bij 
een heerlijk bord eten met een glas wijn en een luisterend oor, om vervolgens de rest van 
de avond over alles behalve werk te kunnen praten. Aeolus-clan, wat een unieke groep van 
mannen, vrouwen, kinderen, honden, paarden en campers zijn jullie! Heerlijk om met jullie 
te kamperen, surfen of feesten en het hoofd helemaal leeg te maken! In het bijzonder wil ik 
Charlotte, Lisanne & Irene bedanken, de hoeveelheid maaltijden die jullie voor mij hebben 
gekookt zijn inmiddels allang niet meer te tellen. Of we nu een meidenavond hebben, op 
surfvakantie gaan, gaan stappen of een stedentrip, ontspannen is het altijd! Jullie zijn iedere 
keer in voor een nieuw avontuur, een gezellige avond of een dagje relaxen om helemaal 
opgeladen weer thuis te komen. Ik zou niet zonder kunnen! Nora & Wim: begon het ooit als 
trainingsmaatje van Nora, inmiddels hoor jij, Wim, er helemaal bij en zijn we zelfs met z’n 
drieën Zuid-Amerika doorgereisd. Super om jullie mooie gezinnetje nu van dichtbij te zien 
groeien. Dirk & Daniëlle: met z’n drieën is het een eeuwige strijd wie er nu weer het eerst, 
verst of langst op vakantie mag. Maar ondanks alle reizen vinden we toch de tijd om elkaar 
steeds weer op te zoeken. Ik zou zeggen proost op ons en op naar de volgende (uiteraard door 
Dirk zorgvuldig uitgezochte) fles wijn. Eline & Marlieke: wat gaan wij alweer lang terug! 
Ooit fantaseerde we nog over de verre toekomst waarin de dertiger jaren oneindig ver weg 
leken, inmiddels is die tijd al aangebroken. Meiden, ondanks dat we elkaar niet meer dagelijks 
spreken blijft het altijd leuk om jullie weer te zien! 
Ook alle andere vrienden en vriendinnen met wie het altijd weer gezellig is, bedankt voor 
jullie support, gezellige avondjes, hardloopsessies, fietstochtjes en meer! 
Familie Betzel: Tini & Peter, Milou, Guiseppe & Guilio: ik ben niet helemaal het standaard 
“Veldes maedje” en regelmatig vragen jullie je hoofdschuddend af waar Bark en ik nu weer 
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aan beginnen, toch voel ik mij inmiddels echt onderdeel van jullie familie. De afgelopen jaren 
waren fi jn, bijzonder, maar ook intens. Peter, in gedachten zit jij er vooraan bij op de eerste rij! 
Richelle & Wilco, zusje, ik ben apetrots dat jij als mede-auteur in mijn boekje staat! Vlenterie 
& Vlenterie et al, als een unieke combinatie op PubMed. Maar niet alleen op Pubmed staan 
we zij aan zij, zo ook fi nishte we zij aan zij de 6e keer de Alpe d’Huez, staan we zij aan zij 
te promoveren, een triatlon te doen en kleding te shoppen… Misschien dat we dan toch wel 
wat op elkaar lijken?! Broertje, jij kan ook alles! Of het nu het doen van klussen in huis 
is, het repareren van computers, de installatie uitvoeren van de televisie, de lay-out van dit 
proefschrift maken, sporten, of het regelen van de leukste meid in Delft! Een betere versie van 
een broertje bestaat niet! Jullie zijn mijn paranimfen en daar ben ik als grote zus ongeloofl ijk 
trots op! 
Lieve pap & mam, nooit is iets te gek: het zoveelste ritje op en neer naar Schiphol, langsgaan 
bij onze stageplekken aan de andere kant van de wereld, juichen bij een sportwedstrijd, weer 
een dag helpen verhuizen of een lamp ophangen in huis! Ik weet dat het hebben van zulke 
lieve ouders, die zo onvoorwaardelijk trots zijn, niet vanzelfsprekend is. Jullie motivatie, 
stimulatie en zorg heeft ons alle drie gemaakt tot wie we zijn en dat zegt genoeg! Bedankt!!
Bark, onze jaren samen zijn alles behalve saai geweest. Samen promoveren, in opleiding, de 
wereld rond reizen, sporten en het huisje-boompje-beestje(s) trio compleet maken, we krijgen 
het allemaal voor elkaar. Nu nog af en toe een avond op de bank en ons realiseren dát we het 
allemaal voor elkaar hebben gekregen... samen!
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Over de kaft 
De kaft laat het noorderlicht zien in de vorm van de krab. Het noorderlicht 
staat voor mij symbool voor de dromen van mensen en het belang van een 
dokter die juist daar oog voor heeft. Het is gebaseerd op een van de vele 
inspirerende dromen die patiënten met mij gedeeld hebben. Het logo van 
de krab staat voor zowel de ziekte kanker als ook mijn sterrenbeeld kreeft.
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